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Abstract 
In this thesis, I sought to explore the biological mechanisms that may underlie the 
chemoprotective effects of broccoli consumption towards bladder cancer. In particular, I was 
interested in the effects of diet on the transition from superficial bladder cancer to a more 
invasive form of this disease. Initially, I characterised global gene expression profiles of 
superficial and invasive bladder carcinomas through tissues obtained from the Norfolk and 
Norwich University Hospital Tissue Bank. Non hierarchical cluster analyses was used to 
identify a suite of genes that characterised these two tumour types. Of particular interest was 
variation in genes involved in the synthesis of the extra cellular matrix, such as COL6A1 that 
was upregulated in the more invasive tumour type. This was subsequently verified by RT 
PCR with independent tissue samples. I then explored how the broccoli isothiocyanates, 
sulforaphane and iberin and their N-acetylcysteine conjugates were able to perturb gene 
expression in two bladder cell lines that differed in their cancer phenotype. I showed that not 
only were these ITCs able to upregulate phase II detoxification genes, which has previously 
been reported in other cell lines, but they, and their conjugates, were able to down regulate 
the COL61A gene.  Studies on the effects of ITCs on gene expression were complemented 
with studies on cell migration and invasiveness. I then sought to see if any of the changes in 
gene expression observed in the cell lines could be observed in tissues obtained as part of a 
human intervention study. I designed and executed a small pilot study that enabled bladder 
tissue biopsies to be obtained before and after a four day intervention with broccoli. Global 
gene expression analyses again suggested alterations in genes determining the extracellular 
matrix, such as Tenascin-C. This study demonstrated the proof-of-principle that these types 
of intervention studies are possible, but was of an insufficient size to draw definite 
conclusions. Finally, I investigated in more details the expression of splice variants of 
Tenascin-C in relationship to bladder cancer grade. In conclusion, this study has suggested 
that dietary ITCs may perturb genes involved in the extracellular matrix and this may be an 
important component of understanding their chemopreventive activities, and has 
demonstrated the feasibility of human intervention studies with the analyses of target tissues 
as opposed to peripheral biomarkers.  
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Chapter 1: General Introduction 
1.1 The Bladder 
The bladder is a hollow, muscular, and distensible organ that sits in the pelvis. Wastes 
are filtered out of the blood stream by the kidneys and enter the bladder via the 
ureters, figure1.1, collecting in the bladder as urine. From the bladder, urine passes 
out of the body through a hollow tube called the urethra (van der Horst and Junemann 
2004), figure1.1.  
The bladder has an outer wall of muscle and connective tissue. Nerves in the 
wall monitor bladder filling and signal the body to urinate. Like other organs the 
bladder's inner surface is lined with epithelial cells (van der Horst and Junemann 
2004).  
 
Figure 1.1 Anatomy of the Bladder 
 
As illustrated in figure 1.1 the inner wall of the bladder is coated with a 
substance called glycosaminoglycan (Parsons 1986)  (GAG). This is a mucus-like 
layer that help to protects the epithelial cells from acids and toxins in the urine and 
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has an antibacterial defence mechanism that operates by resisting bacterial adherence 
and infection (Parsons, Stauffer et al. 1988). The bladder and the urinary tract has 
generally been thought to be solely a storage and transit vehicle for urine made by the 
kidney, however recent in-vivo animal studies suggest that reabsorbtion of urea  and 
other urine constituents also occur across the bladder and urinary tract epithelia 
(Spector, Yang et al. 2007).  
 
1.1.1 Layers of the bladder  
The bladder consists of four structurally distinct tissue layers: 
 Epithelium: The epithelium shown in figure 1.2, which lines the bladder and is in 
contact with the urine, is referred to as transitional cell epithelium. Most bladder 
cancers originate from the cells of this 
transitional epithelium and hence is termed 
transitional cell carcinoma (TCC) 
(pathology2.jhu.edu/bladder_cancer 2007). 
 
 
Figure 1.2 Transitional epithelium also known as urothelium. www.ouhsc.e 
du/histology. 
 
Lamina propria: Under the epithelium is the lamina propria, a layer of connective 
tissue and blood vessels. Within the lamina propria, there is a thin and often 
discontinuous layer of smooth muscle called the muscularis mucosa. This superficial 
layer of smooth muscle is not to be confused with the true muscular layer of the 
bladder called the muscularis propria or detrusor muscle, figure1.1.   
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Muscularis propria or detrusor muscle: This deep muscle layer consists of thick 
smooth muscle bundles that form the wall of the bladder. For purposes of staging 
bladder cancer, the muscularis propria has been divided into a superficial (inner) half 
and a deep (outer) half, figure 1.1.  
Perivesical soft tissue: This outermost layer consists of fat, fibrous tissue and blood 
vessels. If a tumour reaches this layer, it is considered out to be of the bladder 
(pathology2.jhu.edu/bladder_cancer 2007).  
 
1.2 Cancer 
One in three individuals develop cancer during their lives and each year around 
289,000 people are newly diagnosed with cancer. There are many different types of 
cancer, but as can be seen from figure 1.3 four of them, breast, lung, colorectal and 
prostate account for over half of all new cases (Statistics 2004).  Breast cancer is the 
most common cancer in the UK despite the fact that it is rare in men. The 20 most 
commonly diagnosed cancers in the UK are shown in figure 1.3. 
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Figure 1.3 The 20 most commonly diagnosed cancers in the UK Adapted from 
www.cancerresearchuk.org 
 
Although a wide variety of human diseases arise due to defects in gene 
regulation, the human disease that exhibits the most extensive modifications of gene 
expression is cancer (Gerdes 2002).  Mutations affecting transcriptional and post 
transcriptional gene regulation may give rise to an abnormal cell.  An isolated 
abnormal cell that does not proliferate more than its neighbours does no significant 
damage; but if its proliferation is out of control it will give rise to a neoplasm.  If the 
neoplastic cells remains clustered together in a single mass the tumour is said to be 
benign. A tumour is classed as cancer only if it is malignant, that is if the cells have 
the ability to invade surrounding tissue (Gerdes 2002).  Cancers are classified 
according to the tissue and cell from which they arise.  Cancers arising from epithelial 
cells are termed carcinomas, and account for 90% of human cancers.  This is perhaps 
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because epithelial cells line virtually every organ in the body and most of the cell 
proliferation in the body occurs in the epithelia; or perhaps because the epithelial 
tissues are most frequently exposed to the various forms of physical and chemical 
damage that facilitate the development of cancer.     
This particularly applies to bladder cancer, as there is a constant assault on the 
bladder tissue from the waste and toxins contained in the urine.  Most cancers have 
characteristics that reflect their origin, such as specific cell type, location in the body 
and structure of the tumour, and are often named in accordance.  For example 
transitional cell carcinomas of the bladder are termed as such because they arise in the 
transitional cells of the bladder.  Transitional epithelia are multi-layered cells that can 
contract and expand. These cells are predominately found in the urinary tract, 
especially around the bladder. They are also found in the ureters and superior urethra.  
These cells are cuboidal when the organ is not stretched. When the bladder fills up 
these cells are stretched and they look squamous, flat and irregular.  They have the 
ability to change from cuboidal like epithelium to squamous like epithelium so as to 
accommodate fluctuations of volume of the liquid in the organ.  
 
1.2.1 Invasive and metastatic cancer 
The mechanisms facilitating progression from benign to invasive, and finally to 
metastatic carcinoma, remain largely elusive.  Extraordinary demands are placed on 
epithelium-derived carcinoma cells to successfully metastasise, including separation 
from the epithelial collective, degradation of the surrounding matrix, migration and 
invasion through the basement membrane intravasation and survival in the circulation, 
extravasation at a secondary site, survival as a micrometastasis, and finally growth 
into overt metastases (Chaffer, Brennan et al. 2006; Przybylo and Radisky 2007).  To 
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successfully complete these complex steps, cancer cells exhibit both mesenchymal-
and epithelial-like properties at different times, or even at the same time (Chaffer, 
Brennan et al. 2006; Hugo, Ackland et al. 2007).  The loss of epithelial characteristics 
and the acquisition of mesenchymal like migratory phenotype are crucial to the 
development of invasive carcinoma and metastasis (Lee, Dedhar et al. 2006; Chaffer, 
Thompson et al. 2007). Epithelial-mesenchymal transition (EMT) is a programmed 
development of cells characterized by loss of cell adhesion, repression of E-cadherin 
expression, and increased cell mobility.  Initiation of metastasis involves invasion, 
which has many phenotypic similarities to EMT, including a loss of cell-cell adhesion 
mediated by E-cadherin repression and an increase in cell mobility. In both normal 
and pathological EMT this cell adhesion protein E-cadherin is critical to the 
differentiation and maintenance of the epithelial phenotype and loss of this protein is 
rate-limited for EMT (Arima, Inoue et al. 2008).  It is now widely accepted that this 
developmental pathway is exploited in various disease states, including cancer 
progression.  By adopting developmental EMT pathways, sessile epithelial carcinoma 
cells are transformed into cells with migratory and invasive capability, metastasis 
potential and resistance to chemotherapy (Thompson and Williams 2008; Wallerand, 
Robert et al. 2009) and anoikis, a form of apoptosis which is induced by anchorage-
dependent cells detaching from the surrounding extracellular matrix (ECM) (Chaffer, 
Thompson et al. 2007).  Several pathways, such as TGFbeta and RTK/Ras signalling, 
Ras-MAPK and Wnt, Notch-, Hedgehog- and NF-kappaB-dependent pathways, have 
been shown to be involved in regulation of EMT (Huber, Kraut et al. 2005; 
Christofori 2006). In particular, Ras-MAPK has been shown to activate two related 
transcription factors known as Snail and Slug (Przybylo and Radisky 2007; Arima, 
Inoue et al. 2008).  Both of these proteins are transcriptional repressors of E-cadherin 
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and their expression induces EMT (Huber, Kraut et al. 2005; Przybylo and Radisky 
2007). Snail is a transcription factor long studied for its role in physiological EMT but 
which is increasingly recognised as a factor involved in tumour progression and 
malignancy. Twist, another transcription factor, has also been shown to induce EMT, 
and is also implicated in the regulation of metastasis (Wallerand, Robert et al. 2009). 
Interestingly, urine anlysis showed that the twist gene was frequently methylated in 
urine samples collected from bladder cancer patients, including those with early-stage 
and low-grade disease (Renard, Joniau et al. 2009). The study suggests a sensitive and 
specific, noninvasive approach for detecting primary bladder cancer and surveillance 
strategies for bladder cancer recurrence which is significantly better than that of 
cytology, refer to section 1.4.1, (Kim and Kim 2009).  
 
1.2.2 Matrix metalloproteinases (MMPs) 
Matrix metalloproteinases are a family of more than 28 enzymes that were initially 
identified on the basis of their ability to cleave most elements of the ECM but have 
subsequently been found in many physiological processes that require tissue 
remodelling and have also been shown to be up regulated in many tumours 
(Orlichenko and Radisky 2008), where they stimulate tumour growth, invasion, and 
metastasis. Theses enzymes digest components of the ECM, as well as cell surface 
receptors for soluble factors and junction proteins involved in cell-cell and cell-ECM 
interactions (Przybylo and Radisky 2007).  
  Matrix metalloproteinases (MMPs) play an important role in tissue 
remodelling associated with various physiological and pathological processes such as 
cell proliferation, cell migration, cell differentiation, angiogenesis, morphogenesis, 
apoptosis, tissue repair, cirrhosis, arthritis and metastasis.  The gelatinases (MMP-2 
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and MMP-9) are thought to be the most important in the metastatic process. MMP-2 
and 9 have the ability to degrade type IV collagen, which is one of the major 
components of the basement membrane (de Vicente, Fresno et al. 2005; Shah, Shukla 
et al. 2009).  They play a key role during invasion and metastasising of malignant 
cells and they have been shown to be associated with invasive phenotypes and poor 
prognosis in several tumours (Hazar, Polat et al. 2004; Li, Cao et al. 2004; Aref, 
Osman et al. 2007; Shah, Shukla et al. 2009) , including bladder carcinoma (Xu, Hou 
et al. 2002), where the level of the MMP- 2 mRNA was shown to be  proportional to 
TCC grading and staging in human TCC. Contrary to these results, another study 
showed that MMP-2 over expression correlated with bladder cancer stage but not with 
grade (Vasala, Paakko et al. 2003). 
There are many MMPs which are classified in to several groups. The most 
studied are the collagenases, the gelatinases, the stromelysins, and the membrane type 
MMPs (MT-MMPs).  Apart from the six membrane types all other MMPs are 
secreted enzymes. The MMPs are initially synthesized as inactive zymogens with a 
pro-peptide domain that must be removed before the enzyme is active. The pro-
peptide domain is part of the “cysteine switch”. These enzymes are inhibited by 
specific endogenous tissue inhibitor of metalloproteinases (TIMPs), which comprise a 
family of four protease inhibitors: TIMP-1, TIMP-2, TIMP-3 and TIMP-4.  In a recent 
study, serum levels of the inactive enzyme proMMP-2, the active enzyme MMP-2 and 
the inhibitor TIMP-2 were assessed in 84 patients suffering from bladder carcinoma. 
The results indicated that low circulating proMMP-2 and TIMP-2 levels significantly 
correlated with poor prognosis (Vasala, Kuvaja et al. 2008).  The 5-year disease-
specific survival rate was 46% in patients with high levels of proMMP-2 versus 23% 
in patients with low proMMP-2 levels (p = 0.011). Presumably, this is because the 
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high levels of proMMP-2 indicates the circulation of the inactive form as opposed to 
the active form of MMP-2 and the high level of TIMP-2 indicates a greater inhibitory 
effect of the MMP-2.  They conclude by suggesting the results indicate that high 
levels of circulating proMMP-2 and TIMP-2 s are both associated with a better 
clinical course and that total proMMP-2 may be an independent prognostic marker of 
bladder cancer progression (Vasala, Kuvaja et al. 2008).  MMP-2 and 9 activity in the 
urine of patients with bladder cancer has also been studied.  MMP-2 and 9 activities 
were verified in the urine of 25 patients with bladder cancer; ten patients with Ta-T1, 
eight patients with T3 and seven patients with T4 TCC (refer to 1.5.2 for explanation 
of tumour grades).  The urine of healthy volunteers, with no evidence of disease, were 
used as controls.  The majority of cancerous urine samples showed MMP-9 lytic 
activity but only a few contained MMP-2 and in the healthy subjects only traces of 
MMP were detected.  Moreover, MMP-9 content was enhanced in the urine from 
patients with high-grade and advanced-stage bladder tumours (T3 and T4 
respectively) (Di Carlo, Terracciano et al. 2006).   
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1.3 Epidemiology of Bladder Cancer 
Transitional cell carcinoma is the most common malignancy of the urinary bladder, 
urethra and renal pelvis with in excess of 10,000 new cases occurring each year in the 
UK.  Incidences and mortality rates of bladder cancer vary about 10-fold worldwide, 
with the highest rates found in North America and Europe (Engel, Taioli et al. 2002; 
Yancik 2005).  However differences between countries are caused by the differences in 
registration or reporting of low grade tumours (Kirkali, Chan et al. 2005), which are 
recorded as malignant by some cancer registries and as benign by others.  This makes 
comparison between counties very difficult.   
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Figure 1.4 The number of new bladder cancer cases and age specific incidence rates by sex. Adapted 
from www.cancerresearchuk.org 
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Bladder cancer is the fourth most common cancer in men and the ninth most 
common cancer in women.  In the UK more than 7000 new cases were diagnosed in 
men in 2005.  This compares to nearly 3,000 cases in females - giving a male: female 
ratio of 2.5:1.0.  As can be seen from figure 1.4, few cases of bladder cancer occur 
under the age of 50, but thereafter the rates rise with age to reach a peak in the oldest 
age groups (Statistics 2004).  The surveys of cancer incidences and mortality suggest 
that parous women have a lower risk of bladder cancer than nulliparous women, 
probably because of hormones (Cantor, Lynch et al. 1992).   
 
Table 1.1 Number of new cases and rates of bladder cancer in the UK (2005). Adapted from 
www.cancerresearchuk.org 
 
Although it can be seen from figure 1.4 and table 1.1 that bladder cancer is more 
common in males than in females, it has been suggested that the stage-adjusted survival 
of bladder cancer women is worse than in men (Mungan, Aben et al. 2000).  It can be 
seen from the above graph that approximately 88% of male deaths and 90% of female 
deaths occur after the age of 65 years and as expected, for both men and women bladder 
cancer survival rates decrease with age.  Norfolk has one of the largest admission rates 
for bladder cancer compared with other local health authorities in England, although 
this is probably due to the high ageing populations in Norfolk (Statistics 2004). 
 
 
 
  
 England  Wales  Scotland  N.Ireland  UK 
Cases          
Males 6091  619  468  132  7310 
Females 2403  260  247  58  2968 
Persons 8494   879   715   190   10278 
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1.4 Diagnosis of bladder cancer 
There are several methods for the detection of bladder cancer; by intravenous 
pyelogram (IVP), computed tomography (CT) and magnetic resonance imaging 
(MRI), however there is currently no inclusive test for the detection of bladder cancer 
and as such involves a collaboration of techniques and expertise.  The most common 
procedure employed is cytology and cystoscopy examination, but both methods have 
their limitations (www.cancer.gov/cancertopics 2007).  Cystoscopy is increasingly 
being demonstrated to miss both tumour in-situ (Tis) and superficial bladder cancer 
and urine cytology has high specificity, but has low sensitivity and significant 
variability in performance (Lotan and Roehrborn 2003).  Both preparation and the 
experience of the investigator can affect performance of this test. 
 
1.4.1 Cytology 
A preliminary diagnosis may be made by using the oldest urine-based biomarker, 
cytology.  Individual cells from the urine are microscopically looked at, by thinly 
spreading them onto a glass microscopic slide and staining, see figures 1.6 and 1.7.  
Although urine cytology has high specificity and high positive predictive value for high 
grade bladder cancers, it has low sensitivity, particularly for low-grade cancers; 
however it does help to establish a picture to aid diagnosis.  More recent tests, such as 
the bladder tumour antigen (BTA) tests, the BTA stat (Polymedco, Redmond, WA) and 
BTA-TRAK (Polymedco); ImmunoCyt (Diagnocure, Quebec City, Quebec, Canada); 
the urinary nuclear matrix protein (NMP) test, NMP-22 BladderChek (Matritech, 
Newton, MA); and UroVysion (Abbott Molecular/Abbott Laboratories Inc., Des 
Plaines, IL) may have higher sensitivity and better negative predictive value. 
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Figure 1.6 Normal urothelial cells: Normal urothelial cells have a differentiated and uniform appearance 
with abundant cytoplasm and small nuclei (pathology2.jhu.edu/bladder_cancer 2007). 
 
 
 
 
 
 
 
Figure 1.7 High grade bladder cancer: Bladder cancer cells are undifferentiated and enlarged with 
large dark nuclei (pathology2.jhu.edu/bladder_cancer 2007). 
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1.4.2 Flexible cytoscopy 
A cystoscopy is an examination undertaken by a consultant urologist or specialist 
registrar of the inside of the bladder using a thin, flexible tube like telescope called a 
cystoscope.  This instrument is carefully passed up the urethra and into the bladder.  
Cystoscopy is routinely performed as an outpatient or day case procedure, with no 
overnight stay in hospital.  It is usually performed under local anaesthetic, which is 
given in the form of a gel placed into the opening of the urethra.  Once the end of the 
cystoscope is in the bladder, sterile water is passed through it to fill the bladder up and 
make the whole of the lining visible.  A tiny light and lens on the cystoscope enables 
the inspection of the bladder lining for any abnormal growths or disease, refer to 
figure 1.8.  Cytoscopy remains the gold standard for the detection of bladder cancer. It 
enables both detection and minimal invasive treatment of disease that has not invaded 
deeply into the bladder wall.  Nevertheless, cystoscopy has its limitations. Although it 
is generally recognized that cystoscopy often fails to detect carcinoma in-situ, more 
recent data with fluorescence demonstrate that conventional (white light) cystoscopy 
can also fail to detect papillary tumours (Jichlinski, Guillou et al. 2003; Kausch, 
Doehn et al. 2006; Jocham, Stepp et al. 2007) .   
 
Figure 1.8 Shows a cystoscopy of three separate lesions of typical superficial transtitional cell 
carcinoma with feeding blood vessels and papillary morphology (Brinkman, Buntinx et al. 2006). 
 
Three separate 
lesions  
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There is inadequate evidence to determine whether routine screening for bladder 
and other urothelial cancers would have any impact on mortality.  Although due to the 
high rate of bladder cancer recurrence, once an individual has suffered from bladder 
cancer they will attend regular surveillance cystoscopy.  Patients are generally seen by 
an urologist every three months for the first one to two years, then every six months 
for another one to two years, and then once a year thereafter.  At each visit, the 
urologist will perform cystoscopy with or without biopsy and obtain urine for urine 
cytology (Oosterlinck 2004).  
 
1.4.3 Histological examination of bladder biopsy tissue 
The diagnosis of bladder cancer is based on histological examination of cells from the 
bladder biopsy sample.  It can be identified whether the tumour is benign or malignant 
and the type of tumour.  This is essential because tumours of different types behave 
very differently and require different treatment regimens. 
 
1.4.4 Norfolk and Norwich University Hospital Tissue bank and 
pathology/histopathology department 
Norfolk and Norwich University Hospital NHS Trust is a large acute trust that 
provides a range of services to a population of approximately 500,000.  The Norfolk 
and Norwich University Hospital has approximately 1015 beds and provides 
secondary and tertiary cancer services.  It has cancer centre status for chemotherapy, 
radiotherapy and specialist oncology surgery.  The Trust was given a one star rating in 
the NHS Performance Ratings 2003/2004, (Healthcare Commission), following a 2 
star rating in 2003. 
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The NNUH histopathology department routinely receive tissue biopsies for the 
classification and grading of many cancers to aid diagnosis.  Also they will routinely 
receive donations of non transplantable human organs, tissues and donations of 
surgical residue tissue from living patients undergoing surgical operations.  The whole 
organ can be removed and donated for biomedical research, however more commonly 
just biopsies are removed along with routine biopsies for diagnosis.  The information 
concerning the use of donated human tissue to be used for biomedical research is 
approved by the Norfolk Research Ethics Committee and East Norfolk & Waveney 
Research Governance Committee, which involves scientific investigations conducted 
within the hospital, university or other research laboratories, into the causes, treatment 
and prevention of ill-health. 
Tissue received by the NNUH histopathology department from the hospital 
theatres would have been dissected into its constitutive parts of no more than 2cm3 
and placed into an appropriate container.  A request for the necessary work on these 
samples would have been requested on the ICE (Integrated Communications 
Environment) requesting system which is an electronic link between the wards, 
theatres, GP practices and the hospital pathology laboratories.  On receipt of the 
sample in the pathology department, details of the patient (hospital number, date of 
birth, full name, tissue type and date of donation) would have been electronically 
entered into the Labtrack pathology computer system and a unique accession tracking 
reference number generated for each sample.  If the sample was to be stored in the 
tissue bank then it would as be given a tissue bank number (07TB….).  All patient 
related data is stored on this password protected dedicated database.  The Labtrack 
database holds all haematology, biochemistry, histopathology, cytology and 
radiography reports for all patients and is accessible only to the medical and scientific 
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staff of the NNUH pathology department.  Both Labtrack and the ICE computer 
systems are interfaced to the hospitals main patient administration system (PAS), 
allowing the donated tissue, patient and their results to be tracked and audited within 
the NNUH.  Sections of the biopsy sample would have been either paraffin embedded 
and stained for histological examination or snap frozen in liquid nitrogen and stored in 
a -80◦C tissue bank freezer.  The freezing process would have taken no longer than 1 
min per 2cm3 piece.  Material can be stored in a -80ºC freezer indefinitely.    
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1.5 Classification of cancer 
1.5.1 Classification of tumours based on their tissue of origin 
Tumours may be classified not only on their biological behaviour but also on their 
tissue of origin.  Most tumours retain sufficient characteristics to determine the type of 
tissue from which they derived.  Table 1.3 gives the names and definitions of cancers.  
Cancer Definition 
Carcinomas Most cancers (approx 80-90 %) are 
carcinomas. These start in the epithelial 
cells that line internal and external body 
surfaces. The commonest carcinomas are 
lung cancer, breast cancer and bowel 
cancer. 
 
Sarcomas 
 
Sarcomas begin in connective tissues of 
the body, such as muscle, bone, cartilage 
and fat. 
 
Leukaemia 
 
The leukaemias are cancers of the blood 
cells that grow in the bone marrow, which 
are found in the bloodstream. 
 
Lymphomas 
 
Lymphomas develop in the lymph nodes 
and tissues of the immune system. 
 
Adenomas 
 
Adenomas are tumours (often benign) that 
begin in glandular tissue, such as the 
pituitary gland or thyroid. 
 
Blastomas 
 
Childhood cancers often form in the 
embryonic tissues which remain. Tumours 
formed here are often named after the 
blastocytes, for example neuroblastoma, 
nephroblastoma. 
 
Primary of unknown origin 
 
This is where the tissue or origin cannot be 
determined 
Table 1.2 Classification of tumours based on their tissue of origin. Information taken from Eastern 
Cancer Registration & Information Centre (ECRiC) Annual Report 2006 - 2007 
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1.5.2 Classification of bladder cancer 
Tumour, node, metastatic (TNM) classification of urinary bladder cancer World Health 
Organization (WHO)(Oosterlinck, Lobel et al. 2002) gives a pathological stage of the 
tumour.   
 
Superficial 
• TX Primary tumour cannot be assessed 
• T0 No evidence of primary tumour 
• Ta Non-invasive papillary carcinoma 
• Tis Carcinoma in situ (‘flat tumour’) 
• T1 Tumour invades subepithelial connective tissue 
 
Invasive (Non-superficial) 
• T2 Tumour invades muscle 
 T2a Tumour invades superficial muscle  
 (Inner half) 
 T2b Tumour invades deep muscle (outer half) 
• T3 Tumour invades perivesical tissue: 
 T3a Microscopically 
 T3b Macroscopically (extravesical mass) 
 
Tumours are classified by the position of the tumour in the bladder; figure 1.9 shows 
the position of tumours in relation to the above stages of bladder cancer.  
Approximately 90% of bladder cancers are transitional cell carcinomas (TCC) 
(Oosterlinck 2004).  Clinically superficial TCC tumours (Ta, Tis, and T1) account for 
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approximately 75% to 85% of bladder neoplasms, while the remaining 15% to 25% are 
invasive (T2, T3 and T4) or metatastic lesions at the time of initial presentation 
(Oosterlinck, Lobel et al. 2002; Oosterlinck, Lobel et al. 2002; Oosterlinck 2004; 
Oosterlinck, Solsona et al. 2005; Sanchez-Carbayo and Cordon-Cardo 2007).  In a 
recent study by Vrabie et al, histological and immunohistochemical analysis revealed 
that 70% of the clinically superficial tumours were carcinomas infiltrating the lamina 
propria (T1), and almost 22.85% represent with Ta, while only 7.15% of cases 
presented with Tis (Vrabie, Petrescu et al. 2007).    
 
 
Figure 1.9 Diagram showing the position of tumour in relation to stages of bladder cancer.  
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1.5.3 Histopathological grading (Oosterlinck, Lobel et al. 2002) 
Grade is described on a scale of 1-4 
GX  Grade of differentiation cannot be assessed 
G1  Well differentiated 
G2  Moderately differentiated 
G3-4    Poorly differentiated/undifferentiated 
A differentiated cell is one which appears most like the normal cells from the tissue of 
origin.  An undifferentiated cell is one that looks least or less like the normal cells from 
the tissue of origin. 
GRADE 
 
 
1 
 
2 
 
3 
 
4 
% undifferentiated cells 
Best 
 
<25 
 
2 >25 <50 
 
3      >50% <75% 
 
4         >75% Worst 
BEST 
 
 
 
 
 
 
 
 
 
WORST 
Figure 1.10  Diagram adapted from Eastern Cancer Registration & Information Centre (ECRiC) Annual 
Report 2006 - 2007 representing the significance of grade and percentage of cell undifferentation in 
relation to ‘best’ and ‘worst’ outcome.  
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1.5.4 High rate of reoccurrence of bladder cancer 
Disease prevalence is high in western nations due to the predominance of the chronic 
relapsing of bladder cancer that occurs in these countries and this single fact makes 
bladder cancer one of the most expensive cancers to treat (Lerner S P 2005). 
The recurrence rate of treated superficial bladder cancer is very high.  As table 
1.3  shows,  more than 60% of patients first presenting with superficial tumours will 
have one or more recurrences after initial treatment (Oosterlinck, Lobel et al. 2002; 
Oosterlinck, Lobel et al. 2002; Sanchez-Carbayo and Cordon-Cardo 2007), and 40% of 
these patients will later progress to a higher stage or grade and die of the disease 
(Oosterlinck, Lobel et al. 2002; Sanchez-Carbayo and Cordon-Cardo 2007).  Over 50% 
of patients who first present with high grade TCC tumours will have one or more 
recurrences after the initial treatment (Oosterlinck, Lobel et al. 2002), however many of 
these patients will re-present with a higher grade of TCC and 25% will die from the 
disease (Oosterlinck, Lobel et al. 2002).  
GRADES TO PROGRESSION AND RECURRENCE OF TCC 
  
 
RECURRENCE 
ANY STAGE PROGRESSION 
SUBMUCOSAL INVASION 
DETRUSOR MUSCLE INVASION 
METASTASES/DEATH 
LOW GRADE (TA- T1 G1-G2) 
(N=42) 
64.1% 
10.5% 
2.6% 
5.3% 
10.6% 
HIGH GRADE (T2-T4 G3-G4) 
(N=62) 
56.4% 
27.1% 
8.3% 
6.3% 
25.0% 
Table 1.3 Table represents grades of TCC (high; Ta-T1 G1-G2 and low; T2-T4 G3-G4) and the 
percentage of recurrence, progression, invasion into the submucosal, invasion into the muscle and 
metastases/death of TCC. Adapted from a report by the World Health organisation/International society of 
urological pathologist 2005 (Oosterlinck, Solsona et al. 2005). 
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A recent study conducted to determine the effect of polymorphisms in quinone 
reductase (NQO1) on bladder cancer disease, course and clinical outcomes showed 
interesting findings in relation to the recurrence rate and stage progression of the 
recurrence.  A total of 546 patients with bladder cancer were studied over a five year 
period.  Follow up of the patients showed that patients who presented and were treated 
for TaG1 showed no recurrence of bladder cancer over the 5 year period.  Patients 
presenting with and were treated for TaG2 bladder cancer showed the highest 
recurrence rate. However, although patients presenting with and treated for TaG3 and 
T1 bladder cancer were shown to have a lower rate of recurrence than TaG2, they 
showed a high rate of stage progression and a shorter disease free survival then that of 
patients suffering with TaG2 bladder tumours. Most cases of T2+ died within the 5 year 
period (Sanyal, Ryk et al. 2007).  
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1.6 Treatment of Bladder Cancer 
1.6.1 Transurethral resection of bladder tumour 
Figure 1.11 gives a simplified outline of the possible treatment of TCC; however this 
will vary from hospital and/or consultants protocols.  The standard initial treatment of 
superficial tumours includes cystoscopy with trans-urethral resection of the bladder 
tumour (TURBT).  A transurethral bladder tumour resection is a procedure in which 
the tumour is removed from the bladder and does not involve making an incision in 
the body.  The operation is referred to as ‘transurethral’ because it is performed 
through the urethra.  A larger cystoscope is put into the urethra and up to the bladder.  
Water is again passed through the tube to fill the bladder allowing visualization and 
the tumour is shaved down a piece at a time until the entire bladder tumour is 
removed (Kirkali, Chan et al. 2005).  Figure 1.11 represents the possible course of 
action following a cystoscopy investigation.  
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Figure 1.11 The flow diagram shows the possible course of action following a cystoscopy investigation. 
This will vary depending on the hospital and/or consultants protocols. 
 
 
1.6.2 Adjuvant intravesical drug therepy 
Adjuvant intravesical drug therapy after TURBT is commonly prescribed for patients 
with tumours that are large, multiple, high grade or superficially invasive, dependent 
on the hospitals policy.  Intravesical therapy consists of drugs placed directly into the 
bladder through a urethral catheter at the time of resection, in an attempt to minimize 
the risk of tumour recurrence and progression. The most commonly used intravesical 
drugs is the immunotherapeutic agent Bacille Calmette-Guerin (BCG) and the 
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chemotherapy agent Mitomycin C.  Maintenance therapy (repeated therapy on a 
regular basis) with BCG or Mitomycin C, administered intermittently following initial 
diagnosis and treatment of superficial bladder tumour, decreases the likelihood of 
recurrence (Schenkman and Lamm 2004).  Dr. DL Lamm, a pioneer in the field of 
immunotherapy for bladder cancer since the early ‘80’s, reports that patients with a 
solitary tumour that appears to be low grade can be best treated with single instillation 
of chemotherapy.  Single instillations have been demonstrated to be effective with 
other chemotherapy agents such as Thiotepa, Adriamycin and Epirubicin, in these low 
grade patients.  Also BCG is not necessary unless tumour recurrence becomes a 
problem for these low grade patients. The patients with CIS, Ta Grade 3 TCC, or 
lamina propria invasion (T1) are best treated with BCG.  BCG has been proven to be 
superior to chemotherapy (Thiotepa, Adriamycin, Mitomycin, and Epirubicin) in 
comparative controlled studies and BCG, but not chemotherapy, is found to 
significantly reduce disease progression.  Direct contact of BCG with the urothelium 
is essential.  Fibronectin-binding proteins on the surface of the Mycobacteria bind to 
receptors on the surface of the urothelial cells, initiating intracellular signalling which 
results in cell mediated antitumor activity (Lamm 2000).  Lamm et al analysed six 
studies comparing surgery alone and combined with BCG immunotherapy.  This 
meta-analysis found a 42% significant difference in recurrence in favour of BCG 
treatment.  
Some patients become resistant to therapy with BCG and currently there is a 
clinical trial to determine the efficacy and safety of intravesical Mycobacterial Cell 
Wall-DNA Complex (MCC) in patients with non-muscle invasive TCC. 
Mycobacterial cell wall-DNA complex (MCC) is a bifunctional anticancer agent that 
induces cancer cell apoptosis and stimulates cytokine synthesis by immune cells. 
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1.6.3 Cystectomy 
Cystectomy is indicated when bladder cancer is invasive into the muscle wall of the 
bladder or when patients with superficial tumours have frequent recurrences that are not 
responsive to intravesical therapy(Chevallier 1994).  A Cystectomy is either partial or 
complete surgical removal of the bladder and occasionally neighbouring organs, such as 
the prostate (Oosterlinck, Lobel et al. 2002).  The benefits of surgically removing the 
bladder are disease control, eradication of symptoms associated with bladder cancer, 
and long-term survival.  When the bladder is surgically removed, a replacement for the 
bladder needs to be constructed.  The types of bladder reconstruction currently available 
for patients are ileal conduit, catheterizable pouch and neobladder (van der Meijden, 
Sylvester et al. 2005). 
For advanced bladder cancer that has extended beyond the bladder wall, 
radiation and chemotherapy are treatment options.  Local lymph nodes are frequently 
radiated as part of the therapy to treat any cancer cells which may have spread to the 
nodes.  Current treatment of advanced bladder cancer can involve a combination of 
radiation and chemotherapy.  Chemotherapy before surgery nearly doubles survival 
rates in patients with locally advanced bladder cancer compared to surgery alone, 
according to a trial reported at the annual meeting of the American Society of Clinical 
Oncology in San Francisco on May 14, 2003 (Grossman, Natale et al. 2003). The 
clinical trial showed that in the group receiving chemotherapy before surgery, median 
survival, that is the point at which half of the patients were still alive, was 6.2 years.  In 
contrast, median survival was 3.6 years in the patients who had surgery without 
chemotherapy.  Although, despite aggressive surgical resection, radiotherapy, and/or 
chemotherapy, the overall cure of invasive TCC remains, dependent on stage and grade, 
in the range of 20% to 50% (Sanchez-Carbayo and Cordon-Cardo 2007).  
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1.7 Risk Factors 
1.7.1 Environmental risk factors  
There are many aetiological risk factors for the development of bladder cancer.  
Aromatic amines were the first to be recognised in the 1970’s.  Cigarette smoking, 
which is related to socio-economic deprivation, is by far the most relevant risk factor, 
tripling the risk of developing bladder cancer and showing a clear dose-response 
relationship (Golka, Rettenmeier et al. 2006).  Workers in printing, iron and aluminum 
processing, industrial painting, gas and tar manufacturing industries have also been 
shown to be at risk (Ohno and Aoki 1980; Golka, Seidel et al. 2005; Pelucchi, Bosetti et 
al. 2006).  Being exposed to certain substances, such as soot from coal, or chemicals 
used to make rubber, certain dyes, or textiles have also been linked to bladder cancer 
risk.  This industrial occupational exposure may account for the higher incidence of 
bladder cancer in men and the regional variation seen in bladder cancer rates.  
Infections and stones in the urinary tract might cause chronic irritation of the bladder 
epithelium, and thus increase bladder cancer risk (Pelucchi, Bosetti et al. 2006).  
Other possible risk factors may be (www.cancer.gov/cancertopics 2007): 
• Working as a dry cleaner or in places where paper, rope, twine, or clothing is 
made 
• Taking A. fangchi, a Chinese herb  
• Drinking water that has high levels of arsenic  
• Long-term use of urinary catheters 
• Past treatment with certain anticancer drugs or radiation therapy to the pelvis  
• Having a kidney transplant 
• Having the inherited disorder hereditary nonpolyposis colon cancer (HNPCC; 
Lynch syndrome) 
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Pelucchi et a.l suggest that other widely investigated lifestyle habits are probably not 
associated with risk of developing bladder cancer (e.g. coffee consumption, artificial 
sweetener use, hair dyes).   
 
1.7.2 Genetic risk factors 
There is no clear Mendelian inheritance pattern that can explain the observed two-fold 
increased risk of bladder cancer in first degree relatives of patients with the disease 
(Kiemeney 2008).  In a recent review by Pelucchi et al., first-degree relatives of bladder 
cancer patients were shown to have a 50-100% increased relative risk of developing the 
disease(Pelucchi, Bosetti et al. 2006).  The association seen in these relatives could 
simply be caused by a combination of similar environmental exposure to exogenous 
carcinogens and a large number of susceptibility genes with modest effects (Kiemeney 
2008).  
A link between genes such as glutathione-S-transferase (GST) and bladder 
cancer have been made.  GSTs are a family of isoenzymes which activate the 
detoxification of endogenous and exogenous agents and considering the environmental 
risks, are particularly relevant to bladder cancer risk.  GSTs will be discussed in more 
depth in section 1.8.3.  Epidemiological and meta-analysis studies have shown that 
glutathione-S-transferase mu 1(GSTM1) null genotype increases the overall risk of 
bladder cancer (Garcia-Closas, Malats et al. 2005).  The results of the pooled analysis 
and meta-analysis study by Engel and Taioli et al. suggest that persons with the 
GSTM1 null genotype are at increased risk of bladder cancer (Engel, Taioli et al. 
2002).  In a more recent study by Cengiz et al. it was also shown that the incidence of 
the GSTM1 null genotype was increased in bladder cancer patients compared to 
controls, however in this instance they showed no association between the 
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glutathione-S-transferase  theta 1(GSTT1) polymorphism and bladder cancer incidence 
(Cengiz, Ozaydin et al. 2007).  Meta-analysis of N-acetyltransferase 2 (NAT2) slow 
acetylation, GSTM1null genotype and bladder cancer risk by Garcia-Closas et a.l in 
2005 provides compelling evidence for the role of common polymorphisms such as 
GSTM1 and NAT2 slow acetylators in the aetiology of cancer, figure 1.12.  Showing 
that the GSTM1 null genotype increases the overall risk of bladder cancer and it was 
stated that although the relative risks are modest, these polymorphisms could account 
for up to 31% of bladder cancers because of their high prevalence.  The overall 
association for GSTM1 was robust (p<0.0001) and was not modified by smoking 
status (p for interaction 0.86), unlike the NAT2 which also increased overall risk of 
bladder cancer, but was stronger for cigarette smokers than for never smokers (p for 
interaction 0.008) (Garcia-Closas, Malats et al. 2005). 
 
 
 
 
 
 
 
 
Figure 1.12 The GSTM1 null genotype increases the overall risk of bladder cancer and it was stated 
that although the relative risks are modest, these polymorphisms could account for up to 31% of 
bladder cancers because of their high prevalence.  (Modified - Garcia-Closas et al. Lancet. 2005 Aug 
20-26;366(9486):610-12) (Garcia-Closas, Malats et al. 2005).  
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 1.8 Diet and Bladder Cancer 
Epidemiological studies have shown significant decreases in the incidences of bladder 
cancer in individuals with a high intake of cruciferous vegetables.  Zhao et al. 
epidemiological report showed that ITCs from cruciferous vegetable consumption 
protect against bladder cancer (Zhao, Lin et al. 2007).  Data from Michaud et al. 
indicated that many cruciferous vegetables were inversely related to bladder cancer 
risk, however only the associations for broccoli and cabbage were statistically 
significant (Michaud, Spiegelman et al. 1999).  In particular, it is thought that the 
naturally high intake of cruciferous vegetables in such countries as Japan and Singapore 
contribute to the low incidence of bladder cancer seen in these parts of the world (Ohno 
and Aoki 1980; Nakata, Sato et al. 1996).   
Many studies have highlighted the relationship between a decreased cancer risk 
and/or cancer progression and dietary intake of various foods such as cruciferous 
vegetable (Donaldson 2004), soy products (Takahashi, Hursting et al. 2006), green tea 
(Park and Surh 2004; Patel, Hotston et al. 2005) and red wine phenolics (Lopez-Velez, 
Martinez-Martinez et al. 2003; Kaur, Roberti et al. 2007).  Diet may have a greater 
impact on bladder carcinogenesis compared to other cancers, as many compounds 
contained in foods and their metabolites are ultimately stored in the bladder for periods 
of time at high concentrations before excreting through the urinary tract.  Cruciferous 
vegetables such as broccoli, cabbage and Brussels sprouts contain glucosinolates (GLS) 
(Mithen 2001),  a class of organic compounds which are responsible for the bitter or 
sharp taste of many common crucifers such as mustard, horseradish, and cabbage.  GLS 
often attain millimolar levels inside cells, which makes them one of the most highly 
concentrated class of intracellular antioxidant (LC 1998).   These GLS compounds are 
hydrolyzed to form bio- active isothiocyanates (ITCs), figure 1.13.  Glucoraphanin 
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accounts for 34%-60% of glucosinolates in broccoli and is converted to the ITC 
sulforaphane (Joseph, Moysich et al. 2004) and glucoiberin is converted to the ITC 
iberin, figure 1.13 & table 1.4.    
 
 
                                   
 
 
 
 
 
 
 
 
 
Figure 1.13 Biochemical pathway of glucoraphanin hydrolysis to bio-active sulforaphane.  
 
 
 
The primary route of in- vivo metabolism of ITCs is by the mercapturic pathway, a 
major pathway for elimination of many xenobiotics. The glucosinolate, glucoraphanin 
is sequestered within the intact vegetable tissue, figure 1.13. When the plant tissue is 
disrupted by physical damage e.g chewing, myrosinase (thioglucoside 
glucohydrolase) cleaves the thio-glucose bond giving rise to the unstable 
intermediate; thiohydroximate O-sulfonate.  This unstable intermediate undergoes 
further re-arrangement to form isothyocyantes (figure 1.13 showing sulforaphane). 
Most frequently, the unstable intermediate undergoes a lossen-type rearrangement to 
produce an isothiocyanate (Wittstock and Halkier 2002).  During cooking of brassica 
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the glucosinolate-myrosinase system may be modified as a result of inactivation of 
plant myrosinase, loss of enzymic cofactors such as epithiospecifier protein, thermal 
breakdown and/or leaching of glucosinolates and their metabolites or volatilisation of 
metabolites.  
Cooking of brassica affects the site of release of breakdown products of 
glucosinolates, which appear to be in the upper gastrointestinal tract following raw 
brassica consumption containing active myrosinase (Rungapamestry, Duncan et al. 
2007).  After consumption of cooked Brassica, devoid of plant myrosinase, 
glucosinolates are hydrolysed in the colon under the action of the resident microflora 
(Rungapamestry, Duncan et al. 2006).  Cooking by steaming, microwaving and stir-
fry has been shown not to result in a significant loss of glucosinolates and myrosinase 
activity is effectively lost after 2 min of microwave cooking and after 7 min of 
steaming (Rungapamestry, Duncan et al. 2006).  Whereas boiling showed significant 
losses by leaching into cooking water (Song and Thornalley 2007).  Most of the loss 
of the glucosinolates ( 90%) can be detected in the cooking water.  Therefore 
increased bioavailability of dietary isothiocyanates may be achieved by avoiding 
boiling of vegetables (Song and Thornalley 2007). 
 
 
 
 
 
 
 
 
 
 
Table 1.4 Major aliphatic glucosinolates and their hydrolysis products in broccoli. 
 
Results from some case control studies involving cruciferous vegetable intake 
and cancers such as prostate, and ovarian have reported confounded results.  Keum et 
Glucosinolates                    Hydrolyzed products             Trivial names  
Glucoiberin  
 
Glucoraphanin 
 
3(methylsulfinyl)-propane 
 
4-(methylsulfinyl)-butane
    
Iberin (IB) 
 
Sulforaphane (SF)           
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al. suggest this may be due to the remote location of the organs in the body, resulting in 
concentration of ITCs within these organs being at a very low level (Keum, Jeong et al. 
2004).  This may not be the case with bladder cancer, where the ITCs and ITC 
metabolites will be at comparably higher concentration and thus may exerting greater 
effects.  
 
1.8.1 Isothiocyanates and the Bladder 
Cruciferous vegetables high in isothiocyanates such as sulforaphane (4-
methylsulphinyl-butylisothiocyanate) and iberin (3-methylsulphinylpropyl 
isothiocyanate)  have been demonstrated to inhibit carcinogenesis by epidemiological 
studies and in a variety of rodent organs and cell models (Zhang Y 1994; Zhang, 
Munday et al. 2006), including rat bladder (Zhang, Munday et al. 2006).  The effects of 
the ITC sulforaphane (SF) and its metabolite N-acetylcysteine conjugate have been 
extensively studied.  Iberin (IB) has been far less studied and I am unaware of any work 
looking at its effects on bladder cancer. 
Cruciferous vegetables such as broccoli contain high concentrations of the 
glucosinolate glucoraphanin, which yield SF when hydrolyzed by the plant enzyme 
myrosinase.  The effect of SF, which occurs as the precursor glucosinolate in broccoli 
and other cruciferous vegetables, and its metabolite N-acetylcysteine conjugate has been 
extensively studied.  The effect of IB which occurs as the precursor glucosinolate 
glucoiberin and its metabolite N-acetylcysteine conjugate has been far less studied.  
Table 1.4 lists these major aliphatic glucosinolates and their hydrolysis products found 
in broccoli.  The anticancer activity of IB, SF and other ITCs lies partly in the induction 
of phase II enzymes of xenobiotic transformation, such as quinone reductase and 
glutathione S-transferase (GST).  These ITCs are substrates for phase II enzymes and 
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can also induce these enzymes, which may afford protection against certain 
carcinogens and other toxic electrophiles, including reactive oxygen species.  
Therefore it has been suggested that subjects with GST null genotypes (ie lacking 
enzyme activity), in particular GSTM1 null genotype, could benefit from greater fruit 
and vegetable consumption.  However a recent large scale case control study indicated 
a greater significant inverse associations with bladder cancer risk and high intakes of 
berries, liliaceae vegetables and yellow-orange vegetables among GSTM1 positive 
individuals compared to GSTM1 null indidiviuals (Garcia-Closas, Garcia-Closas et al. 
2007).  As Garcia-Closas points out the interaction maybe a false positive finding or 
could act through different mechanisms then previously suggested. 
 
1.8.2 Phase II enzymes 
Phase II enzymes are part of the body’s defence system against environmental 
substances and carcinogenic compounds, which can alter these toxic compounds and 
facilitate their excretion (Tijhuis, Visker et al. 2006).  Enzyme systems such as, UDP-
glucuronosyltransferases (UGT), quinone reductase (NQO1), glutathione s-transferase 
mu, glutathione s- transferase theta and glutathione s-transferase pi may afford 
protection against certain carcinogens and other toxic electrophiles, including reactive 
oxygen species.  Data from Munday and Munday also suggests that genetic and 
associated functional variation in these phase II enzymes, and also polymorphisms in 
receptors and transcription factors that interact with these compounds, may further 
contribute to variation in response to cruciferous vegetable intake (Munday and 
Munday 2004).  Genetic polymorphisms of these phase II enzyme may increase 
susceptibility to oxidative stress, therefore leading to an increase risk of chronic 
disease, meaning that a higher intake of micronutrients and active plant compounds 
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may be required to maintain health (Reszka, Wasowicz et al. 2006).  ITCs have the 
capacity to not only modulate these phase II enzymes but also to inhibit phase 1 
enzymes which are responsible for the bioactivation of carcinogens (Zhang Y 1994).  
Munday and Munday studies indicated that various ITCs, especially benzyl, are potent 
inducers of phase II enzymes in rat bladder tissue (Munday and Munday 2004). 
 
1.8.3 Glutathione S-transferase  
Glutathione S-transferases (GST) are a family of related isoenzymes that catalyse the 
conjugation of reduced GSH to a wide range of electrophilic substances (Mannervik 
1985).  There are seven distinct classes of soluble and membrane GSTs in humans - 
alpha, kappa, mu, omega, pi, sigma and zeta.  GSTs activate the detoxification of 
endogenous and exogenous agents.  Genetic polymorphism in these genes may change 
the response of individuals to environmental toxicants. 
The genetic polymorphisms of GSTT1, GSTM1 and GSTP1 have been studied 
extensively in the determination of cancer risks.  Some studies have shown a strong 
relationship between polymorphism of GSTs and cancer risk.  Zhang et al. recently 
showed that a broccoli sprout extract rich in several ITCs, particularly SF, was a potent 
inducer of GST in both rat bladder tissue in-vivo and cultured bladder cells in-vitro 
(Zhang, Munday et al. 2006).  Although the molecular mechanisms of action were not 
explored in this study, it is thought that GST enzymes are transcriptionally activated 
though Nrf2-dependent signalling pathway (Keum, Jeong et al. 2004; Keum, Jeong et 
al. 2005; Zhang, Munday et al. 2006).  It was shown that knockdown of Nrf2 in mouse 
embryonic fibroblasts completely abolished GST induction and markedly attenuated 
NQO1 induction (Zhang, Munday et al. 2006).  ITCs have been shown to activate this 
Nrf2/antioxidant response element (ARE) pathway (Thimmulappa, Mai et al. 2002), 
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figure 1.14, emphasised by Romos-Gomez et al. studies which showed that Nrf2 null 
mice eliminated induction of GST(Ramos-Gomez, Kwak et al. 2001). 
ARE
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Figure 1.14 Nrf2-dependent signalling pathway shows a model of the signalling pathways involved in 
activation of Nrf2. Nrf2 is tethered to Keap1 in the cytosol. Upon activation of upstream protein 
kinases (MAPKs, PI3K, PKC and PERK), and/or direct effect on Keap1, Nrf2 is released from Keap1 
and translocates into the nucleus, where Nrf2 binds to the ARE with association of small Maf proteins 
inside the nucleus leading to induction of phase II enzymes. Isothiocyanates also directly cause the 
cleavage of disulfide bond between Nrf2 and Keap, adapted from Keum et al. (Keum, Jeong et al. 
2004).  
  
 The mu family GST (GSTM), on chromosome 1p13.3, comprises GSTM from 1 to 
6.  Deletion of the GSTM1 gene is found in approximately 50% of Caucasians and 
Asians resulting in a lack of the GSTM1 enzyme activity and is associated with a risk of 
cancer and other diseases (Engel, Taioli et al. 2002).  However it was shown that 
patients with head and neck carcinoma have a suppressed total GST activity, but this 
did not correlate with GSTM1 genotype (Konig-Greger, Riechelmann et al. 2004), 
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therefore susceptibility to cancer maybe counterbalanced by overlapping substrate 
affinities within the GST family.  Also it maybe possible that susceptibility to cancer 
is affected by a variation in the combination of GST deletions and mutations and thus 
the resulting enzymes formed.   
 The most extensively studied GSTs, in relation to bladder cancer, are GSTM1 and 
GSTT1 null genotypes, the GSTpi (Ile105Val polymorphism/ Ala114Val 
polymorphism), and the GSTM3 3 base pair deletion genotype.  In tumours and 
adjacent mucosa of patients with TCC, three major cytosolic GST classes, Mu, Pi, and 
Theta, are expressed (Simic, Mimic-Oka et al. 2005).  Although the GST enzyme 
pattern in TCC was similar to that of the corresponding adjacent mucosa, during cancer 
progression a clear increase in all the GST subtypes expressed was noted (Simic, 
Mimic-Oka et al. 2005).  GSTP1-1 and GSTT1-1 activities were demonstrated in all 
bladder epithelial and TCC samples (24 patients), and GST Mu activity was 
detectable in 11 of 24 patients.  In the tumour specimens, significant upregulation of 
all expressed GST subtypes was observed.  
 A previous human intervention study investigating how broccoli consumption 
interacts with GSTM1 genotype was conducted in a healthy population (Gasper, Al-
Janobi et al. 2005), but there are no existing studies in populations with bladder cancer. 
 GSTP1 is frequently over expressed in many cancers, including tumours of the 
brain, breast, ovary, colon, skin and kidney (Cengiz, Ozaydin et al. 2007).  However 
GSTP1 has also been reported to be down regulated in particular cancers such as 
prostate, pituitary adenomas and breast (Beer, Evans et al. 2002) (Yuan, Qian et al. 
2008), to the extent that GSTP1 hypermethylation and thus the down regulation of 
GSTP1 in breast cancer is said to be a statistically significant prognostic factor (Arai, 
Miyoshi et al. 2006).   In TCC bladder tumour tissue significant up regulation of 
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GSTP1 expression was detected; showing the mean level of GSTP1 increasing by 2.3-
fold compared to the mean level in normal adjacent mucosa from 28 of 30 patients 
with TCC.   Moreover GSTP1 expression in TCC gradually increases with tumour 
grade and the difference in GSTP1 expression between superficial and muscle-
invasive tumours was also significant (Savic-Radojevic, Mimic-Oka et al. 2007).  A 
recent study conducted to determine the effect of polymorphisms on the disease 
course and clinical outcomes of urinary bladder neoplasm showed a lower chance of 
disease-free survival over a 5 year period, in patients diagnosed with TCC (≥T2) who 
genotyped with the variant allele than non-carriers of the GSTP1 (I105V) 
polymorphism (Sanyal, Ryk et al. 2007).  In contrast, loss of GSTP1 expression by 
promoter hypermethylation is a signature of prostate cancer (Jeronimo, Varzim et al. 
2002; Nakayama, Bennett et al. 2003; Nakayama, Gonzalgo et al. 2004; Rosenbaum, 
Hoque et al. 2005). 
 Distinct GST theta 1  activity has been demonstrated in normal human bladder 
epithelium, as well as its pronounced up regulation in TCC.  GSTT1-1 activity was 
demonstrated in 24 patients with TCC, from both tumour tissue and normal adjacent 
mucosa.  During cancer progression the mean GST theta 1 level in TCC was increased 
3.6-fold, compared with the mean level in the adjacent mucosa (Simic, Mimic-Oka et 
al. 2005).  A study investigating polymorphisms in DNA repair and metabolic genes 
in bladder cancer reported an association of increased bladder cancer risk with the 
GSTT1 null genotype (OR 2.54, 95% CI, 1.32-4.98, P 0.003) (Sanyal, Festa et al. 
2004). 
 The extent to which any one GST gene contributes to the actual GST activity in 
mammalian urinary bladders is less clear. Whilst the mouse bladder shows high 
GSTM1 activity, which occurs at its sharpest increase during early development, 
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studies suggest that the human bladder GSTM1 subunit even when present, represents 
a very minor fraction of the GST protein in human bladder (Chico and Listowsky 
2005).  However the GSTP1 gene has been detected in human bladder post-mortem 
tissue specimens and comprised at least 80% of the total cytosolic GST subunit pool.  
The human GSTM2 and GSTM3 subunits were also detected at much lower levels 
than GSTP1. 
 Although associations indicate that GST expression may have important 
protective functions in the bladder, an overexpression of both GSTP1 and GSTM1 in 
patients with TCC exhibit increased resistance to chemotherapeutic drugs (Hung, 
Boffetta et al. 2004). 
  
1.8.4 Apoptosis and Isothiocyanates 
Tang et al. showed that an aqueous extract of broccoli sprout inhibited the growth of 
human bladder carcinoma cells in-vitro, showing potent anticancer activity at 7.5 to 
30µmol/L ITC concentration.  Also another recent study showed that sulforaphane 
suppressed the growth of T24 bladder cancer cells in-vitro in a dose-dependent manner 
(Tang and Zhang 2004).   
The activation of the Nrf2/antioxidant response element (ARE) pathway is not 
the only potential chemopreventative mechanism elicited by ITCs, for example 
induction of apoptosis and cell cycle perturbations have also been extensively studied in 
bladder cancer.  Sulforaphane has been show too suppress proliferation of bladder cell 
growth in culture as well as in-vivo by inducing apoptosis (Tang and Zhang 2004).  Bax 
and Bak have been shown to play a critical role in apoptosis induction by sulforaphane, 
as well as irreversible arrest in the G (2)/M phase of the cell cycle, but the sequence of 
events leading to cell death appears to be poorly defined, refer to figure 1.15. 
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Figure 1.15 The cell cycle, adapted from Leland H. Hartwell, R. Timothy Hunt and Paul M. Nurse 
diagram.  
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1.9 Nutritional cell culture studies and the rational for studying the role of diet and 
nutrition in relation to bladder carcinogenisis  
Identifying bioactive compounds, such as Isothyocyanates, and establishing their health 
effects are active areas of scientific inquiry. There are exciting prospects that select 
bioactive nutritional compounds will reduce the risk and/or progression of many 
diseases, including chronic diseases such as bladder cancer. However many different 
environmental factors may affect the bladder in-vivo; these include diet, medication, 
stress, age and general life style choices, such as smoking and exercise. Due to the 
potential number of bioactive compounds consumed in our diet the diversity of 
biological effects of diet alone on the bladder are vast and as such, cells in culture may 
behave differently from cells in-vivo in many ways . A further problem is the possibility 
that the cell culture media can catalyse the oxidation of compounds added to them, 
resulting in apparent artefactual cellular effects which would not be observed in-vivo. 
Furthermore it should be remembered that in this study, cell cultures are treated with 
concentrations of the pure compound, whereas in-vivo exposure to this compound 
would be accompanied by a diverse mixture of compounds.  As such caution must be 
taken when extrapolating findings from cell culture studies to the possible effects of a 
single compound in-vivo. 
It is fair to say that little work has been carried on bladder cancer in relation to 
diet in comparison to other cancers such as breast and prostate. The underlying rationale 
for studying the role of diet and nutrition in relation to bladder carcinogenisis is for two 
main reasons. Firstly, because the impact of nutrition on bladder carcinogenisis is 
entirely plausible since most substances or metabolites, including carcinogens, are 
excreted through the urinary tract and stored in the bladder. Previous studies have 
shown that isothyocyantes are primarily metabolised through the mercapturic acid 
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pathway, and their metabolities are bioactive and almost exclusively excreted and 
stored in the bladder adjacent to the epithelial tissue were most bladder cancer arises 
(Zhang 2004). Secondly, although bladder cancer has a lower insistence than other 
cancers such as breast and prostate, the rate of reoccurance is significantly higher and as 
such makes bladder cancer the most expensive of all cancers to treat from diagnosis to 
death  (Botteman, Pashos et al. 2003). A systematic review of available literature on the 
economic burden of bladder cancer in develping countries states that indiviual patient 
management is more costly for bladder cancer than for prostate cancer (mean cost per 
patient - £8349 vs.£7294, respectively) but less is invested in research than for prostate 
cancer (Botteman, Pashos et al. 2003; Sangar, Ragavan et al. 2005). The annual 
research fund allocated to bladder and prostate cancer in the year 2001-2002 were 20.56 
million UK pounds and 4.62 million pounds respectively (Sangar, Ragavan et al. 2005). 
The report suggests a need to re-evaluate future statigies for cost effectiveness in cancer 
research and more interventions aimed at reducing the ecomomic burden of bladder 
cancer. 
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1.10 Aims 
Transitional cell carcinoma is a common malignancy characterized by a poor clinical 
outcome when tumours progress from superficial disease into invasive disease.  The 
majority of bladder cancer mortality is associated with invasion into the bladder wall 
leading to metastatic disease.  Diet may have a greater impact on bladder 
carcinogenesis compared to other cancers, as many compounds contained in foods and 
their metabolites are ultimately stored in the bladder for periods of time at high 
concentrations.  I sought to define genes or gene profiles which are modulated in 
invasive disease and to assess the potential effects of selected isothiocyanates on the 
invasive potential of bladder cancer. 
The following aims were set at appropriate stages through out the project: 
1) To characterise superficial and invasive bladder tissue.  To compare global gene 
expression profiles between superficial and invasive transitional cell carcinoma and 
define gene expression profiles or selective genes that are characteristic of aggressive 
clinical behaviour in invasive bladder tumours for further studies in-vitro. 
2) To characterise human bladder cell cultures and assess the effects of sulforaphane 
and iberin and their N-acetylcysteine conjugate on phase II gene expression. 
3) To use whole genome array analysis to enable the identification of genes which are 
modulated by a short term dietary intervention in bladder tissue from patients with 
recurring bladder cancer, and to select genes for further studies in-vitro.  
4) To investigate the effects of sulforaphane, iberin and their conjugates on the cellular 
motility of the characterised UM-UC-3 cell line and their potential capability to reduce 
invasion into extracellular matrix.  
5) To evaluate the differential expression of Tn-C splicing domains in human 
transitional cell carcinoma of the bladder with respect to the invasive behaviour. 
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Chapter Two 
General Methods and Materials 
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2.1 Cell Culture 
Human bladder cancer UM-UC-3 and RT4 cells were purchased from the European 
Collection of Cell Cultures (ECACC) and grown in EMEM and McCoy’s (Sigma-
Aldrich UK) medium respectively, supplemented with 2mM L-glutamine (Sigma-
Aldrich UK), 5mg/ml penicillin/streptomycin antibiotics and 1X non essential amino 
acids (Invitrogen).  UM-UC-3 and RT4 cells were also supplemented with 10% (v/v) 
foetal bovine serum. All cells were maintained in an incubator at 37◦C with 5% CO2 
and according to the experimental design cells were grown in 6 well plates, 12 well 
plates, 6 well transwell or 10cm dishes.  See table 2.1 for the recommended volume of 
media for each culture plates.  Iberin and Sulforaphane were purchased from LKT 
Laboratories. Cell treatments occurred in complete media with less than 0.1% 
dimethyl sulphoxide (DMSO, Sigma-Aldrich). Each treatment, including control 
treatment was carried out in three separate wells to produce three biological replicates.  
 
Size of cluster 
plate/dish/flask 
Growth area 
(cm2) 
Relative area Recommended 
volume of media 
96 well 0.32 0.04 x 200µl 
24 well 1.88 0.25 x 500 µl 
12 well 3.83 0.50 x 1.0ml 
6 well 9.4 1.20 x 2.0ml 
24 transwell 0.33 0.04 x 100 µl (insert) 
3.5 cm dish 8 1.0 x 2.0ml 
6cm dish 21 2.6 x 5.0ml 
10cm dish 55 7.0 x 10.0ml 
T25 flask 
T75 flask 
25 
75 
3.0 x 
9.0 x 
5.0ml 
20.0ml 
Table 2.1 Culture plate conversions. Dependent on the experiments requirements the following culture 
plates were used and the recommended volume of media. 
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2.1.1 Cell viability Assay WST-1 
The Roche WST-1 assay is a colourimetric assay for the quantification of cell 
proliferation and cell viability. The assay can be used to measure cell proliferation in 
response to nutrients and also to analysis the potential cytotoxic effects of such 
compounds at varying doses to find an optimal treatment concentration. The assay uses 
the principle that tetrazolium salts are cleaved to formazan by cellular enzymes. An 
expansion in the number of viable cells results in an increase in the overall activity of 
mitochondrial dehydrogenases in the sample. This augmentation in enzyme activity 
leads to an increase in the amount of formazan dye formed, which directly correlates to 
the number of metabolically active cells in the culture. Cell viability assays were 
performed for UM-UC-3 and RT4 cell lines. Cells were seeded in 96 well plates and 
treated at 70-80% confluence with 0 to 30µM of SF, IB or their conjugates in a total 
volume of media with less than 0.1% DMSO. Six biological replicates were performed. 
After 24 hours treatment, 10% of WST-1 reagent was added and further incubation at 
37◦C, 5% CO2 until a colour reaction occurred. The absorbance was measured at a 
wavelength of 420-480 nm using a reference value of 600 nm against a blank on the 
Dynex 96 well microplate reader. The cell viability of treated cells was calculated as a 
percentage of the control cells. The value at which half the cells will die, the IC50, was 
calculated using CalcuSyn Statisics package. 
 
2.1.2 Cell counting using a counting Chamber 
A counting chamber can determine the number of cells per unit volume of a suspension. 
In this particular instance a hemocytometer was used, so named as it was originally 
designed for performing blood cell counts.   
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Figure 2.1 Diagram of counting chamber  
A coverslip is placed over the counting surface prior to introducing the cell 
suspension.  The suspension is introduced into one of the V-shaped wells with a pipette 
and the area under the coverslip filled by capillary action, see figure 2.1.  The counting 
chamber was then placed on the microscope stage and the counting grid was brought 
into focus at low power.  One entire grid on standard hemacytometers with Neubauer 
rulings can be seen at X40 magnification, as seen in figure 2.2.  The main divisions 
separate the grid into 9 large squares.  Each square has a surface area of one square mm, 
and the depth of the chamber is 0.1 mm.  Thus the entire counting grid lies under a 
volume of 0.9 mm-cubed.  Microscope magnification was set at X100 (10 X ocular and 
10X objective) for UM-UC-3 cells.  Cells were systematically counted in the four large 
corner squares so that the total count is approximately 100 cells.  For cells that 
overlapped a ruling, a cell was counted as "in" if it overlapped the top or right ruling, 
and "out" if it overlapped the bottom or left ruling.  
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39 cells 
counted
43 cells 
counted
40 cells 
counted
37 cells 
counted
 
Figure 2.2 Counting grid with Neubauer rulings 
Each large square of the hemocytometer, with cover-slip in place, represents a 
total volume of 104.  Since 1 cm3 is equivalent to approximately 1 ml, the total number 
of cells per ml will be determined using the following calculations:  
Cells/ml = average cell count per square x 104;  
Total cells = cells/ml x the original volume of fluid from which the cell sample was 
removed. 
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2.2 RNA stabilization in frozen tissue bank bladder tissue with RNAlater-ICETM 
RNALater™ ICE stabilizes and protects RNA and thus gene transcription in fresh and 
frozen tissue specimens, so that the RNA can be extracted at a later stage.  The 
bladder tissue obtained from the NNUH tissue bank was stored at -20 °C in RNAlater-
ICE, to enable both DNA and RNA extraction. 
The RNAlater-ICE was chilled for 24 hours at -80 °C. Following this 24 hour 
period the RNAlater-ICE was placed on dry ice. The tissue samples were removed 
from the -80 °C freezer and the weight of tissue was estimated (weighed precisely 
following RNAlater-ICE incubation) to determine the approximate volume of 
RNAlater-ICE needed to preserve the tissue sample (10 µl of reagent per 1mg of 
tissue). The appropriate volume of RNAlater-ICE was dispensed directly into the tube 
containing the tissue, assuring the tissue was completely submerged and floated freely 
in tube. The lid was secured and the sample was placed in the -20 °C freezer.  
Biopsies were incubated at -20°C overnight before being analysed. Steps were 
performed as quickly as possible. 
 
2.3 DNA extraction from human bladder cell lines 
DNA was extracted using the QIAGEN DNeasy mini kit (Qiagen, UK), according the 
manufacturer’s instructions.  Bladder cells were grown in a monolayer to 80% 
confluency, media was removed and the layer was washed twice with warmed PBS.  
200µl of warmed PBS was added to the dish and the cells were removed using a 
scraper into a 2ml centrifuge tube.  20µl of proteinase K was added to the lysate and a 
200µl of AL buffer was added, mixed by vortexing and incubated at 56 °C for 10 min.  
200µl of 96 % ethanol was added to the sample and mixed thoroughly by vortexing.  
The mixture was added to the DNeasy mini spin and centrifuged at 13000g for 1 min.  
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The flow through was discarded and the column was placed into a new collection 
tube.  500µl of AW1 buffer was added to the spin column and centrifuged at 13000g 
for 1 min. The flow through and collection tube was discarded.  500 µl of AW2 buffer 
was added to the column and once again centrifuged at 13000g for 3 min to dry the 
membrane.  The spin column was placed into a new 1.5 ml microcentrifuge tube and 
200 µl of AE buffer was added directly onto the membrane.  The column was 
incubated at room temperature for 1min and then centrifuged at 13000g to elute DNA.  
DNA was quantified using a spectrophotometer and stored at -20 °C until analysis. 
  
2.4 RNA extraction from human bladder cell lines 
RNA was extracted using the QIAGEN RNeasy mini kit (Qiagen UK), according the 
manufacturer’s instructions.  Bladder cells were grown in a monolayer to 70-80 % 
confluency, media was removed and the monolayer was washed twice with warmed 
PBS.  350µl of RLT/ β-Mecaptoethanol (10µl β-ME per 1 ml of RLT buffer) was 
added to the dish and cells were collected with a cell scraper.  The lysate was 
dispensed into a microcentrifuge tube, vortexed and dispensed directly into a QIAgen 
QIAshredder and centrifuged for two minutes at full speed.  The lysate was removed 
and transferred into new microcentrifuge tube.  350µl of 70 % ethanol was added to 
the lysate and mixed immediately by pipetting.  The 700µl sample was transferred to 
an RNeasy MiniElute spin column which was placed in a 2 ml collection tube and 
centrifuged for 15s at 13000g.  The flow through was discarded and the 2 ml 
collection tube reused.  700µl of RW1 buffer was added to the column and 
centrifuged for15 s at 13000 g. The flow though was discarded and a the column was 
placed in a new collection tube 500µl of RPE buffer was added to the column and 
once again centrifuged for 15 s at 13000g. The flow through was discarded and 500µl 
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of 80 % ethanol was added to the column and centrifuged for 2 min at 13000g to dry 
the silica-gel membrane.  The spin column was transferred to a new collection tube; 
the cap was opened and centrifuged at 13000 g for 5 min.  Any flow through was 
discarded and the spin column was placed into a 1.5 ml tube.  To elute the RNA, 14µl 
of RNase-free water was added directly to the centre of the silica membrane and the 
column was centrifuged for 1 min. All RNA samples were stored at -80 °C until 
analysis.  
 
2.5. DNA extraction from human bladder tissue  
DNA was extracted using the QIAGEN DNeasy blood & tissue kit (Qiagen, UK), 
according the manufacturer’s instructions.  Two heating blocks were set at 56 °C and 
the other to 70°C prior to the experiment.  The tissue samples and buffer AE were 
allowed to equilibrate to room temperature.  The tissue was removed with sterile 
forceps and blotted to remove excess RNAlater solution.  On the sterile glass slide, 
10-25 mg of tissue was washed with PBS, blotted then cut into small pieces and 
placed in a 1.5 ml microcentrifuge tube.  180µl of buffer ATL and 20 µl of proteinase 
K was added to the tissue and mixed by vortexing.  The sample was incubated at 56 
°C for 1-3 hours, vortexing occasionally to disperse the sample.  Following incubation 
the sample was briefly centrifuged to remove droplets from inside the lid.  4µl of 
RNase A was added, pulse vortexed for 15 sec and incubated for 2 min at room 
temperature.  The sample was briefly centrifuged before adding 200µl of buffer and 
mixed again by pulse vortexing for 15 sec followed by an incubation at 70 °C for 10 
min.  The sample was briefly centrifuged again prior to adding 200µl of 100% 
ethanol, mixed by pulse vortexing for 15 sec and briefly centrifuged.  The mixture 
was carefully applied to the QIAamp Spin column.  The cap was closed and spun at 
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6000 g for 1min.  The column was placed in a clean 2 ml collection tube and the 
filtrate was discarded.  500 µl of buffer AW1 was added and column was centrifuged 
at 6000 g for 1min, placing the column in a clean 2 ml collection tube and the filtrate 
was discarded.  500 µl of buffer AW2 was added and the column was centrifuged at 
13000 g for 3 min.  The column was placed in a clean 2ml collection tube and the 
filtrate discarded.  The column and filter was centrifuged again at 13000 g for a 
further 1 min to eliminate carryover.  The column was placed in a clean 2 ml 
collection tube and any filtrate discarded.  200µl of buffer AE was added to the 
column and incubated at room temperature for 5 min.  The column was centrifuged at 
6000 g for 1min.  This collection tube was capped and put to one side.  The column 
was placed in a clean 2 ml collection tube and a further 200 µl of buffer AE was 
added and incubated at room temperature for 5 min.  The column was centrifuged at 
6000 g for 1 min and the filtrate was mixed with the filtrate in the tube which had 
been set aside. The DNA was eluted in a total of 400 µl of AE buffer.  
 
2.6 RNA extraction from human bladder tissue 
Total RNA was extracted from the biopsies following an overnight incubation at -20 
°C in RNAlater-ICETM.  Total RNA isolation was performed using the QIAGEN 
RNeasy micro or mini kit, protocol for fibrous tissue, according to the manufacturer’s 
instructions.  RNeasy micro or mini kits for RNA extraction were used according to 
tissue biopsy size. (Micro < 5 mg – Mini 17 mg – 20 mg) 
All surfaces were wiped with RNA ZAP to remove all RNase contamination 
from surfaces.  β-Mecaptoethanol (β-ME) was added to the RLT buffer prior to use 
(10 µl β-ME per 1ml of RLT buffer) and 80 % ethanol was prepared with the RNase-
free water.  The tissue was removed with sterile forceps and blotted to remove excess 
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RNAlater solution.  On a sterile glass slide, 5-15 mg of tissue was cut into small 
pieces and placed in a 1.5ml microcentrifuge tube.  350 µl of buffer ATL/ β-ME mix 
was added to the tissue and the microcentrifuge tube was placed on ice.  The tissue 
was disrupted and homogenized using a rotor-homogenizer until it was uniformly 
homogeneous (15-30 sec) and this homogenised sample was centrifuged for 3 minutes 
at full speed, the supernatant was carefully removed and transferred into new 
microcentrifuge tube.  350 µl of 70% ethanol was added to the lysate and mixed 
immediately by pipetting.  The 700 µl sample was transferred to an RNeasy MiniElute 
spin column which was placed in a 2ml collection tube and centrifuged for 15 sec at 
≥8000 g. The flow through was discarded.  350µl of RW1 buffer was added to the 
spin column and centrifuged for 15 sec at ≥8000 g to wash the spin column.  10 µl of 
DNase 1 stock solution was added to 70 µl RDD and mixed by inverting to form the 
DNase 1 mix.  This DNase 1 mix was pipetted onto the RNeasy MiniElute silica gel 
membrane and incubated at room temperature for 15 minutes.  350µl of RW1 buffer 
was added to the spin column and centrifuged for 15 sec at ≥8000 g to wash the spin 
column.  The RNeasy MiniElute spin column was transferred into a new 
microcentrifuge collection tube and 500µl of RPE buffer was added to the spin 
column and centrifuged for 15 sec at ≥8000 g.  500 µl of pre-prepared 80% ethanol 
was added to the spin column and centrifuged for 2 minutes for 15 sec at ≥8000 g to 
dry the silica gel membrane and the RNeasy MiniElute spin column was transferred to 
a new 2ml collection tube and centrifuged at full speed for 5 minutes with the lid open 
to further dry the silica gel membrane.  The RNeasy MiniElute spin column was 
transferred to a new 1.5 ml collection tube and 14 µl of RNase-free water was pipette 
directly onto the centre of the RNeasy MiniElute spin column silica gel.  The lid was 
closed and centrifuged for 1 min at maximum speed.  The concentration and the purity 
57 
 
of the RNA eluted was determined initially, using a spectrometer, as with the DNA 
extractions.  Concentrations were determined at an absorbance of 260 nm and the 
purity of DNA elute was determined by the A260/A280 ratio.   
RNA profiling techniques such as real time RT-PCR and microarray analysis 
require generation of a cDNA copy of the RNA sample through a reverse transcription 
reaction. Therefore, good RNA quality is essential for the success of these 
applications because degraded RNA or RNA that contains impurities will perform 
poorly in most enzymatic applications. 
 
2.7 Measurement of DNA and RNA concentration and quality 
DNA concentration and purity was assessed using a spectrometer. The concentrations 
were determined at an absorbance of 260nm and the purity of DNA elute was 
determined by the A260/A280 ratio. Samples were stored at -20°C for later use.  
 
2.7.1 Using the Nanodrop Spectrophotmeter 
'Nucleic Acid Measurements' was selected from the Nanodrop software menu.  1 µl of 
RNAse free water was added and 'Blank' was pressed.  The blanking was repeated 
until there was a stable baseline, close to zero.  The baseline was confirmed by 
measuring 1 µl of water, as if it were a first sample.  1 µl of the RNA was added and 
the instrument initialised.  After each and all subsequent measurements the pedestal 
was cleaned by wiping with a dry lint-free tissue.  The baseline was reconfirmed to be 
correct after the last sample by measuring 1 µl of RNAse free water. 
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2.8 RNA Integrity – Agilent Bioanalyser 
Although mRNA is often the RNA species of interest, the fact that mRNA only 
comprises 1-3% of total RNA sample makes assessing the integrity of mRNA difficult 
in a total RNA sample. Good quality RNA will have an OD 260/280 ratio of 1.8 to 2 
and an OD 260/230 of 1.8 or greater. This is because nucleic acid is detected at 260 
nm, whereas protein, salt and solvents are detected at 230 and 280 nm. A high OD 
260/280 and OD 260/230 ratio therefore indicates that you have extracted RNA 
devoid of any of these contaminants. Degraded RNA should not be hybridised to 
GeneChips for array analysis, therefore it is important to assess the quality of RNA. 
  One can use northern analysis or RT PCR to study only the integrity of an 
individual transcript in a RNA sample.  Since the ribosomal RNA (rRNA) makes up 
more than 80% of total RNA samples, the integrity of the major rRNA species (18S 
and 28S for mammalian rRNA) is used to assess the RNA sample integrity. This can 
be done by analyzing total RNA sample by denaturing agarose gel electrophoresis. 
The ethidium bromide-staining pattern of intact total RNA will have clearly defined 
28S and 18S rRNA bands.  The ratio of 28S:18S band intensities should be close to 2. 
Partially degraded RNA appears as smeared rRNA bands with increasing lower 
molecular weight smear.  However the Agilent 2100 Bioanalyser (Agilent 
Technologies) is an alternative tool that provides better and more consistent 
assessment of total RNA quality.  The instrument uses a combination of a nucleic acid 
intercalating dye and capillary electrophoresis to analyze both RNA concentration and 
integrity simultaneously.  Agilent RNA kits contain chips and reagents designed for 
analysis of RNA fragments.  Each RNA chip contains an interconnected set of 
microchannels that is used for separation of nucleic acid fragments based on their size 
as they are driven through it electrophoretically.  The sample passes through these 
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microchannels into the separation channel, the RNA fragments are separated 
according to their size by means of molecular sieving and the fragments are detected 
by florescence peak that is greater in area compared with the 18S peak. An example 
of an eletropherogram is shown in figure 2.3 
 
Time (seconds) 
Figure  2.3 Example of an electropherogram showing good quality RNA generated by the Agilent 
2100 Bioanalyzer. 
 
 
2.8.1 Preparing sample for the 6000 Nano Chip 
All reagents were allowed to equilibrate to room temperature for 30 minutes.  Dye and 
dye mixtures were protected from light at all time by wrapping in tin foil.  The RNA 
6000 Nano gel matrix gel was prepared by pipette 550 µl of gel into a spin filter and 
centrifuging at 1500 g ± 20 % for 10 minutes at room temperature.  65 µl the filtered 
gel was pipetted into 0.5 ml RNase-free microcentrifuge tubes. The RNA 6000 Nano 
dye concentrate was vortexed for 10 seconds, spin down and 1 µl of the dye was 
added into a 65 µl aliquot of filtered gel.  The gel-dye mix was vortexed well and 
centrifuged at 13000 g for 10 min at room temperature.  All RNA samples and RNA 
ladder were denatured before use by heating to 70°C for 2 minutes.  The RNase 
decontamination procedure for the electrodes was performed before running the assay.  
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A new RNA 6000 Nano chip was put on the chip priming station and 9 µl of the gel-
dye mix was pipetted in the appropriate well. See figure 2.4 for graphical 
representation. 
 
9.0 µl gel-dye 
mix
9.0 µl gel-dye mix
9.0 µl gel-dye mix
1 µl ladder
1 µl of 
Samples 
plus 5 µl
Nano 
Marker 
 
Figure 2.4 RNA 6000 Nano chip 
 
2.8.2 Using the Agilent 2100 bioanalyzer 
The chip priming station was closed and plunger was pressed down until it was held 
by the clip. The release clip was released after exactly 30 seconds.  A further 9.0 µl of 
the gel-dye mix was pipetted into appropriately marked wells and the remaining gel-
dye mix was discarded.  5 µl of the Agilent RNA 6000 Nano Marker was loaded in all 
12 sample wells and in the well marked ‘ladder’.  1 µl of the prepared ladder was also 
loaded into the well marked ‘ladder’.  1 µl of sample was loaded in each of the 12 
sample wells and 1 µl of RNA 6000 Nano Marker was loaded into each unused 
sample well.  The chip was put horizontally in the adapter and vortex for 1 min at 
2400 rpm and run on the Agilent 2100 bioanalyzer within 5 min.  
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2.8.3 Concentration and clean-up of RNA samples for array hybridisation and 
analysis 
The RNA extracted from the biopsy samples was concentrated using QIAgen RNeasy 
MiniElute Cleanup Kit according to the manufactures instructions (Qiagen, UK).  
 
2.9 Array hybridisation and Dchip analysis 
The RNA extracted from the biopsy samples was concentrated, and its quality 
assessed using the Agilent 2100 Bioanalyser.  If there was insufficient quantity the 
RNA was amplified via PCR (array 2, intervention samples chapter 7).  Microarrays 
are used to detect the transcript levels of thousands of genes simultaneously; the 
working principle of the technique is based on duplex (hybridnisation) between target 
RNA extracted form cell lines or tissues and complementary short DNA-nuclotides 
oligomers grafted to thre solid surface of the chip (Zhu 2003)). Targets bound to the 
probe-ologomers are detected using florescence labels. RNA of sufficient quantity and 
quality was hybridised onto human Affymetrix U133 Plus 2.0 probe arrays at the 
Nottingham Arabidopsis stock centre, University of Nottingham. The arrays carries 
>47,000 transcripts, expression profiling was performed for each transcript and the 
data produced was analysed using DNA-Chip analyser 2006 software (dChip) (Li and 
Wong 2001).  Double stranded synthesis and generation of biotin-labelled cRNA was 
performed according to the manufactures protocol (Affymetrix Inc).  The fluorescence 
intensity for each chip was captured with an Affymetrix HP GeneArray laser confocal 
scanner (Agilent, UK).   
The raw files generated containing the summary intensities for each probe was 
loaded into the dChip 2006 software, for normalisation, generation of expression 
values and statistical analysis.  Following normalisation, probe expression levels was 
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calculated MM (perfect match-miss match substraction) model and the PM-only 
model showed that applying the later model consistently produces less variable results 
and the PM only model is more suited to this type of study (Li and Hung Wong 2001). 
The PM probe binds cDNA exactly, forming exclusively Watson-Crick pairing, 
whereas the MM probe has a single base difference in the middle of the probe giving 
rise to self-complementary pairing. Therefore, the the PM pairing produces a 
higher/brighter signal than that of the MM pairing, as the stability of the Watson-
Crick pairing is always stronger than that of the self-complementary pairing. Probe 
intensity values need to be normalised to adjust the brightness of the arrays to a 
comparable level as different arrays produce different image brightness and so are 
generally not comparable. dChip chooses an array with a median overall intensity, as 
measured by the median CEL intensity in an array, as the baseline array against which 
other arrays are normalised at the probe intensity level. The dChip software uses the 
Invariant Set Normalization method, which chooses a subset of PM probes with small 
within-subset rank difference in the two arrays (baseline and target), to serve as the 
basis for fitting a normalization curve. The normalized curve is used to generate new 
normalized values for every probe on the chip.  
After normalization the expression levels were calculated using the PM model. 
Three comparisons criteria were applied to the data to detect differentially expressed 
genes by model based expression: 1) the fold change between the group means was 
chosen to exceed a specific threshold 2) absolute difference between the two groups 
means was set to > 100 to eliminate the low expressing genes that have intensity close 
to the background levels and 3) a chosen p – value for Welch modified 2-sample t-
test, adjusted to compensate for multiple testing using False discovery rate (FDR). 
False discovery rate testing is a method used in multiple hypothesis testing as a means 
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to correct for multiple comparisons to gain more confidence in the statistical analysis 
of the data. The FDR is the expected false positive rate, in dChip the FDR was 
estimated by a 1000 permutations. This assess how many probes would be obtained 
by the same comparison criteria when permuting group labels rendomly by 1000 
times, that is 1000 observations were experimentally predicted to be different, and a 
maximum FDR for these observations was 0.10, then 100 of these observations would 
be expected to be false positives. After 1000 permutations, there will be 1000 values 
generated. The median of these 1000 values is reported as the median false discovery 
rate (MFDR) and the 90th percentile (90th largest value) of these 1000 values is 
reported as 90% FDR. Although many comparison criterions were applied to the data 
to detect differentially expressed genes by model based expression, only the more 
stringent criteria is shown in this thesis (fold change of 2, p-value of 0.001 and an 
absolute difference between the two groups means was set to > 100) so as to provide a 
manageable data lists 
After obtaining model-based expression values, unsupervised hierarchical 
clustering was performed using a list of genes obtained by filtering probes using the 
criteria of standard deviation divided by the mean between 0 and 1000 across the 
samples. Unsupervised clustering analysis is used to identify novel sample clusters 
and their associated “signature genes” and to see if replicate samples or samples under 
similar conditions are clustered together. 
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2.10 Primer and Probe design 
Forward and reverse primers, and the fluorogenic TaqMan probes for target genes, 
were designed using Primer Express Software (Applied Biosystems). Sequence 
homology of selected oligomers was checked using a National Centre for 
Biotechnology Information BLAST search to ensure that sequences will be specific to 
target genes. Primer and probe sets were synthesised by SigmaGenosys and assays 
optimised.  A 5 µM solution of probe and a 10 µM solution of primers were made 
with double autoclaved RNase free water for regular use. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2 Primer and probe sequences used the real time RT-PCR and PCR assays. Primers and probes were designed to be intron spanning and human specific. 
 
  
Forward primer Sequence 
(5’-3’) 
Reverse primer Sequence 
(5’-3’) 
Probe Sequence 
(5’-3’) 
CO6A1 TGCATAGACAAGAAGTGTCCAGATT GGAGCCGTCCAGCAGGAT CTGCCCCATCACGTTCTCCTCCC 
Moesin GCTACCTGGCCGGAGACA CCACTGGTCCTTGTTGAGTTTG TTGCTCCCGCAGAGAGTCCTG 
P4HA1 ATTATGGAGTTGGAGGACAGTATGAA CTTTGAAAGCATCTGGCTCATCT CCCATTTTGACTTTGCACGGA 
GSTP1   
 
GSTM1 GGAGACAGAAGAGGAGAAGATTCG TGCCCAGCTGCATATGGTT TCCATGGTCTGGTTCTCCAAAATGTCCA 
GSTM1 A*/B* TTCACGTGTTATGGAGGTTCCA GGGAGATGAAGTCCTTCAGATTTG AAGCACTTGGGCTCA 
GSTT1 CCTGGCAGAGTTGGATGTGA GGAGATGTGAGGACCAGTAAGGA CCTGCAGTTGCTCGAGGACAAGTTCC 
GSTM3 A*/B* GCCGGGGAAAAGGTAGGAA AGGAGTAGTAGCCTGCAGAGATAGAGA AGGGAAAAGAAGAGGAT 
18S GGCTCATTAAATCAGTTATGGTTCCT GTATTAGCTCTAGAATTACCACAGTTATCCA TGGTCGCTCGCTCCTCTCCCAC 
BRCA1 GTCTGCTTTTACATCTGAACCTCTGT AGCCCTGAGCAGTCTTCAGAGA ACTCTCACACCCAGATGCTGCTTCACCT 
  
2.11 TaqMan Real Time polymerase chain reaction (PCR) 
DNA extracted from either bladder biopsy tissue or cell lines were amplified using 
real-time PCR.  Target gene levels were determined by real-time PCR using the 7500 
or 7700 Sequence Detection System (Applied Biosystems, Foster City, CA).  The 
PCR reactions were carried out in a microamp optical 96-well plate in a total volume 
of 25µl per well containing TaqMan one-step PCR master mix reagent (Applied 
Biosystems).  The TaqMan real time PCR chemistry allows detection of PCR 
products via the generation of a fluorescent signal.  TaqMan probes depend on Förster 
Resonance Energy Transfer (FRET) to generate the fluorescence signal via the 
coupling of a fluorogenic dye molecule and a quencher moeity to the same or 
different oligonucleotide substrates.  TaqMan probes depend on the 5'- nuclease 
activity of the DNA polymerase used for PCR to hydrolyze an oligonucleotide that is 
hybridized to the target amplicon.  TaqMan probes are oligonucleotides that have a 
fluorescent reporter dye attached to the 5' end and a quencher moeity coupled to the 3' 
end.  These probes are designed to hybridize to an internal region of a PCR product.  
In the unhybridized state, the proximity of the fluor and the quench molecules 
prevents the detection of fluorescent signal from the probe. During PCR, when the 
polymerase replicates a template on which a TaqMan probe is bound, the 5'- nuclease 
activity of the polymerase cleaves the probe.  This decouples the fluorescent and 
quenching dyes and FRET no longer occurs.  Thus, fluorescence increases in each 
cycle, proportional to the amount of probe cleavage.  The threshold cycle (Ct) is 
defined as when the fluorescence signal reaches ten-times the noise signal level 
(baseline).  
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2.11.1 GSTM1, GSTM3 and GSTP1 Allelic Discrimination Assay 
An allelic discrimination assay is a multiplexed, end-point assay that detects variants 
of a single nucleic acid sequence.  A multiplexed assay is one that uses more than one 
primer/probe pair per reaction.  The presence of two primer/probe pairs in each 
reaction allows genotyping of the two possible variants at the single-nucleic 
polymorphism (SNP) site in a target template sequence.  This is a qualitative assay as 
the actual quantity of target sequence is not determined.  For each sample a unique 
pair of florescent detectors is used.  One florescent dye detector is a perfect match to 
the wild type (allele 1) and the other florescent dye detector is a perfect match to the 
mutation (allele 2).  The assay measures the changes in florescence of dyes associated 
with the probes.  For example, a subsequent increase in the VIC dye florescence only 
would indicate homozygosity for allele 1, a subsequent increase in the FAM dye 
florescence only would indicate homozygosity for allele 2 and an increase in both 
signals would indicate heterozygosity (both allele 1 and 2).  For GSTM3 the A* (wild 
type) allele was labelled with FAM and the B* was labelled with VIC.  Similarly for 
GSTM1 the A* allele was labelled with FAM and the B* allele was labelled with 
VIC.  Again for GSTP1 the A* allele was labelled with FAM and the G* allele was 
labelled with VIC. 
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2.12 TaqMan Real Time reverse transcriptase polymerase chain reaction  
In real-time relative RT-PCR a standard curve is generated from a dilution series 
constructed from a "reference" sample.  The identity of the reference sample is not 
important as long as the relevant PCR target is present.  The units used to describe the 
dilution series are relative, not absolute values, are based on the dilution factor.  In all 
experiments RT-PCR has been performed on both the experimental samples and 
reference standards and the relative values for target abundance in each experimental 
sample have been extrapolated from the standard curve generated from the reference 
standard. Although the absolute values calculated for the experimental samples are 
meaningless, the relative differences in mRNA abundance between samples are 
accurate.  The efficiency (Eff) of the reaction can be calculated by the following 
equation: Eff=10(-1/slope) –1.  The efficiency of the PCR should be 90-110% (3.6 > 
slope > 3.1) and is shown in every RT-PCR/PCR graph shown.  A number of 
variables can affect the efficiency of the PCR. These factors can include length of the 
amplicon, secondary structure, and primer.  
RNA extracted from either bladder biopsy tissue or cell lines was amplified 
using real-time RT-PCR.  Gene expression was determined by real-time RT-PCR 
using the 7500 or 7700 Sequence Detection System (Applied Biosystems, Foster City, 
CA).  The RT-PCR reactions were carried out in a microamp optical 96-well plate in a 
total volume of 25 µl per well containing TaqMan one-step RT-PCR master mix 
reagent (Applied Biosystems).   
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2.12.1 Normalizing the absolute quantification according to the 18S 
housekeeping gene. 
Quantitative real-time RT-PCR is a very useful technique for estimating gene 
expression at the mRNA level.  The expression of a tested gene has to be compared 
with that of a control gene or housekeeping gene because the amount of assayed 
mRNA may fluctuate due to differences in tissue mass, cell number, experimental 
treatment or variations in the efficiency of RNA extraction.  For instance the RNA 
content per cell or per gram of tissue may vary in different tissues in vivo, in cell 
culture in vitro, between individuals and under different experimental conditions and 
a control gene can also correct for sample to sample variations in RT-PCR efficiency 
and errors in sample quantification.  Therefore, normalisation of target gene 
expression levels must be performed to compensate intra- and inter-kinetic RT-PCR 
variations (sample-to-sample and run-to-run variations).  Data normalisation in real-
time RT-PCR is a further major step in gene quantification analysis (Pfaffl 2001; 
Bustin 2002).  
To normalize the absolute quantification according to a single housekeeping 
gene, a second set of kinetic PCR reactions has to be performed for the invariant 
endogenous control on all experimental samples and the relative abundance values are 
calculated for internal control as well as for the target gene.  For each target gene 
sample, the relative abundance value obtained is divided by the value derived from 
the control sequence in the corresponding target gene.  The normalized values for 
different samples can then directly be compared (Pfaffl 2001). 
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2.13 Total protein extraction from cultured cells and BCA assay 
Cells were cultured on a monolayer to 90% confluency.  The media was removed and 
the monolayer was washed three times with cold PBS.  The dish was put on ice and 
1ml of complete RIPA buffer (50 mol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 1% 
(v/v) Triton-X , 0.5% (w/v) Na deoxycholate, 0.2 % (w/v) SDS, 1 mmol/L Na3VO4 1 
50 mg tablet/10 mL complete protease inhibitor cocktail tablet (Roche Diagnostics, 
Lewes, UK)) was added (10cm dish).  The plate was left on ice for two minutes until 
the cells began to detach from the surface of the plate.  The detachment of cells was 
verified under the microscope.  The cell suspension was dispensed into 2ml eppendorf  
tubes and left on ice for a further 15 minutes.  The suspension was vortexed three 
times during this 15 minutes.  The cell suspension was centrifuged at 13000 g at 4 oC 
for ten minutes.  The supernatant was removed and the pellet was discarded. The 
protein concentration was determined using the bicinchoninic acid (BCA) method, 
with bovine serum albumin (BSA) as the standard.  The protein was quantified by 
measuring absorbance at 562nM plate reader (Dynex, UK). 
 
 
 
 
 
 
 
 
 
71 
 
2.14 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)  
All SDS-PAGE and western blotting was performerd using the XCell surelockTM 
Mini-Cell NOVEX® protein electrophoresis system and NuPage® gels and buffers 
(Invitrogen). 
Tubes were labelled and samples were prepared by adding the follow volumes of 
reagents.   
 
Reagent                                        Reduced Sample          
Sample                                                      x µl                                          
NuPage® LDS Sample Buffer (4X)          2.5 µl                                       
NuPage® Reducing Agent (10X)              1 µl                                          
Deionised Water                                   to 6.5 µl                                  
Total Volume                                            10 µl                                     
Table 2.3 Preparation of samples for SDS-PAGE. Samples were prepared in accordance with the 
manufactures instructions, as above. 
 
All samples were incubated at 70 oC for 10 minutes.  The gel was removed from the 
packet and washed with deionised water.  The comb was gently slipped out and the 
white strip removed.  The gel was placed in the chamber with wells at the top, and 
writing facing forward so as to be readable.  The chamber was set up with transparent 
plate and wedges.  1X concentration of SDS running buffer was prepared by adding 
50 ml of 20 x NuPage® MOPS SDS running buffer to 950 ml of deionised water.  500 
µl of NuPage® antioxidant was added to the middle chamber then filled with 600mls 
of 1x NuPage® SDS running buffer.  The front chamber was filled with 200ml of 1x 
NuPage® SDS running buffer.  30 µl of each protein sample were loaded into the 
wells, 2 µl each of MagicMark™ XP (Invitrogen) and SeeBlue® (Invitrogen) was 
added as markers.  Western protein MagicMark™ XP standards allow direct 
visualization of protein size standards on membrane blots without the need for protein 
modification or special detection reagents.  The standard proteins are derived from E. 
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Coli cells containing a construct with repetitive units of a fusion protein forming the 
size variation and an IgG binding site.  The proteins can be visualized with the 
colorimetric, chemiluminescent, or fluorescent detection system of choice simply by 
processing the membrane for the specific protein.  The IgG binding site will allow all 
the standard proteins to react with the specific primary and secondary antibodies 
(Sasse and Gallagher 2008).  The SeeBlue® pre-stained protein standard allows 
monitoring of the progress of the gel run and is an excellent tool for judging western 
transfer efficiency.  Polypeptides that resolve into sharp, tight blue bands in the range 
of 4 kDa to 250 kDa (depending upon buffer system).  An excellent indicator for 
judging western transfer efficiency as well as protein size.  The gel was run at 200 
volts for 60 minutes. 
 
2.14.1 Western Transfer 
Proteins were transferred on to nitrocelloluose membrane (BioRad, Hemel 
Hempstead, UK) as follows.  1X concentration of NuPage® transfer buffer was 
prepared by adding 50 ml 20X concentration of NuPage® transfer buffer and 100ml of 
methanol to 850ml of deionised water.  1ml of NuPage® antioxidant was added to the 
transfer buffer. 
Six blotting pads, filter papers and membrane were soaked in 700 ml of 1X NuPage® 
transfer buffer.  Three pieces of filter paper and one nitrocellulose membrane were cut 
8cm X 7cm.  The right hand corner was cut, so as to insure gel/membrane sandwich is 
not assembled in a reverse direction.  The Gel casing was broken open leaving the gel 
on the larger side of its casing and the groove line at the bottom cut off.  A piece of 
soaked filter paper was placed over the gel and air bubbles removed.  Gel/filter paper 
was removed from casing and placed over the membran
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soaked blotting pads were placed into the cathode core of the blot module.  The 
gel/membrane assembly was placed on the blotting pad in the correct orientation, so 
the gel is closest to the cathode core.  The remaining soaked blotting pads were added 
to rise to 0.5cm over the rim of cathode core.  The anode core was placed on top of 
these pads.  The blot module was held together firmly and slid into the guide rails on 
the lower buffer chamber.  The gel tension wedges were inserted into the lower 
chamber and locked into position and the blot module was filled with the 1X 
concentration NuPage® buffer until gel/membrane sandwich was covered in buffer, 
careful not fill all the way to the top, as this will generate extra conductivity and heat.  
The outer buffer chamber was filled with 650ml of deionised water.  The water level 
should reach approximately 2 cm from the top of the Lower Buffer Chamber.  This 
serves to dissipate heat during the run.  The lid was placed on and transferred using 30 
volts constant for 1 hour. 
 
 
2.14.2 Western Blot 
 
Firstly 10mls of 5% blocking agent were made up using 0.5 g milk power in 10mls 
Tris buffered saline 0.1% Tween 20 (v/v) (TBST).  The membrane was removed from 
the blot module and washed in the 5% blocking agent for 30 minutes at room 
temperature, with rocking.   Following the 30 minute wash the membrane was then 
rocked in the above blocking solution with a dilution of the primary antibody. 
Dilution , temperature and time of exposure was dependent on each particular 
antibody.  For example AP-2α rabbit polyclonal IgG primary antibody: 10 mls 
blocking solution 1:1000 dilution.  The membrane was left rocking/washing over 
night at 4 oC.  The following day the membrane was given 2 brief washes with TBST; 
then one wash with TBST for 15 minutes and a further wash with TBST for 5 
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minutes.  The membrane was rocked for 60 minutes room temperature in the blocking 
solution and anti-rabbit IgG horseradish peroxidise (HRP) conjugate secondary 
antibody (Sigma Aldrich), 1:20, 0000 dilution.  Finally the memberane was washed 
three times in TBST to remove surplus HRP. 
 
2.14.3 Immunodetection 
Chemiluminscence detection was performed using a Pierce West Pico 
Chemiluminescent kit (Thermo Scientific, UK).  The membrane was washed and 
incubated with equal volumes of solutions A and B for 5 minutes, room temperature.  
After incubation the membrane exposed to HyperfilmTM ECL (GE Healthcare, 
Amersham UK) and the film developed on a X-ograph xray film developer.  Or the 
chemilusmiscence was captured using a Fluor-S™ Multimager (BioRad, UK).  Time 
of exposure for either method was dependent on strength of signal. 
 
2.15 Gelatin-sodium dodecyl sulfate polyacrylamide (SDS-PAGE) zymography  
2.15.1 Treatment of UM-UC-3 cells  
On day one the cells were split from a 10cm dish into the 12 well plates.  The 
following day the cells were left undisturbed to ensure good adhesion of cells to the 
plate surface.  On day three the monolayer was washed with warm PBS and the 
conditioned media was added to the appropriate wells. 
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Figure 2.5 Twelve well culture plate 
On day four the monolayer/cell morphology was examined under the microscope for 
any adverse effects of the treatments.  If none were seen the plate was placed back 
into the incubator.  On day five following the 48 hour treatment of the cells the 
conditioned media was removed and subjected to sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis on a 10 well, 1mm, 10% Tris-Glycine zymogram 
gel with 0.1% gelatin incorporated as substrate (Invitrogen).  Electrophoresis was 
carried out at a constant voltage of 125 V for 90 minutes.  The assay was normalised 
against the cell number in each well.  Each well was seeded at the same density; 
however there was some well to well variation and therefore enzyme levels may 
fluctuate due to cell numbers in individual wells.  Also enzyme/protein/cell levels 
may fluctuate due to the experimental treatment or variable efficiency of sample 
preparation.  Therefore the monolayer was removed and the total protein 
concentration was determined using the BCA method (see total protein extraction 
from cultured cells and protein quantification using the bicinchoninic acid (BCA) 
method).  Therefore enzymes can be expressed as enzyme activity per mg of protein 
to enable normalisation of the assay.  Following collection of media the gel was 
removed from the packet and washed with deionised water.  The comb was gently 
slipped out and the white strip removed. The sample wells were rinsed with 1X 
running buffer and the gel was inverted to remove buffer.  This was repeated two 
Three test wells 
with either 
SF,SF-NAC, IB 
or IB-NAC 
Three controls 
for each test 
plate (DMSO) 
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more times.  The gel was placed in the chamber with wells at the top, and writing 
facing forward so as to be legible.  The chamber was then set up in accordance with 
the mini-cell manual (Invitrogen IM-9003) with plastic buffer dam and locked into 
position. 
Samples were prepared under non reduced conditions by adding 10 µl of 
sample mixed with 10 µl of sample buffer and loaded immediately on the gel without 
heating the sample.  20µl of SeeBlue® Plus2-stained standard (Invitrogen) was loaded 
in to well 1 and 20µl of each sample was loaded into each of the following wells 2-10. 
The 1X running buffer was prepared by adding 100 ml of (10X) running buffer with 
900 ml of deionised water.  A small amount of buffer was added to the upper chamber 
of the XCell surelockTM Mini-Cell to check for tightness of seal.  Once no leaks were 
observed between the upper and lower chamber the upper chamber was filled with 
200 ml and the lower buffer chamber with 600ml of the (X1) Tris-Glycine running 
buffer. 
After 90 minutes the XCell surelockTM Mini-Cell power was turned off and 
electrodes disconnected and the gel within its cassette was removed.  The cassette was 
carefully opened and the top plate removed.  A piece of blotting paper was placed 
over the gel for ease of handling and the gel was removed and placed into a plastic 
dish. 100ml of both Novex® Zymogram 1X renaturing buffer and Novex® Zymogram 
1X developing buffer were prepared by adding 10 ml of the 10X buffer to 90 ml of 
deionised water (100ml required per gel).  The gel was incubated in the 1X renaturing 
buffer at room temperature for 30 minutes with gentle agitation.  The 1X renaturing 
buffer was then decanted and 1X developing buffer was added to the dish containing 
the gel.  The gel was equilibrated for 30 minutes at room temperature with gentle 
agitation.  The 1X developing buffer was decanted and fresh 1X developing buffer 
77 
 
was added to the gel.  The gel was incubated in the developing buffer at 37° C for 
varied times.  
 
2.15.2 Staining of zymogram 
The Invitrogen basic protocol for staining Novex® gels with SimplyBlueTM was 
followed.  As the zymography gels do not need fixing, they were rinsed three times 
for 5 minutes with 100 ml deionised water to remove the SDS and buffer salts.  The 
gels were stained for 1 hour at room temperature with gentle shaking with enough 
SimplyBlueTM stain to cover the gel (approx 20-100 ml, dependent on the area of the 
bottom of the dish that the gel was in).  Following staining the gel was washed in 100 
ml of deionised water for 2 hours.  
 
2.16 UM-UC-3 bladder cell line migration using the wound healing assay 
Passage 8 UM-UC-3 cells were split 1:4 and were grown as monolayer in four six 
well plates until they reached confluence; typically 5 day (refer to for general cell 
culture methods).  On days two and four cells were treated with ITCs, either 12µM of 
SF, IB, SF-NAC, or IB-NAC.  Each ITC was tested in triplicate and on day five a 1-
mm scrape wound was made across the confluent layer monolayer with a sterile 
pipette tip and the displaced cells were removed by rinsing with PBS.  The remaining 
cells were allowed to migrate in fresh medium.  A microscopy imaging system 
(Olympus) was used to assess the wound at 0 hrs at x 200 magnification. The 
migration was assessed at specific time points (0, 24 and 36 hours) by measuring the 
leading edge of wound relative to the same position at 0 hours.  The migration 
distances between the leading edge of the migrating cells and the edge of the original 
wound at 0 hours were compared.  The migration rate of the treated cells was 
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expressed as a percentage and quantified as the following equation: migration rate = 
(migration distance of ITC treated cells/migration distance of untreated controls) x 
100%. 
 
2.17 BD BioCoat™ Matrigel™ Invasion Chamber to study cell invasion of 
treated and untreated UM-UC-3 cells. 
BD BioCoat™ Matrigel™ 6 well plates (BD Biosciences, Oxford UK) were removed 
from -20°C storage and allowed to come to room temperature.  Warmed (37°C), 
serum free culture medium was added to the interior of the inserts and the bottom 
wells (receiver well) of the companion plate.  The plates were allowed to rehydrate for 
2 hours in humidified tissue culture incubator, 37 °C, 5 % CO2 atmosphere.  After 
rehydration, the medium was removed without disturbing the layer of Matrigel™ 
matrix on the membrane.  An equal number of control inserts were prepared by using 
sterile forceps to transfer them to empty wells of the BD Falcon™ TC Companion 
Plate (BD Biosciences, Oxford UK).  Cell suspensions were prepared in serum free 
culture medium containing 1.25x10 5 cells/ml for 6-well chambers.  The media was 
conditioned with 12 µM of SF, IB, SF-NAC, IB-NAC or DMSO as a control all in 
triplicate.  2.5 ml of culture media containing serum was added to each well of the 
companion plate. 2ml of the cell suspension was added to each well chamber. BD 
BioCoat™ Matrigel™ Invasion Chambers were incubated in a incubator, at 37 oC, 5 
% CO2 atmosphere.  After incubation, all the media was removed and the chambers 
were rinsed with warmed PBS.  The non-invading cells were removed from the upper 
surface of the membrane by wiping with cotton tipped swab.  To determine an optimal 
fixing and stain time for the UM-UC-3 cells a series of stain times from 3 to 5 minutes 
were completed following a series of fixing times of 2 and 3 minutes.  Once an 
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optimal time was established, the cells were fixed using 1 ml of cold 100 % methanol 
and stained with 1 ml of Gill’s No 1 Hematoxylin stain.  The filter was carefully cut 
away from the transwell and mounted onto a microscope slide for cell counting.
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CHAPTER 3: Characterisation of bladder tissue 
 
3.1 Introduction 
Transitional cell carcinoma is a common malignancy characterized by a poor clinical 
outcome when tumours progress into invasive disease.  The aim of this chapter is to 
compare global gene expression profiles between superficial and invasive transitional 
cell carcinoma of the bladder to enable identification of a subset of genes for 
subsequent cell experimental studies with cell cultures.  I sought to define gene 
expression profiles or selective genes that are characteristic of aggressive clinical 
behaviour in invasive bladder tumours.  Epidemiology studies have demonstrated that 
bladder cancer is strongly associated with cigarette smoking, and the risk of 
development of neoplasia may be modified by differences amongst individuals in 
carcinogen-metabolising enzymes, such as GSTs.  I also sought to explore the 
frequency of genetic polymorphisms of GSTT1, GSTM1, GSTM3 and GSTP1 in 
superficial and invasive transitional cell carcinoma. 
82 
 
3.2 Specific materials and method 
Following biopsy extraction, tissue was stored at the Norfolk and Norwich University 
Hospital (NNUH) Tissue Bank at -80 oC.  Seventeen frozen bladder biopsies were 
transferred to the IFR laboratory from the Norfolk histopathology laboratory (see 
chapter 2 regarding the ethics).  The samples were classified and graded by the 
NNUH histopathologist, Professor Richard Ball, prior to collection, in accordance 
with TNM classification World Health Organization system (Oosterlinck, Lobel et al. 
2002; Oosterlinck, Lobel et al. 2002; Oosterlinck 2004)  (section 1.9).  RNA and DNA 
extraction, RNA quantification, quality assessment, Affymetrix U133 plus 2.0 
GeneChip hybridisation and analysis were carried out according to section 2.   
Prior to the DNA extraction the frozen tissue was weighed to determine the volume of 
RNALater™ ICE the biopsy should be incubated in to ensure optimal RNA extraction 
at a later date.  Table 3.1 shows the tissue bank number, weight, time of 
commencement of incubation and volume of RNALater™ ICE that was used.  Refer 
to chapter two for full explanation of RNALater™ ICE reagent and the detailed 
method of RNA stabilisation with RNALater™ ICE.  Table 3.2 shows diagnosis, age, 
and gender of the individuals from which the biopsies were obtained.  Refer to section 
1.7 for an explanation of the tissue bank number and refer to section 1.9 for a more 
detailed explanation of grade.  Biopsies with tissue bank numbers 02TB040, 
02TB058, 02TB093, 04TB119 and 04TB125 had two biopsies taken from the bladder 
and therefore have the same tissue bank numbers but were distinguishable by their 
vial numbers.  The first sample was seen to be TCC and graded accordingly, the 
second biopsy was taken from an adjacent histologically benign area of their bladder 
and therefore graded as ‘normal’.  Following a 48 hour soaking in the appropriate 
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volume of RNAlater ice, a weighed section of biopsy tissue was extracted for DNA 
isolation.  All times, dates and volumes were recorded in table 3.1. 
 
Tissue bank 
no 
vial WT of sample mg volume of 
RNA later 
ice added 
ml 
date/time 
soaking 
commenced  
WT of tissue for 
DNA isolation mg 
date of 
extraction of 
DNA 
02TB040 1 105 2ml 05.10.06 at 
15.00 
10.6 6.10.06 at 
10.45 
02TB040 5 159.1 2ml 05.10.06 at 
15.01 
22.5 6.10.06 at 
10.46 
02TB058 1 90.1 2ml 08.10.06 at 
10.15 
12.7 10.10.06 at 
10.00 
02TB058 9  56.1 2ml 08.10.06 at 
10.15 
    
02TB065 9 64.8 2ml 08.10.06 at 
10.15 
23.2 10.10.06 at 
10.20 
02TB067 10 60.6 2ml 08.10.06 at 
10.15 
11 10.10.06 at 
10.30 
02TB044 14 49.9 2ml 08.10.06 at 
10.15 
12.8 10.10.06 at 
10.40 
02TB093 1 195.1 2ml 08.10.06 at 
10.15 
13.5 10.10.06 at 
13.15 
02TB093 10  56.0 2ml 08.10.06 at 
10.15 
    
03TB132 1 150.2 2ml 08.10.06 at 
10.15 
21.5 10.10.06 at 
13.15 
03TB146 1 124.5 2ml 08.10.06 at 
10.15 
13.2 10.10.06 at 
13.15 
03TB179 1 70 2ml 08.10.06 at 
10.15 
15.2 10.10.06 at 
13.15 
04TB021 1 75.1 2ml 08.10.06 at 
10.15 
11.3 10.10.06 at 
13.15 
04TB119 1 36.5 2ml 08.10.06 at 
10.15 
8.6 10.10.06 at 
13.15 
04TB119 4 36.0  2ml 08.10.06 at 
10.15 
    
04TB125 1 19.3 2ml 08.10.06 at 
10.15 
5.4 10.10.06 at 
13.15 
04TB125 4  32.0 2ml 08.10.06 at 
10.15 
    
 
Table 3.1 Tissue bank number of biopsy, weight of frozen biopsy received, volume of RNAlater ice 
the biopsy was soaked in and the weight of sample dissected for DNA extraction. 
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3.3 Results   
3.3.1 Bladder tissue genotyping  
Table 3.2 shows the genotype results of the 12 bladder biopsies obtained from the 
NNUH tissue bank, 17 tissue samples in total.  Four (02TB040, 02TB093, 04TB119 
and 04TB125) were samples taken from the cancerous bladder, but in an adjacent area 
to the actual tumour.  These biopsies appeared histologically benign.  GSTM1 and 
GSTT1 null genotypes, the GSTP1 (Ile105Val polymorphism/ Ala114Val 
polymorphism), and the GSTM3 3 base pair deletion genotype plus allele 
discrimination of GSTM1 positive individuals were investigated in all tissues obtained 
from the NNUH tissue bank.  GSTM1 and GSTTI null individuals have genetically 
deleted (non-functional alleles) and consequently do not produce the enzyme.  The 
GSTM3*B affects the detoxification activity of the enzyme and the Valine residue at 
position 105 of the GSTP1 protein results in decreased enzyme activity.  
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Table 3.2 Histological results of bladder tissue and GSTM1, GSTM3, GSTT1 and GSTP1 genotypes. 
Genotype Tissue bank 
number 
Age 
 
Gender Diagnosis Grade Interpretation of grade 
GSTM1 GSTM3 GSTT1 GSTP1 
02TB040 66 M TCC G3,pT3b,pTis 
Poorly differentiated/undifferentiated. 
Infiltrative beyond muscularis, extravesical 
mass.  Also seen was a situ flat tumour. 
Null A/A A/0 G/0 
02TB040 66 M normal       
02TB058 71 F TCC G3,pT3a 
Poorly differentiated/ 
Undifferentiated. 
Infiltrative beyond muscularis, 
microscopically. 
B/0 A/A A/A A/0 
02TB058 71 F dysplasia  Pre-cancerous change in cellular structures.     
02TB065 82 M TCC G3,pT3a 
Poorly differentiated/ 
Undifferentiated. 
Infiltrative beyond muscularis, 
microscopically. 
Null A/A A/0 G/0 
02TB067 76 M TCC G2,pT1 Moderately differentiated.   Superficial subepithelial connective tissue. 
Null A/A A/0 G/A 
02TB044 76 M TCC G3,pT3b 
Poorly differentiated/ 
undifferentiated. 
Infiltrative beyond muscularis, extravesical 
mass.  
A/B A/B A/0 A/0 
02TB093 76 F TCC G3,pT2b 
poorly differentiated/ 
undifferentiated.   
Infiltrative outer half of muscularis. 
Null A/B A/A A/0 
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Table 3.2 continued: Histological results of bladder tissue and GSTM1, GSTM3, GSTT1 and GSTP1 genotypes. 
Genotype Tissue bank 
number 
Age 
 
Gender Diagnosis Grade Interpretation of grade 
GSTM1 GSTM3 GSTT1 GSTP1 
02TB093 76 F normal       
03TB132 85 M TCC G2,pT1 Moderately differentiated.   Superficial subepithelial connective tissue. Null A/B A/A G/A 
03TB146 82 M TCC G3,pT1 
Poorly differentiated/ 
undifferentiated. 
Superficial subepithelial connective tissue.   
A/0 A/A Null G/A 
03TB179 80 M TCC G2,pTa Moderately differentiated.  Non-invasive superficial papillary.  A/A A/A A/A G/0 
04TB021 78 M TCC G2,pTa Same as above Null A/B A/A G/A 
04TB119 83 F TCC G3, pT3b  
Poorly differentiated/ 
Undifferentiated. 
Infiltrative beyond muscularis, extravesical 
mass.  
A/A A/B A/A G/0 
04TB119 83 F normal       
04TB125 66 F TCC G3, pT3b  
Poorly differentiated/ 
undifferentiated.   
Infiltrative beyond muscularis, extravesical 
mass.  
Null A/A A/A G/A 
04TB125 66 F normal       
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3.3.2 Bladder tissue array 
Of the 17 bladder tumour biopsy samples received from the NNUH tissue, 12 were 
transitional cell carcinomas of varying grades, from superficial to muscle invasive, one was 
graded as dysplasia and four were graded as normal (see table 3.2).  RNA was successfully 
extracted from 10 of these bladder tumour biopsies for microarray analysis.  Normalisation 
of the signal intensities across all the arrays was performed to achieve signals that would be 
comparable between them.  Following calculation of expression values for each probe set 
the data were submitted to higher-level analysis.  Pair-wise comparisons between the 
superficial and invasive samples were performed to identify genes that were differentially 
expressed more than two-fold at a statistically significant level (p<0.005).  Sample and gene 
clustering was performed, the former to identify any similarity between the two groups and 
the latter to identify genes with similar patterns of expression across all samples (refer to 
section 2.9.2 for full explanation of array data analysis). The resulting dendrogram in figure 
3.1, red illustrates an increase in probe expression, blue represents a decrease in probe 
expression and white represents no change in expression. 
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CDNA FLJ37605 fis, clone BRCOC2010510
transmembrane protein 154
hypothetical protein LOC284837
chromosome 1 open reading frame 93
farnesyl-diphosphate farnesyltransferase 1
nuclear receptor subfamily 2, group F, member 6
aminoacylase 1
pterin-4 alpha-carbinolamine dehydratase/dimerization cofactor of hepatocyte nuclear factor 1 alpha ...
ladinin 1
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit E
Ectonucleoside triphosphate diphosphohydrolase 5
solute carrier family 14 (urea transporter), member 1 (Kidd blood group)
Solute carrier family 14 (urea transporter), member 1 (Kidd blood group)
TP53 activated protein 1
V-set and immunoglobulin domain containing 2
growth arrest and DNA-damage-inducible, beta
chromosome 1 open reading frame 24
moesin
annexin A6
Wiskott-Aldrich syndrome protein interacting protein
collagen, type VI, alpha 1
filamin A, alpha (actin binding protein 280)
procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II
interleukin 7 receptor /// interleukin 7 receptor
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Hierarchical clustering dendrogram of 21 genes (P value of 0.005). Comparing superficial bladder 
cancer (Ta-T1) with invasive bladder cancer (≥T2).   
 
 
 
 
1 2 3 4 5 6 7 8 9 10 
Number on  
dendrogram 
Tissue Bank 
number 
Grade 
1 03TB179 G2pTa 
2 03TB146 G3pT1 
3 03TB132 G2Pt1 
4 04TB021 G2pTa 
5 02TB065 G3pT3a 
6 02TB040 NORMAL 
7 04TB125 G3pT3b 
8 04TB119 G3pT3b 
9 02TB044 G3pT3b 
10 02TB099 G3pT2b 
Superficial Invasive 
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Table 3.3 A list of probes altered in bladder tissue when comparing superficial bladder cancer with invasive 
bladder cancer (21 probes) 
Table 3.3 continued A list of probes altered in bladder tissue when comparing superficial bladder cancer with 
invasive bladder cancer (21 probes) 
 
 
 
 
 
 
Accession No Gene title Fold 
change1  
P- 
value2 
AA931476 CDNA FL37605 fis, clone BRCO201510 -2.91 0.004 
AA806282  Transmembrane protein 154 -2.04 0.004 
BC034348 Hypothetical protein LOC284837 -2.8 0.003 
AL35975 Chromosome 1 open reading frame 93 -2.01 0.003 
AA872727 Farnesyl-diphosphate farnesyltransferase 1 -2.5 0.005 
BC002669 Nuclear receptor subfamily 2, group F, member 6 -2.54 0.002 
NM_000666 Aminoacylase 1 -2.25 0.002 
NM_000281 Pterin-4 alpha-carbinolamine dehydratase/demerization 
cofactor of hepatocyte nuclear factor 1 alpha (TCF1) 
-2.1 0.004 
NM_005558 Ladinin 1 -2.49 0.004 
NM_007100 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit E 
-0.207 0.004 
 Ectonucleoside triphospate diphosphohydrolase 5 -2.78 0.001 
BE673587 Solute carrier family 14 (urea transporter), member 1 (Kidd 
blood group) 
-7.85 0.004 
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Accession No Gene title Fold 
change1 
P- 
value2 
NM_015865 Solute carrier family 14 (urea transporter), member 1 (Kidd 
blood group) 
-7.44 0.003 
B007457 TP53 activated protein 1 -2.23 0.002 
NM_014312 V-set and immunoglobulin domain containing 2 -3.99 0 
NM_015675 Growth arrest and DNA-damage-inducible, beta  3.21 0.005 
AL359575 chromosome 1 open reading frame 24 3.71 0.003 
NM_002444 Moesin 2.73 0.004 
NM_001155 Annexin A6 3.75 0.001 
AW058622 Wiskott-Aldrich syndrome protein interacting protein 3.83 0.003 
AA292373 Collagen, type VI, alpha 1 5.7 0.001 
 
Table 3.3 A list of probes altered in bladder tissue when comparing superficial bladder cancer with invasive 
bladder cancer (21 probes). 1 The fold change shown represents the mean gene expression ratio calculated 
using the PM-only model on normalised arrays in dChip between the superficial bladder cancer tissue and the 
invasive bladder cancer tissue. The positive values represent an up-regulation and the negative values 
represent a down-regulation and as such correspond to the red and blue of the heat map in figure 3.1   
2 Genes that were differentially expressed more than two-fold at a statistical significant level (p<0.005) 
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3.3.3 GeneOntology 
The biological role of genes that were differentially expressed more than two-fold at a 
statistical significant level (p<0.005), their relationship with cancer and bladder cancer, if 
any, are discussed below: 
 
Farnesyl-diphosphate farnesyltransferase 1 
This gene encodes a membrane-associated enzyme located at a branch point in the 
mevalonate pathway.  The encoded protein is the first specific enzyme in cholesterol 
biosynthesis, catalyzing the dimerization of two molecules of farnesyl diphosphate in a 
two-step reaction to form squalene (RefSeq) Inhibition of squalene synthase maybe a 
method of lowering cholesterol levels in the prevention of cardiovascular disease (Do, Kiss 
et al. 2009). 
Nuclear receptor subfamily 2, group F, member 6  
The protein transcribed by this gene has many functions such as metal ion binding, 
sequence-specific DNA binding, steroid hormone receptor activity, transcription factor 
activity and zinc ion binding, however there is no association with cancer in the literature 
(RefSeq) 
Aminoacylase 1 
Aminoacylase-1 (Acy1) is a cytosolic, homodimeric, zinc-binding enzyme that catalyzes 
the hydrolysis of acylated L-amino acids to L-amino acids and acyl group(RefSeq). Its 
expression has been reported to be reduced or undetectable in small-cell lung cancer cell 
lines and tumours (Miller, Minna et al. 1989).  The Acy1 gene which is highly expressed in 
the kidney, displays a significantly decreased level of expression in rat renal cell carcinoma 
and an increased number of apoptotic cells were observed following Acy1 transfection 
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(Hwa, Park et al. 2005).  The array results also indicate a decrease of 2.25 fold in the 
invasive tissue.   
Pterin-4 alpha-carbinolamine dehydratase/demerization cofactor of hepatocyte 
nuclear factor 1 alpha (TCF1) 
This gene encodes pterin-4 alpha-carbinolamine dehydratase, an enzyme involved in 
phenylalanine hydroxylation.  A deficiency of this enzyme leads to 
hyperphenylalaninemia.  The enzyme regulates the homodimerization of the transcription 
factor hepatocyte nuclear factor 1 (HNF1) (RefSeq). 
Ladinin 1 
The protein encoded by the Ladinin 1 gene may be an anchoring filament that is a 
component of basement membranes (RefSeq).  It may contribute to the stability of the 
association of the epithelial layers with the underlying mesenchyme (RefSeq). A decrease 
of 2.49 fold was seen in the invasive bladder tissue, perhaps indicating destruction of the 
ECM and basement membrane as the tumour invades.  However gene expression profile 
analysis of ovarian serous papillary carcinomas (OSPCs) and normal ovarian (NOVA) 
epithelium showed an over expression of the Ladinin 1 gene in OSPC compared to NOVA 
(Santin, Zhan et al. 2004). 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit E (ATP5I) 
 
Mitochondrial ATP synthase catalyzes ATP synthesis, utilizing an electrochemical gradient 
of protons across the inner membrane during oxidative phosphorylation.  A study has 
shown that antisense of ATP5I inhibits the growth of human hepatocellular carcinoma 
cells. The authors suggested that antisense of ATP5I can inhibit cell proliferation through 
the MAP kinase pathway and also that ATP5I may become a new target in gene therapy 
(Ying, Yu et al. 2001). 
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Ectonucleoside triphospate diphosphohydrolase 5 (ENTPD5/ PCPH) 
 
The protein which is encoded by this gene may play an important role in mediating 
catabolism of extracellular nucleotides (RefSeq).  Reports have shown that ENTPD5 is 
mutated or deregulated in some human tumours, suggesting its participation in malignant 
progression.  A recent immunohistochemical analyses study has shown that ENTPD5 is not 
expressed in normal prostate, but its expression increases along cancer progression stages, 
being detectable in benign prostatic hyperplasia, highly expressed in prostatic 
intraepithelial neoplasia, and remaining at high levels in prostate carcinoma (Villar, Arenas 
et al. 2007).  However in this study ENTPD5 shows a decrease in expression in the 
invasive tissue.  
Solute carrier family 14 (urea transporter), member 1 (Kidd blood group) 
 
The protein encoded by this gene is a membrane transporter that mediates urea transport in 
erythrocytes.  This gene forms the basis for the Kidd blood group system and the literature 
does not associate the gene with cancer. 
TP53 
p53, is a transcription factor which in humans is encoded by the TP53 gene. p53 is 
important in multicellular organisms, responding to diverse cellular stresses to regulate 
target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in 
metabolism and thus functions as a tumor suppressor (RefSeq).  p53 protein is a DNA-
binding protein expressed at low level in normal cells and at a high level in a many 
transformed cell lines.  If the TP53 gene is damaged, tumour suppression is severely 
reduced and more than 50 percent of human tumours contain a mutation or deletion of the 
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TP53 gene.  The array data indicates a down regulation of this tumour suppressor gene in 
the more invasive TCC. 
Growth arrest and DNA-damage-inducible, beta 
Growth arrest and DNA-damage-inducible, beta responds to environmental stresses by 
mediating activation of the p38/JNK pathway(RefSeq).  This activation is mediated via 
their proteins binding and activating MTK1/MEKK4 kinase, which is an upstream 
activator of both p38 and JNK MAPKs(RefSeq).  The gene has been verified to be specific 
in hepatocellular carcinoma and consistent with the degree of malignancy (Qiu, Zhou et al. 
2007).  A recent study showed the induction of growth arrest DNA damage-inducible gene 
in human hepatoma cell lines by S-adenosylmethionine (Yamamoto and Negishi 2008)  
Also, a DNA microarray analysis study investigating gastroenteropancreatic 
neuroendocrine tumours, showed an up-regulation of this gene in the malignant group 
(Qiu, Zhou et al. 2007).  In this study an up-regulation of 3.21 was observed in the invasive 
bladder tissue. 
Moesin 
Moesin functions as a cross-linker between plasma membranes and actin-based 
cytoskeletons.  Moesin is localized to filopodia and other membranous protrusions that are 
important for cell-cell recognition and signalling and or cell movement.  An increase in 
Moesin protein expression is a marker of the basal subtype breast tumours (Charafe-
Jauffret, Ginestier et al. 2006).  In a recent study increased Moesin expression was shown 
to be nearly an independent prognostic marker of poor outcome in these patients (Charafe-
Jauffret, Monville et al. 2007).  From the bladder array study an increase of 2.73 fold in 
gene expression can be seen in the invasive TCC biopsy samples.  
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Annexin A6 
 
Annexin A6 has been shown to inhibits Ras signalling in A431 breast cancer cells(RefSeq).  
Over expression of epidermal growth factor receptor (EGFR) is associated with enhanced 
activation of wild-type (hyperactive) Ras in breast cancer and the association of AnxA6 
with H-Ras-containing protein complexes may contribute to regulate p120GAP/Ras 
assembly in EGFR-overexpressing breast cancer cells (Vila de Muga, Timpson et al. 
2009).  Annexin A6 has also been identified as a possible new markers of minimal residual 
disease (MRD) in B-lineage acute lymphoblastic leukemia (ALL)(Chen JS 2001).  Using 
cDNA array analysis, Annexin A6 was shown to be expressed in B-lineage ALL cells at 
higher levels than in normal.  In this study Annexin A6 was shown to have a increased fold 
change of 3.75 in the more invasive bladder biopsies.  
Wiskott-Aldrich syndrome protein interacting protein (WASP) 
 
This protein is involved in transduction of signals from receptors on the cell surface to the 
actin cytoskeleton and plays a role in the regulation of actin-based motility(RefSeq).  
WASP is predominantly expressed in hematopoietic cells and regulates the reorganisation 
of the actin cytoskeleton in response to various cell stimuli, including T cell receptor 
signalling (RefSeq).  Mutations in this gene encoding the WASP protein causes Wiskott-
Aldrich syndrome (WAS) which is an X-linked primary immunodeficiency (Ramesh and 
Geha 2008).  The WASP family proteins initiate directed actin assembly in the leading 
edge of the migrating cell (RefSeq).  It has been shown that IQ motif containing GTPase 
activating protein 1 (IQGAP1) stimulates actin assembly through the N-WASP-Arp2/3 
pathway.  IQGAP1 is a conserved modular protein over expressed in many cancers and is 
involved in organising actin and microtubules in motile processes such as adhesion, 
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migration, and cytokinesis (Le Clainche C 2007).  In this study the gene showed an 
increase of expression. 
There is very little information in the literature regarding the following genes and no 
associations with cancer. 
• V-set and immunoglobulin domain containing 2 
 
• Chromosome 1 open reading frame 24 
 
 
• CDNA FL37605 fis, clone BRCO201510 
 
• Transmembrane protein 154 
 
• Chromosome 1 open reading frame 93 
There is very little literature regarding the following gene and its function is unknown. 
• Hypothetical protein LOC284837 
 
Collagen, type VI, alpha 1 
 
Will be discussed later in this chapter (section 3.4.5) 
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3.3.4 Confirmation of Affymetrix Array results 
For publication purposes, microarray results require verification and validation by an 
alternative and complementary gene expression profiling method. RT-PCR was used to 
validate the microarray data, analyzing transcript levels for two genes which significantly 
changed. Time permitting it would have been helpful to analyzing transcript levels for genes 
significantly changed in each direction and also transcript levels of genes whose expression was 
unchanged between the two sample populations. In this instance the selection of the genes for 
follow-up analysis was influenced by their possible biological function within the ECM in 
relation to cancer invasion . As such, perhaps does not validate/confirm the large data sets that 
was generated by the microarray but does confirm the up-regulation of these two genes in 
invasive tissue in independent sample. To confirm the large data set more conclusively a 
combination of analysis would be required. Independent confirmation of results such as in silico 
analysis and further laboratory-based analysis would be required. Furthermore to investigate 
whether the expression profiles are a universal feature of the biological phenomenon under 
study—in other words, are the data an essential descriptor of the biological state? This question 
could be addressed by evaluating a critical gene set in a larger and more extensive study group, 
which can be done either in silico or in the laboratory (Chuaqui, Bonner et al. 2002).  
To validate the changes in these two chosen genes primers and probes were designed and 
optimised for Moesin and Collagen, type VI, alpha 1 (section 2).  The invasive bladder 
tissue showed a significant (p<0.005) increase of COL6A1 and Moesin expression in the 
array data of 5.7 and 2.73 fold respectively (Table 3.3).  This was further confirmed with 
real time RT-PCR, and the extent of the increase of Moesin was approximately five fold 
greater than observed in the array data (data not shown).  The extent of COL6A1 mRNA 
expression was much greater in the real time RT-PCR data, showing approximately a 40 
fold increase of mRNA expression when comparing the superficial with the most invasive 
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tissue (Figure 3.4).  This phenomenon of Affymetrix arrays underestimating the actual 
mRNA level expression has previously been reported to occur in Caco2 cells (Traka, 
Gasper et al. 2005).  RT-PCR is more sensitve than microarray analysis and as such 
microarray results can rather underestimate actual changes in gene expression. From the 
seven remaining tissue samples I was able to select one sample with an invasive 
classification and one sample with a superficial classification for real time RT-PCR analysis 
(figure 3.2) 
  
 
Figure 3.2 The relationship of COL6A1 gene expression and grade of bladder cancer. Real time RT-PCR 
confirmation of COL6A1 expression in human bladder tissue. Data is shown from three biological replicates 
plotted with SD (*p<0.005). It can be seen from the graph that COL6A1 significantly increases with the 
grade of bladder cancer.  
 
3.4 Discussion  
3.4.1 Glutathione-S-transferase  
There are three alleles at the GSTM1 locus: GSTM1 0, GSTM1 A, and GSTM1 B.  GSTM1 
0 is a deletion and homozygotes (GSTM1 0/0 or GSTM1 null genotype) express neither 
mRNA nor GSTM1 protein/enzyme.  Alleles GSTM1 A and GSTM1 B encode monomers 
that form the homo- and heterodimeric enzymes.  GSTM1 A and GSTM B differ by a CG 
substitution at base position 534, resulting in LysAsn substitution at amino acid 172.  In 
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many studies GSTM1 0/A, 0/B, A/A, A/B, and B/B are typically categorized together as a 
single functional GSTM1 positive phenotype as there is said to be little evidence of 
functional difference between GSTM1 A and GSTM1 B.  The enzyme activity of GSTM1 
and GSTT1 is absent in approximately 50 % and 15 % of the population, respectively, due 
to deletions of both chromosomal copies of the genes.  A trimodal phenotype pattern exists 
in which individuals with two, one, or no functional genes are fast, intermediate, or slow 
"conjugators" respectively (Buchard, Sanchez et al. 2007).  Most studies investigating the 
effect of the GSTM1 and GSTT1 deletions do not distinguish between fast and 
intermediate conjugators.  Here the three alleles were distinguished although there are too 
few samples to draw any real conclusions.  
From the 12 tissue biopsy samples 58 % were GSTM1 null, which would result in a 
lack of GSTM1 enzyme activity in these individual’s bladder tissue.  This corresponds to 
the observed homozygous deletion of this gene in approximately 51 % for those of 
European descent.  The prevalence of GSTT1 null individuals is 10% to 20% among 
Caucasians.  In this data set only one individual was GSTT1 null (8%), which is also 
consistent; however once again there are too few samples to draw any real conclusions.  
The GSTM3 gene has a three-base-pair deletion in intron 6, and the two alleles are referred 
to as GSTM3*A and GSTM3*B.  This deletion creates a recognition motif  (-aagata-) for 
the YY1 transcription factor which could potentially affect detoxification activity by 
GSTM3 B allele.  That is, genotypes GSTM3*AB and GSTM3* BB potentially affect 
detoxification activity of GSTM3 enzyme.  There is little work in relation to bladder 
cancer and the GSTM3*B allele, however risk of developing prostate cancer has been 
associated with GSTM3 AB, and BB was 2.5-fold as compared to AA genotype 
(Kesarwani, Singh et al. 2008).  The GSTP1 gene displays a polymorphism at codon 105 
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(Ile105Val) resulting in an enzyme with altered substrate affinity (Ali-Osman, Brunner et 
al. 1997).  Approximately 10% of Caucasians are homozygous for this mutation and 40% 
are heterozygous (Voho, Impivaara et al. 2006).  A Valine residue at position 105 of the 
GSTP1 protein results in decreased enzyme activity.  None of the samples were 
homozygous for the mutation and 33% were heterozygous G/O for the mutation and 42% 
were G/A heterozygous for the mutation and the remaining 25% did not have the mutation 
and were heterozygous A/O. 
I sort to explore the frequency of the GSTT1, GSTM1, GSTM3 and GSTP1 genetic 
polymorphisms between the superficial and invasive tissue types however the small number 
of cases makes it impossible to reach substantial conclusions.  As discussed above, many of 
the results correspond to published data and a difference in genetic polymorphism 
frequency between superficial and invasive tissue was not observed.  In order to achieve 
this, a much larger sample population would be needed.  
 
 3.4.2 Specific bladder tumour grades have distinct gene expression profiles 
The fold changes in table 3.3 correspond to the colour intensities in Figure 3.1.  The fold 
changes and the colour intensities are the amount of florescence omitted, and is a reflection 
on the expression of the corresponding gene.  When comparing superficial with invasive 
bladder cancer, a mean decrease in expression of a particular gene is indicated by blue and a 
mean increase of expression is indicated by red.   Pair-wise comparisons between the 
superficial (Ta-T1)  and invasive (≥T2) samples identified 21 genes that were differentially 
expressed more than two-fold at a statistical significant level (p<0.005).  It can be observed 
that this microarray analysis identified patients with two clinically distinct phenotypes. That 
is clinically relevant subclasses of bladder TCC have been identified.  Using unsupervised 
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sample clustering, genes clustered into two clinically distinct groups; the superficial 
transitional cell carcinoma of the bladder (Ta- T1) into one group and the muscle invasive 
transitional cell carcinoma of the bladder (≥T2) into another. These findings suggest the 
possibility of not only distinguishing invasive from superficial lesions, but also separating 
carcinoma in-situ from superficial lesions and subgroups within early-stage and invasive 
tumours displaying different overall patient urvival. Additionally it may be a valuble tool to 
recognized early-stage tumours showing gene profiles similar to invasive disease and as 
such gene profiling maybe used to successfully classifiy bladder tumours based on their 
progression and clinical outcome. Further studies to identified molecular biomarkers of 
potential clinical significance and identification of genes differentially expressed between 
invasive bladder cancer and invasive bladder cancer progression are needed.  
 
3.4.3 The field effect theory of urothelial epithelial cells carcinogenesis 
The concept of "field cancerization" (field effecy theory) was first introduced by Slaughter 
et al. (Slaughter, Southwick et al. 1953) in 1953 when studying the presence of 
histologically abnormal tissue surrounding oral squamous cell carcinoma. It was proposed to 
explain the development of multiple primary tumours and locally recurrent cancer in oral 
squamous cell carcinoma. Recent molecular findings support the carcinogenesis model in 
which the development of a field with genetically altered cells plays a central role in 
reoccurance of cancer. In this study an invasive-like pattern was observed in the bladder 
tissue taken from the ‘normal’ area of the cancerous bladder of patient 0TB040 (Sample 6 
in the dendrogram, figure 3.1), indicating molecular changes in the tissue which 
histologically presented as benign to the histologist.  This supports the ‘‘field effect’’ theory 
of urothelial epithelial cells carcinogenesis (Jones, Wang et al. 2005).  It has been shown 
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that multiple coexisting tumours often arise before clinical symptoms become apparent and 
that separate tumours may or may not share a similar histology.  Two theories have been 
proposed which suggest a monoclonal or an oligoclonal origin of multifocal urothelial 
carcinomas (Cheng, Jones et al. 2005).   The field effect theory suggests that carcinogenic 
changes have altered the epithelium rendering it more susceptible than "healthy" tissue to 
developing malignant tumours. Another possible cause for this apparent breakdown of the 
urothelium is the implantation theory which proposes that multiple tumours are the result of 
tumour cells that have been shed from an original tumour higher in the urinary tract. The 
tumour cells then attach to the urothelium in a different site and begin to grow.  Recurrences 
occur in more than 60% of patients and are found at sites remote from the primary tumour 
and therefore both these theories may not only account for the frequent development of 
genetically unrelated tumours within the bladder, but also the high rate of reoccurrence of 
bladder TCC.  Obviously it is of clinically important to develop genetic detection for 
recurrent or residual tumour cells and these results provide evidence to suggest that 
diagnosis and treatment of bladder cancer should not only be focused on the tumour but also 
on the field from which it developed.  
 
3.4.4 Rationale for gene selection from microarray results of tissue to investigate in 
bladder cell culture models.  
Bladder cancers represent a spectrum of diseases that can be grouped into three general 
categories: superficial, invasive and metastic.  Each differs in clinical behaviour, prognosis 
and primary management.  The choice of genes to study was based upon the sample 
population of the tissue array data.  As the array data was comparing superficial with more 
invasive grades of bladder cancer and there was neither a benign nor a metastatic group to 
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compare with, the molecular changes between the two groups may imply changes which 
would occur during progression of disease to an invasive state.  Tumour invasion is defined 
as the penetration of tissue barriers, such as the basement membrane, by migrating 
cancerous cells (Pirila, Ramamurthy et al. 2003; Pirila, Sharabi et al. 2003; Matias-Roman, 
Galvez et al. 2005; Hwang and Lee 2006).  Muscle invasive bladder cancer (≥T2) and high 
risk superficial bladder cancer carry a significant metastic potential despite radical surgical 
treatment (Hart and Saini 1992; Cheng, Weaver et al. 2000; Dalbagni, Genega et al. 2001; 
Gontero, Banisadr et al. 2004).  Since the majority of bladder cancer mortality is associated 
with invasion into the bladder muscle wall and the progression to metastic disease, the 
ability to inhibit cell segregation from the primary tumour and invasion of surrounding 
tissues would significantly reduce bladder cancer related morbidity and mortality.  Early 
detection of molecular changes that enable or facilitate cancer cells to metastasize may help 
to identify low risk superficial from high risk superficial and more invasive bladder cancer 
that deserve more aggressive treatment (Gontero, Casetta et al. 2004).  These molecular 
changes are said to be over and above those required for tumorigenesis, such as changes in 
cell cycle related proteins.  Cell cycle related proteins and oncogenes have been shown to 
able to confer unrestricted growth potential to cells but not necessarily have invasive and 
metastasis properties(Gontero, Banisadr et al. 2004).  Tumour cells frequently invade 
surrounding tissues as the tumour begins to grow.  Next, capillary endothelial cells invade 
the tumour and create tumour blood vessels.  Thereafter, some tumour cells intravasate into 
the blood circulation for metastasis, where host immune cells invade the tumour.  Finally, 
tumour cells arrest in distant organs, extravasate and migrate into new metastic sites and 
then start the invasion cycle again (Matias-Roman, Galvez et al. 2005; Hwang and Lee 
2006).  Current models of carcinogenesis suggest that there are three major steps in the 
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molecular pathway that allow the cancer cells to acquire the metastatic phenotype: 1) 
breakdown in cell-cell and cell matrix adhesion, 2) modulation of the extracellular matrix 
(ECM), proteolysis and adhesion and 3) induction of angiogenesis. Therefore it was thought 
that the gene and protein expression patterns of ECM genes such as Collagen, type V1, 
alpha 1 maybe of more importance and more relevance to this particular study group.  The 
microarray results show that the expression of COL6A1 was increased in the invasive group 
in comparison with the superficial group and therefore selected for further study with 
bladder tissue and in the bladder cell culture model, UM-UC-3.  
Collagen VI has a ubiquitous distribution throughout connective tissues where it forms an 
extensive microfibrillar network, linking cells and many matrix components (Baldock, 
Gilpin et al. 2002; Baldock, Sherratt et al. 2003; Ball, Bella et al. 2003).  They are 
important in maintaining the integrity of the tissues.  Collagen types VI are integral to the 
formation of collagen fibres which are a major component of the ECM.  The ECM supports 
most tissues and gives cells structure from the outside and is essential for cell differentiation 
and associated gene expression 
Collagen VI is a large collagenous glycoprotein composed of three different a-chains, the a1 
(VI), a2 (VI) and a3 (VI) (Chu, Mann et al. 1987; Baldock, Sherratt et al. 2003).  Collagen, 
type V1, alpha 1, which has been shown to be unregulated in the more invasive tissue type 
by the microarray data, is an adhesive glycoprotein of the ECM and is evenly distributed 
throughout the stroma, but mainly associated with the basal lamina, collagen fibrils, and 
around the stromal cells. 
Although there is no known work that I’m aware of on collagen V1 and bladder cancer, the 
potential importance of collagen VI protein has been studied in relation to other cancers 
such as prostrate, colon and breast cancer.  Increased stromal expression of collagen VI has 
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been correlated with various aspects of tumorigenesis and malignant progression and 
Lyengar et al. suggests collagen VI maybe an early diagnostic marker of mammary 
hyperplasia and a growth-promoting factor that maybe inhibited to reduce mammary 
tumour progression (Iyengar, Espina et al. 2005). 
It has been shown that type VI collagen is upregulated during murine mammary tumour 
progression (Iyengar, Combs et al. 2003).  Specifically, the α3 subunit of collagen VI is 
upregulated in the stroma surrounding colonic tumours compared with that surrounding 
normal tissue (Iyengar, Espina et al. 2005).  Exposure of fibroblasts to collagen VI 
promotes proliferation and upregulation of cyclin D1 (Ruhl, Johannsen et al. 1999).  
Furthermore, the protein inhibits apoptosis in a variety of cell types (Howell and Doane 
1998).  TGF-β–expressing melanoma cells induce collagen VI expression in mammary 
stroma, facilitating tumour progression and invasiveness (Berking, Takemoto et al. 2001). 
Most recently, increased collagen VI, in particular COL6A3 expression in the ECM has 
been associated with the promotion of chemoresistance in ovarian cancer cells (Sherman-
Baust, Weeraratna et al. 2003; Varma, Hector et al. 2005).  In contrast 
immunohistochemical investigation of primary biphasic synovial sarcomas showed low 
frequency of collagen type II and VI expression in the extracellular matrix of the tumours 
(Osmanov Iu, Petrovichev et al. 2005).  In prostate, collagen XXIII expression has been 
associated with prostate cancer recurrence and distant metastases.  The levels of collagen 
XXIII is a significant independent predictor of PSA-defined disease recurrence, suggesting 
a potential role as a molecular biomarker of prostate cancer progression and metastasis 
(Banyard, Bao et al. 2007).  Although in a recent experiment the gene expression of human 
collagen type VI was shown to be remarkably decreased in suspension-adapted PC-3 (saPC-
3) cells (Patrikainen, Porvari et al. 2007). However Kopp et al. provide evidence that the 
106 
 
expression of collagen VI is completely inhibited in virally transformed fibroblasts and in 
many cell lines derived from spontaneous mesenchymal tumours and that DNA methylation 
plays an important role in this inhibition (Kopp, Winterhalter et al. 1997).   
Collagen prolyl hydroxylases are required for proper collagen helix synthesis. Hypoxia is 
the microenvironment in which carcinomas thrive and results in the induction of a cluster of 
hypoxia related genes, shown in a recent cell culture study using hepatoma HepG2 cells 
(Cutroneo, White et al. 2007).  The cellular response to hypoxia is characterized by an 
enhanced deposition of extracellular matrix (ECM) components, mainly collagens (Fahling, 
Perlewitz et al. 2004) and therefore may account for the increased expression of COL6A1 
in the more advanced tumour tissue.  The results from the Fahling et al. study indicate that 
hypoxia affects collagen homeostasis in a biphasic manner concerning basic mechanisms of 
gene expression. Proline 4 hydroxylase (P-4-H-alpha) subunits are said to be up-regulated at 
the transcriptional and translational level (Fahling, Perlewitz et al. 2004) and this is also 
observed in this microarray data.  Collagen homeostasis is determined by the rate of 
synthesis and degradation.  An earlier study using rat vascular smooth muscle cell line 
A7r5, found that an hypoxic atmosphere caused a characteristic time-dependent 5 to 12-fold 
up-regulation of the mRNAs of  P-4-H, among other hypoxia related enzymes and strong 
evidence suggests that the expression of these enzymes during hypoxia is coordinated by 
HIF-1(Hofbauer, Gess et al. 2003; Cutroneo, White et al. 2007; Cutroneo, White et al. 
2007).  
It has been speculated that in gastric carcinoma, activated fibroblasts participate in collagen 
biosynthesis at the tumour periphery rather than in the tumour centre and that increased 
collagen biosynthesis at the tumour periphery in gastric carcinoma may assist further 
invasion of tumour cell (Matsui, Kubochi et al. 1999).  A quantitative RT-PCR assay was 
107 
 
designed and optimized for COL6A1 to validate array data and for further investigation in 
chapter five. 
In summary, although the prevalence of the GST polymorphisms studied were in 
accordance with published data, it was very difficult to make any real conclusions regarding 
the results, due to the inadequate sample size.  However the array analysis successfully 
identified two clinically distant phenotypes following unsupervised sample clustering.  For 
the first time it has been shown that bladder tumours have distinct gene expression profiles 
in accordance to their grade.  The array data also supported the field effect theory of 
urothelial cell carcinogenesis, by highlighting molecular changes in tissue which appeared 
histologically benign.  In the following chapter the aim is to characterise the human bladder 
cancer cell lines UM-UC-3 and RT4 for the GST polymorphisms most extensively studied 
in bladder cancer and to explore the effects of two isothiocyanates, iberin and sulforaphane 
on phase 2 gene expression in these cell lines.  Furthermore in chapter five these 
characterised cell lines will be used to explore the relationship of the COL6A1, highlighted 
in this chapter, on the grade of bladder cancer and explore the effects of iberin and 
sulforaphane on COL6A1 gene expression.  
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CHAPTER 4: Characterisation Of Human Bladder Cell Cultures And The Effects Of 
Sulforaphane And Iberin On Phase 2 Gene Expression. 
4.1 Introduction 
In the previous chapter I characterised the bladder tissue for the most extensively studied 
GST polymorphisms; GSTM1 and GSTT1 null genotypes plus allele discrimination of the 
GSTM1 positive samples, the GSTpi (Ile105Val polymorphism/ Ala114Val polymorphism), 
and the GSTM3 3 base pair deletion.  In this chapter I describe the characterisation of UM-
UC-3 and the RT4 human bladder cell lines, investigating genotype, gene expression, 
methylation status and enzyme activity of the GSTM1 gene.  
 Subsequently I explore the effects of sulforaphane and iberin and their N-acetyl-L-
cysteine conjugate on the GST, and NQO1 expression in these human bladder cell lines.  SF 
is highly reactive and has a very short half-life in the body, forming a glutathione conjugate 
that is further metabolized to the N-acetylcysteine conjugate (SF-NAC), which is the major 
excretory product found in the urine (Hwang and Jeffery 2005).  This conjugate is a 
reversible complex, able to release free SF (Tang and Zhang 2004; Hwang and Jeffery 
2005).  As bladder cancer is being investigated in this project and the urine, with its 
potentially high concentration of SF and/or SF-NAC, collects and is stored in direct contact 
with the bladder epithelial tissue where the tumour originates, I also aim to investigate 
whether the SF-NAC and IB-NAC have a similar biological effect as their parent 
compounds.  
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4.2 Specific material and methods 
Both DNA for genotyping and RNA for gene expression analysis were carried out in 
accordance with the manufactures recommendation (see section two).  Total GST activity 
was determined in both bladder cell lines (see section two).  A quantitative methylation 
specific PCR (QMSP) assay approach was used for the measurement of the methylation 
status of the GSTM1 gene in six bladder tissue biopsies and two bladder cell lines (see 
section two).  UM-UC-3 and RT4 cell lines were obtained from the European collection of 
animal cell cultures (ECACC).  UM-UC-3 (passage 18) and RT4 (passage 9) established cell 
cultures were seeded into a six well plate and treated with 12µM of SF, IB or SF-NAC for 48 
hours (see section 2).  Iberin and sulforaphane were purchased from LKT Laboratories and 
the cell treatments occurred in complete media with less than 0.1% dimethyl sulphoxide 
(DMSO, Sigma-Aldrich).  The N-acetylcysteine conjugates were made by Dr Paul Needs, 
IFR chemist.   
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4.3 Results  
4.3.1 Genotyping of UM-UC-3 and RT4 cell lines and base line gene expression. 
 
 
Figure 4.1 GSTM3 allelic discrimination of bladder cells.     
Indicate both A and B alleles resulting in A*B* genotype for the UM-UC-3 bladder cell line. 
 
Indicates two copies of the A allele resulting in A*A* genotype for the RT-4 cell line 
 
Negative control 
 
 
As can be seen in Figure 4.1, RT4 cells show a high reading on the Y axis with a low 
reading on the X axis which suggests two copies of the A allele and therefore corresponds 
with the wild type A*A* genotype.  A high reading on the X axis with a low reading on the 
Y axis would suggest two copies of the B allele and as such, correspond with the B*B* 
genotype.  Therefore, as the UM-UC-3 bladder cells show similar readings on both the X 
and Y axis which is roughly half the intensity of the A*A* genotype, then this would 
suggest one of each allele which corresponds with the A*B* genotype. 
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Figure 4.2 GSTP1 allelic discrimination of bladder cells 
    Indicates two copies of the A allele resulting in A*A* genotype for the RT-4 cell line. 
     Indicates two copies of the G allele resulting in G/G genotype for the UM-UC-3 cell line 
    Positive control (known G/A genotype) 
     Negative control 
 
 
As ssen in Figure 4.2, RT4 cells show a high reading on the Y axis  with a low reading on 
the X axis suggesting two copies of the A allele and therefore corresponds with the A*A* 
genotype.  UM-UC-3 cells show a high reading on the X axis with a low reading on the Y 
axis which suggests two copies of the G allele and as such corresponds with the G/G 
genotype. 
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The RT4 cell line is null for the GSTM1 gene and therefore no gene expression was 
observed.  Although it was shown in table 4.1 that the UM-UC-3 cell line has 1 copy, there 
is no detectable expression of this gene.  This may be due to methylation of the GSTM1 
gene and this will be investigated later in this chapter.   
 
Cell line GSTM1  GSTM3 GSTT1 GSTP1 
UM-UC-3 1 copy A/B A/A G/G 
RT4 Null A/A null A/A 
Table 4.1 Genotype characterisation of the two bladder cells lines 
 
 
 
 
Cell line GSTM1  GSTM3 GSTT1 GSTP1 
UM-UC-3 No  yes yes Yes 
RT4 N/A yes N/A No 
 
Table 4.2 Baseline gene expression of the two bladder cell lines 
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4.3.2 Total GST activity and the methylation of the GSTM1 gene. 
Interestingly, it was observed that although the cell line UM-UC-3 has a positive GSTM1 
genotype, there was no detectable gene produce.  The subsequent low expression of the 
GSTM1 enzyme appears to correlate with the relatively high percentage of methylation of 
the gene in this cell culture (64.1%, table 4.3), however further investigations are needed to 
be able to connect the two findings.  Another interesting observation is that the UM-UC-3 
cell line shows comparably high total GST activity; since the cell line is not expressing the 
GSTM1 gene and thus the protein/enzyme, this high total GST activity can not be as a 
result of the GSTM1 gene. 
 
 
Figure 4.3 Total GST activity in the human cell lines. 
 
The UM-UC-3 cell type shows a much greater degree of total GST activity than the RT4 
cell type.  As the RT4 cell type is null for both GSTM1 and GSTT1 and does not express 
GSTP1, and the UM-UC-3 cell type expresses all the GSTs studied except GSTM1, this 
may explain the low degree of total GST activity of the RT4 cell type in comparison to the 
UM-UC-3 cell type.  
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The results in Table 4.3 show the percentage of methylation detected by two methylation 
primer pairs in the GSTM1 gene and the standard deviation (Std. Dev) of the three 
replicates.  Another bladder cell line was investigated (R24) as the RT4 cell line could not 
be used in this study as it is null for the GSTM1 gene.  
 
Tissue bank 
number/cell type Primer 1
1 
 Primer 22   
 %  methylation Std. Dev %  methylation Std. Dev 
02TB058 9.99 0.91 10.79 0.49 
02TB044 0.53 0.03 0.44 0.01 
03TB146 0.62 0.09 0.49 0.01 
03TB179 5.36 0.37 6.41 0.37 
04TB119 3.32 0.39 2.87 0.10 
04TB119 0.50 0.05 0.48 0.01 
UM-UC-3 64.10 14.86 18.70 0.41 
R24 0.34 0.03 0.34 0.01 
Table 4.3 Methylation studies of the GSTM1 gene in UM-UC-3 and R24 bladder cell lines and selected 
bladder biopsy samples (in collaboration with Mr Jim Bacon)  
1
 - Primer 1  
2 - Primer 2  
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4.3.3 Modulation of phase 2 gene expression following physiologically relevant 
treatments of SF, IB or SF-NAC in the UM-UC-3 and RT4 cell line. 
 
In the UM-UC-3 human bladder cell line GSTP1 gene expression is significantly up-
regulated following the 48hr treatments with 12µM of SF (up-regulation of 1.7. p0.008) 
and IB (up-regulation of 1.4, p0.3), but not following 48hr treatments with 12µM of SF-
NAC.  The RT-4 cell line showed no altered GSTP1 gene expression. 
In the UM-UC-3 cell line GSTM3 gene expression is significantly up-regulated 
following 48hr treatments with 12µM of SF (up-regulation of 1.7, p0.01) and IB (up-
regulation of 1.4, p0.02), but not following 48hr treatments with 12µM of SF-NAC.  In the 
RT4 cell line GSTM3 gene expression is significantly up-regulated following 48hr 
treatments with 12µM of SF (up-regulation 12, p-0.001) and IB (up-regulation 7, p0.002)  
and also following the treatment of 12µM of SF-NAC (up-regulation 6, p0.002). 
NQO1 gene expression is significantly up-regulated following 48hr treatments with 
12µM of SF (up-regulation 7, p0.001), IB (up-regulation 5, p0.005) and also to a greater 
extent SF-NAC (up-regulation 8, p0.01) in the RT4 cell line.  NQO1 gene expression is 
significantly up-regulated following 48hr treatments with 12µM of SF (up-regulation 3.5, 
p0.007) and IB (up-regulation 2.1, p0.03) and 12µM of SF-NAC (up-regulation1.4, p0.03) 
in the UM-UC-3 cell line. 
 The RT-4 cell line was null for GSTM1 and GSTT1 and therefore showed no 
expression of these genes.  The UM-UC-3 cell line is also null for the GSTT1 gene and as 
such showed no expression of the gene.  The UM-UC-3 cell line showed no modulation of 
expression in the GSTM1 gene following the 48hr treatments. 
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12µM 48hr treatment Gene 
  SF IB SF-NAC 
  Fold1 p-value fold p-value fold  p-value 
GSTP1 1.7↑2 0.008 1.4↑ 0.3  ns3 
GSTM1  ns3  ns3  ns3 
GSTM3 1.7↑ 0.01 1.4↑ 0.02  ns3 
GSTT1  N/A4  N/A4  N/A4 
NQO1 3.5↑ 0.007 2.1↑ 0.03 1.4↑ 0.03 
Table 4.4 Changes in gene expressions following physiologically relevant treatments of SF, IB or SF-NAC 
in the UM-UC-3 cell line 
1-
 Mean gene fold change following 48 hour treatment  
2 - ↑/↓ Increase or decrease in mean gene folds change 
3- No significant change in gene expression  
4 –
 Not applicable as the cell line is null for the gene. 
Real time RT- PCR expression of GSTs in the UM-UC-3 cell line following a 48 hour treatment with 12µM of SF, IB or 
SF-NAC. The results are shown as mean expression of the three replicates.  
 
 
12µM 48hr treatment gene 
  SF IB SF-NAC 
  Fold1  p-value fold  p-value fold  p-value 
GSTP1  ns3  ns3  ns3 
GSTM1  N/A4   N/A4  N/A4 
GSTM3 12↑2 0.001 7↑ 0.007 6↑ 0.002 
GSTT1  N/A4  N/A4  N/A4 
NQO1 7↑ 0.001 5↑ 0.005 8↑ 0.014 
 Table 4.5 Changes in gene expressions following physiologically relevant treatments of SF, IB or SF-NAC 
in the RT4 cell line. 
 1
- Mean gene fold change following 48 hour treatment  
2 
- ↑/↓ Increase or decrease in mean gene fold change 
3 - No significant change in gene expression 
4-
 Not applicable as the cell line in null for the gene 
Real time RT- PCR expression of GSTs in the RT-4 cell line following a 48 hour treatment with 12µM of SF, IB or SF-
NAC. The results are shown as mean expression of the three replicates. 
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4.4 Discussion 
In this chapter I have characterised the two bladder cell lines by investigating GST 
genotype, gene expression and enzyme activity of the GSTM1 gene. The biological 
consequences of failure to express some GST proteins such as hGSTMI or hGSTTI can 
include susceptibility to bladder, colon, skin, and possibly lung cancer. A decrease in GST 
enzyme activity could result in inefficient detoxification of various carcinogens, which 
could lead to genetic damage and increased cancer risk. This decrease maybe a result of 
deletion polymorphisms, such as GSTM1 and GSTT1 or substitution A-G polymorphism as 
observed in the GSTP1 gene, resulting in an amino acid substitution (Ile105Val). This 
residue lies in the substrate binding site of the enzyme and the polymorphism has been 
shown to affect enzyme activity. Also where no expression of a gene is detected, such as 
the GSTp1 gene in the RT4 cell line would result in no enzyme activity. Furthermore it 
was demostrated that SF, IB and their conjugates significantly augmented expression of the 
phase II enzyme genes GST and NQO1 in these cell lines, which may suggest that ITC 
treatment increases phase II activity.  
4.4.1 Characterisation of UM-UC-3 and RT4 cell lines 
It was observed that whilst the cell line UM-UC-3 had a positive GSTM1 genotype, 
it is not expressing this gene. The subsequent low expression of the GSTM1 enzyme 
appears to correlate with the relatively high percentage of methylation of the gene in this 
cell culture, however further investigations are required to be able to connect the two 
findings.  The UM-UC-3 cell line showed a much greater degree of total GST activity 
compared with the RT4 cell line, this may be due to the nature of the cell line, that is, UM-
UC-3 is derived from a much higher/invasive form of bladder cancer than the RT4 cell 
line.  This is not surprising as over-expression of GSTs have been demonstrated in a 
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number of different human cancer cells.  Another interesting observation is that the UM-
UC-3 cell line shows comparably high total GST activity, as the cell line is not expressing 
the GSTM1 gene and thus the enzyme and the high total GST activity can not be due to the 
GSTM1 gene.  Several sub-classes of GST exist (section 2) and strong induction of a 
particular subunit may be partially masked by the background activity of other subunits 
when measuring total GST activity (Juge, Mithen et al. 2007).  If time permitted, 
investigating specific GST activity between the two cell lines would have been valuable. 
Significant concordance between methylated genes and the high rate of bladder 
cancer recurrence have been observed (Friedrich, Weisenberger et al. 2004; Christoph, 
Hinz et al. 2007).  GSTpi was shown to be methylated, along with a panel of genes, in 
disease recurrence in superficial bladder cancers (Tada, Wada et al. 2002).  It has been 
suggested that GST-pi CpG island hypermethylation may account for EBV-associated 
gastric carcinoma, as the loss of GSTpi expression is clustered in a subset of gastric 
carcinomas with EBV incorporation, but not EBV-negative gastric carcinomas (Kim, Lee 
et al. 2005).  
Epigenetic inactivation via methylation of members of the glutathione pathway has 
been studied in relation to Barrett's adenocarcinoma (BAC), a form of esophageal cancer. 
Seven GST genes were shown to have CpG islands around their transcription start sites in 
BAC samples; GSTM2-M5, GSTA4, GSTP1, GSTZ1, GSTT2, GSTO1 and GSTO2, 
demonstrating mRNA down regulation of GSTM2, GSTM3 and GSTM5 in more than half 
of the BAC samples (Peng, Razvi et al. 2009).  Furthermore treatment of oesophageal 
cancer cell lines with 5-aza-2'-deoxycytidine and trichostatin-A led to reversal of the 
methylation pattern and re-expression of these genes (Peng, Razvi et al. 2009).  
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The prostate cancer cell lines LNCaP, PC3, and Du-145 have been used to identify 
candidate genes, which are inactivated by CpG methylation in prostate cancer, by 
microarray analysis (Lodygin, Epanchintsev et al. 2005).  The cells were treated with 5-
aza-2' deoxycytidine and trichostatin A, which leads to reversion of epigenetic silencing of 
many candidate genes, including GSTM1.  However several hundred genes were found to 
be induced by 5-aza-2' deoxycytidine when compared with cells treated with trichostatin A, 
suggesting a much higher degree of epigenetic inactivation via methylation than via 
phosphorylation.  Furthermore the study investigated the frequencies of CpG methylation 
in the promoter regions of primary prostate cancer samples derived from 41 patients and 
observed that in 58% of the 41 patients they detected methylation in the promoters of 
GSTM1 (Lodygin, Epanchintsev et al. 2005).   
4.4.2 Effects of SF, IB and their conjugates on GST and NQO1 gene expression 
Consumption of cruciferous vegetables, such as broccoli has long been associated 
with a reduced risk of disease especially cancer.  The protective effect is most often 
attributed to SF, as SF has been shown to be the most potent naturally occurring inducer of 
phase 2 enzymes in in-vitro and in-vivo studies (Petri, Tannergren et al. 2003; Munday and 
Munday 2004).  However it is important to highlight other phytochemicals such as 
dithiolethiones which are organosulfur compounds also present in cruciferous vegetables 
and have been shown to have similar anticarcinogentic effects as ITCs (Zhu, Jia et al. 
2009).  The induction of GSTs by ITC has been extensively explored in cell culture and 
animal models.  Furthermore several epidemiological studies also indicate that the dietary 
consumption of ITCs or ITC-containing foods, inversely correlates with the risk of 
developing lung, breast, and colon cancers.  The proposed methods of induction have been 
discussed in chapter one.  
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Briefly, the anticarcinogenic properties of ITCs have been attributed to their ability to alter 
detoxification pathways leading to decreased activation of procarcinogens and increased 
excretion of carcinogens.  Mechanistically, ITCs are capable of inhibiting both the 
formation and development of a cancer cell through multiple pathways; i.e. the inhibition 
of carcinogen-activating cytochrome P450 mono-oxygenases, induction of carcinogen-
detoxifying phase 2 enzymes, induction of apoptosis, and inhibition of cell cycle 
progression (Juge, Mithen et al. 2007).  The biological interactions of ITCs are strongly 
related to modulation of cellular redox status, and a number of studies have documented 
their indirect antioxidant properties, particularly related to induction of phase-2 enzymes 
(Valgimigli and Iori 2009).  SF induces antioxidant response element (ARE) expression 
through disruption of the Keap1–Nrf2 complex.  SF can interact directly with sulfhydryl 
residues on Keap1, causing Nrf2 to be released.  Alternatively, SF can activate the MAPK 
pathway, causing phosphorylation of Keap1 and release of Nrf2.  Once released, Nrf2 
enters the nucleus, where it transactivates ARE-responsive genes.  A study showed that 
dietary isothiocyanates modulate phase I and phase II enzyme expression and increase the 
rate of detoxification of the dietary carcinogen PhIP in human HepG2 cells.  SF decreased 
the number of PhIP-DNA adducts by approximately 40% in human HepG2 cells pre-
treated with 1 µM SFN followed by 10 ng PhIP.  However, there was no decrease in DNA 
adduct formation with post-treatment of SF, suggesting that SF had no effect on PhIP 
DNA-adduct repair, but rather prevented PhIP interactions with DNA (Bacon, Williamson 
et al. 2003). 
Recently it has been shown that many ITCs and their N-acetylcysteine conjugates 
are potent inducers of phase 2 enzymes in rats bladder (Munday and Munday 2002; 
Munday and Munday 2004; Munday, Zhang et al. 2006).  It is clear from these in vitro 
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studies that SF and possibly SF-NAC have the capability to modulate some phase 2 gene 
expression.  In concordance with these findings, a study investigating the effects of ITCs 
on the expression of both NQO1 and GST in rat tissues in vivo found the urinary bladder to 
be the most susceptible to the inductive activity of the ITCs.  However, in contrast, this 
induction of GST and NQO1 in vivo did not correlate with that in bladder cells in vitro 
(Munday, Zhang et al. 2008).  
It has been observed that GSTpi protects mitochondria against oxidative stress in 
human hepatic mitochondria (Gallagher, Gardner et al. 2006).  The mitochondrial 
environment is rich in reactive oxygen species (ROS) that may ultimately peroxidize 
mitochondria membrane proteins and generate unsaturated aldehydes.  These chemicals 
decrease cell viability and reduced mitochondrial membrane potential.  However it was 
observed that over expression of GSTpi diminished these changes(Goto, Kawakatsu et al. 
2009).    
Overall NQO1gene expression appears to be the most sensitive to induction by the 
ITC.  This is not surprising, as this has been shown at a functional enzyme level in many 
studies (Jones and Brooks 2006; Zhang, Munday et al. 2006).  NQO1 was also shown to be 
induced by SF-NAC in both cell lines.  The RT4 showed the greatest induction of the gene 
by SF-NAC (8 fold).  A similar study compared quinone reductase activity induced by SF 
and SF-NAC in murine hepatoma cells. This study showed a SF and SF-NAC dose-
dependent induction of QR and a greater induction of the gene was seen in the SF-NAC-
treated cells.  These are important considerations, as the half life of free SF in plasma is 
very short, being approximately an hour (Ye, Dinkova-Kostova et al. 2002), whereas SF-
NAC is several times longer.  Therefore it is important to consider the possibility that ITC 
conjugates are as effective, if not more effective than the free ITC, especially in the 
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bladder, where the SF and its conjugates maybe in direct contact with the bladder epithelia 
for long periods of time.  
GSTM3 showed a marked up-regulation in the RT4 cell line by both SF and IB and 
also a six fold increase in GSTM3 gene expression by SF-NAC.  The effect of 
polymorphisms of GSTM3 on the influence of cigarette smoking on urinary bladder 
(Golka, Schmidt et al. 2008), larynx (Jourenkova-Mironova, Voho et al. 1999) and lung 
(Reszka, Wasowicz et al. 2007) carcinogenesis has been investigated with conflicting 
results.  Genotypes GSTM3 A*B* and GSTM3 B*B* potentially affect detoxification 
activity of GSTM3 enzyme.  The RT4 cells have been shown to be the A*A* wild type 
genotype (table 4.2) and thus this up-regulation of the GSTM3 would potentially be more 
beneficial than the moderate up regulation of the GSTM3 gene in the UM-UC-3 cell which 
have a genotype of GSTM3 A*B* (table 4.1).  Note that it is the more invasive/high grade 
cell line (UM-UC-3) which exhibits the high risk genotype.  
Although many cell lines respond to SF treatment, there appears to be some 
variability in the extent and type of Phase 2 enzyme induction, depending on cell type.  For 
instance, in HT29 cells a decrease in GST activity was observed, whereas CaCo-2 cells 
demonstrated a dose- and time-dependent induction of GSTA1 and UGT1A1 upon SF 
administration (Svehlikova, Wang et al. 2004).  These effects of SF in cell culture can be 
extrapolated to in vivo situations, as induction of GST and QR activities was observed in 
tissues of mice given SF orally, demonstrating that systemic uptake and bioavailability of 
SF and/or its metabolites was feasible (Zhang, Talalay et al. 1992).  In concordance with 
these results, rats treated by gavage for 5 consecutive days demonstrated a dose-dependent 
(200–1000 µmol SF/kg per day) increase in QR and GST activity in the liver, colon and 
pancreas (Matusheski and Jeffery 2001); and 40 µmol SF/kg per day for 5 days by gavage 
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increased QR and GST activities in the rat forestomach, duodenum, and bladder (Munday 
and Munday 2004).  Confirming these observations, that oral administration of SF induces 
phase 2 enzymes in bladder tissues, male F344 rats were gavage fed 50 mg/Kg/day of SF 
and the prostate, liver, kidney and bladder tissues were harvested on day six.  Compared to 
control animals, SF significantly induced NQO1 or total GST enzyme activity in the liver, 
kidney and, most significantly, in the bladder tissues.  A study investigating the antioxidant 
capacity in human TCC, observed a marked increase in the GSTP1 protein which 
correlated with the tumour grade.  The GSTP1 isoenzyme was expressed in all normal and 
tumour TCC tissue samples.  The study compared tumour samples with adjacent 
histological benign tissue biopsies (n=30).  All normal TCC tissue samples expressed 
similar levels of GSTP1.  In the tumour tissue significant up regulation of GSTP1 
expression was observed (mean ng/mg cystolic protein).  The mean level of GSTP1 
expression in TCC was increased 2.3 fold compared to the mean level in the normal 
adjacent mucosa.  Furthermore, when comparing the mean level of GSTP1 expression of 
superficial and invasive tissue biopsies, it was observed that although the benign tissue 
expressed similar levels of GSTP1, the expression in the tumour samples were significantly 
up regulated in the invasive tumour tissue compared to the benign tissue, suggesting 
GSTP1 protein expression correlates with the grade of TCC (Pljesa-Ercegovac, Savic-
Radojevic et al. 2009).  This highlights the importance of further studies investigating the 
up regulation of the GSTP1 in invasive TCC in relation to chemotherapy resistance, as it’s 
unknown whether GSTP1 is active towards the agents used in the chemotherapy of TCC 
(Berendsen, Peters et al. 1997). 
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Chapter Five: The Relationship COL6A1 Expression And The Grade Of Bladder 
Cancer And The Modulation Of The Expression Of COL6A1 In Human Cell 
Cultures. 
5.1 Introduction 
The first aim of this chapter is to investigate the association between COL6A1 gene 
expression in human bladder tissue in relation to the severity of bladder cancer.  A 
significant 5.7 fold change was observed in the array analysis in chapter three, showing an 
increase in this gene’s expression in the invasive bladder cancer samples.  To investigate 
these results further, subsequent samples were received for RT-PCR analysis.  Although 
there is no know work on collagen type VI alpha 1 and bladder cancer, the potential 
importance of collagen VI protein has been studied in relation to other cancers such as 
prostrate, colon and breast cancer.  Increased stromal expression of collagen VI has been 
correlated with various aspects of tumorigenesis and malignant progression and it has been 
suggested that collagen VI maybe an early diagnostic marker of mammary hyperplasia and 
a growth-promoting factor that maybe inhibited to reduce tumour progression.  An initial 
investigation into the effects of SF and IB was carried out in the last chapter; the second 
aim of this chapter is to examine these phenomena in more detail.  The possibility of 
modulating the expression of the gene encoding COL6A1 and the COL6A1 protein by 
exposing the previously characterised human bladder cell cultures to nutritionally relevant 
doses of sulforaphane, Iberin and their congulates will be investigated.  
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5.2 Specific materials and methods 
RNA for gene expression analysis was carried out in accordance with the manufactures 
recommendation (see section two).  UM-UC-3 and RT4 cell lines were obtained from the 
European collection of animal cell cultures (ECACC).  Briefly, UM-UC-3 (passage 20) and 
RT4 (passage 11) established cell cultures were seeded into a six well plate and treated with 
12µM of SF, IB or SF-NAC for 48 hours (see section 2).     
A preliminary study was carried out to assess the feasibility of a larger study 
investigating the relationship of COL6A1 expression and grade of bladder cancer.  From 
the seven remaining tissue samples I was able to select four samples with increasing 
grades.  Further samples were requested from the NNUH tissue bank. The samples were 
analysis blinded; that is, the histological results were unknown at the time of the RT-PCR 
analysis.  
The protein expression of COL6A1 was endeavoured to be assessed using western 
blotting.  UM-UC-3 (passage 22) and RT4 (passage 14) established cell cultures were seeded 
into a 10 cm dishes and treated with 12µM of SF, IB or SF-NAC for 48 hours (see section 2).  
Briefly, protein was extracted with RIPA buffer and separated by SDS-PAGE as outlined 
in section 2.  Proteins were trasnferred onto nitrocellulose membrane and probed with 
human COL6A1 antibody.  
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5.3 Results 
 
5.3.1 Correlation of COL6A1 gene expression with the grade of bladder cancer 
 
 
Figure 5.1 Real time RT-PCR analysis of COL6A1 expression in human bladder tissue with varying severity 
of grades. RNA was extracted from four biopsies taken from four individuals and data is shown from three 
biological replicates of each sample plotted with SD (*p<0.005).  
 
It can be seen from figure 5.1 that COL6A1 gene expression significantly increases with 
the grade of bladder cancer.  This was a preliminary study to firstly confirm the results 
from chapter 3 (figure 3.4) and secondly to assess the feasibility of a larger study 
investigating the association of COL6A1 expression and grade of bladder cancer.  Figure 
5.1 shows a steady increase of COL6A1 gene expression from the lowest grade to the 
highest grade and a 40 fold increase in COL6A1 gene expression from the superficial (G2 
pTa) to the invasive (G3 pT3b). Analysis of variance (ANOVA) was employed to test the 
hypothesis that the means of the four populations are equal. The null hypothesis stated that 
all population means are equal. The resulting overall P value (<0.001) was small and 
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therefore it was unlikely that the differences observed are due to random sampling. The 
large F (F=56038.96) is evidence against the null hypothesis, since it indicates that there is 
more difference between groups than within groups. The Null hypothesis was rejected; not 
all the means are equal. 
 
Grade* 
Tissue bank 
sample number  Grade if known** 
              
***COL6A1 gene 
expression                      
03TB179   Ta 155.1 
03TB192   533.4 
03TB163  T1 1490.3 
04TB067    
 
1606.3 
04TB023   2149.3 
04TB018   2365 
03TB135   
 
2476.3 
Ta
-
T1
 
03TB195    2634.4 
03TB165    3387.4 
04TB035   3514.9 
04TB269   
 
3966.1 
T2
 
04TB093   T2b 5691.1 
03TB180  
  
7856.2 
04TB099  9087.2 
03TB189   9680.3 
T3
 
02TB040   T3b 11943.5 
T4
 
04TB280    17391.2 
Table 5.1 COL6A1 gene expression in 17 bladder cancer tissue samples. 
*refer to section 1 for a detailed explanation of grading system. 
**Samples from the previous experiment (results shown in figure 5.1) are highlighted in red and as such the 
grade of cancer is known. 
***Real time RT-PCR result. 
 
Table 5.1 gives the results of RT-PCR analysis of the 13 further biopsy samples received 
with unknown grades and also the four samples previously analysised with known grades 
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(total of 17 samples).  All samples were analysed together in one RT-PCR experiment and 
the ‘unknown samples’* results were entered into table 5.1 in accordance to the COL6A1 
gene expression result. 
T4T3T2T1Ta
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
C
O
L
6
A
1
 g
e
n
e
 e
x
p
re
s
s
io
n
Individual Value Plot of Ta, T1, T2, T3, T4
 
Figure 5.2 COL6A1 gene expression plotted against the histological results of the seventeen bladder 
biopsies.  
Finally the unknown histological results were requested from the histopathologist and the 
COL6A1 gene expression was plotted against grade of bladder cancer, Ta being the lowest 
grade and T4 the highest grade.  Although there is variation and overlap in the degree of 
COL6A1 gene expression, especially in the lower Ta grade, it can be seen that the degree 
of gene expression does follow a definite trend towards increasing with severity of grade, 
showing approximately an 18 fold increase in COL6A1 gene expression at the highest 
grade of T4 compared to the lowest, Ta. As for the prelimary analysis (Figure 5.1) 
ANOVA was employed to test the hypothesis that the means of the five populations (TA, 
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T1, T2, T3 & T4) are equal. The null hypothesis stated that all population means are equal. 
The resulting overall P value (<0.001) was small and therefore it was unlikely that the 
differences observed are due to random sampling. The large F (F=147.90) is evidence 
against the null hypothesis, since it indicates that there is more difference between groups 
than within groups. The Null hypothesis was rejected; not all the means are equal. 
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5.3.2 Modulation of COL6A1 gene expression in bladder cell lines by physiologically 
relevant treatments of sulforaphane, iberin and their N-acetylcysteine conjugates. 
 
Figure 5.3 Real time RT-PCR of COL6A1 gene expression in human bladder UM-UC-3 cell cultures.  The 
data is shown from three biological replicates plotted with SD.  
Figure 5.3 shows that COL6A1 gene expression is significantly down regulated following 
48hr treatments of 12µM of SF (fold change of 1.7, *p0.005), IB (fold change of 1.3, 
*p0.001) and SF-NAC (fold change of 1.3, *p0.004) in the UM-UC-3 human bladder cell 
line.  No significant decrease in gene expression was observed following the 48hr 
treatment of IB-NAC.  
 
 
 
      * 
     * 
* 
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Figure 5.4 Real time RT-PCR of COL6A1 gene expression in human bladder RT4 cell cultures. The data is 
shown from three biological replicates plotted with SD. 
COL6A1 gene expression is significantly down regulated following 48hr treatments of 
12µM of SF (fold change of 2.1, *p0.03), IB (fold change of 2.3, *p0.02) and SF-NAC 
(fold change of 2.2, *p0.02) in the RT4 human bladder cell line.  No significant decrease in 
gene expression was observed following the 48hr treatment of IB-NAC.  
 
 
 
 
 
 
 
 
 
 
 *  * 
 * 
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Figure 5.5 Real time RT-PCR analysis of COL6A1 gene expression in the UM-UC-3 human cell culture 
following treatment with 12µM of Sulforaphane N-acetylcysteine conjugate or N-acetylcysteine. Data is 
shown from three biological replicates plotted with SD.  
 
 
Figure 5.5 shows a significant decrease in COL6A1 expression following a 48 hour 
treatment of SF-NAC (2 fold change, *p0.005).  These results are in accordance with the 
previous experiment, figure 5.3, where a fold change of 1.3 was observed in the UM-UC-3 
cell line.  However no change in gene expression was observed following treatment with 
N-acetylcysteine alone.  
 
    * 
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5.3.3 COL6A1 protein expression in the UM-UC-3 cell line 
The presence of the COL6A1 protein was not detected in protein lysate from either the 
cells, Figure 5.6, or the media in which the cells were grown, Figure 5.7.  Modulation of 
the protein by treatment with SF, IB and their conjugates was not observed in either cell 
lysate or media protein lysate, results not shown.  
 
 
 
 
 
Figure 5.6 Western blot analysis of the protein lysate from treated UM-UC-3 cells. 
Western blot with different concentrations of cell lysate are in wells 2-6 (5, 10, 20, 40, 80 µg of protein was 
subjected to SDS-polyacrylamide gel electrophoresis), MagicMark™ XP (M/M) are in wells 1 and 8 and the 
positive control (10 µg) is in well 7.  
 
 
 
 
 
 
Figure 5.7 Western blot analysis of the protein lysate from culture media of treated UM-UC-3 cells. Western 
Blot with different media concentrations are in wells 2-6 (5, 10, 20, 40, 80 µg was subjected to SDS-
polyacrylamide gel electrophoresis), MagicMark™ XP (M/M) are in wells 1 and 8 and the positive control 
(10 µg) is in well 7.  
 
 
positive 
control 
(10µg/ml) 
Positive 
control 
10µg/ml 
M/M 
M/M 
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5.4 Discussion  
COL6A1 is an extracellular matrix protein and like other collagen proteins plays an 
important role in maintaining the integrity of various tissues (see section 1).  Mutations in 
the genes that code for the collagen VI subunits result in the autosomal dominant disorders 
known as Bethlem myopathy and the less servere, Ullrich congenital muscular dystrophy. 
As such the greatest area of research on this gene is concerned with these conditions. These 
conditions, once thought to be completely separate entities, are dominantly inherited 
disorders associated with mutations in the three COL6 genes encoding type VI collagen 
(Lampe and Bushby 2005).  Ullrich congenital muscular dystrophy is characterized by 
congenital muscle weakness, proximal joint contractures and marked distal joint 
hyperextensibility (Baker, Morgelin et al. 2005).  Bethlem myopathy is a relatively mild 
dominantly inherited disorder, characterised by proximal weakness and distal joint 
contractures.  Ullrich congenital muscular dystrophy causes severe muscle weakness with 
proximal joint contractures and distal hyperlaxity (Bertini and Pepe 2002). 
The COL6A1 gene first highlighted by the microarray analysis in chapter 3 also 
appears to be modulated following treatment with SF and IB.  In this chapter the 
relationship of COL6A1 gene expression with the grade of bladder cancer and the 
modulation of this expression was explored in more detail.  The results reveal for the first 
time that the expression of COL6A1 increases with the grade of TCC and that SF and IB 
can alter the mRNA expression of COL6A1 in vitro and thus potentially modulate the 
extracellular matrix and stroma in vivo.  
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5.4.1 The expression on COL6A1 is increased with the grade of Transitional Cell 
Carcinoma. 
The COL6A1 gene was highlighted in the microarray analysis and an observed increase in 
the genes expression in the invasive tissue was a novel finding.  It can be seen in figure 5.2 
that the degree of gene expression does follow a definite trend towards increasing with 
severity of grade.  An approximate 18 fold increase in COL6A1 gene expression was 
observed when comparing the lowest grade (Ta) with the highest grade (T4).   
Identification of the COL6A1 gene being differentially expressed in human 
astrocytomas has recently been discovered (Fujita, Sato et al. 2008).  The study showed 
very similar results to this bladder study.  That is, the tumours are classified by the WHO 
according to their histopathological and clinical characteristics into four classes: grade I 
(pilocytic astrocytoma), grade II (diffuse astrocytoma), grade III (anaplastic astrocytoma), 
and grade IV (glioblastoma multiforme).  The expression of the gene had significantly 
different means when normal glia was compared with low-grade astrocytomas (grades I 
and II) and high-grade astrocytomas (grades III and IV), with a tendency to be greater in 
higher grade samples (Fujita, Sato et al. 2008).  Once again this was a novel finding in this 
tissue type.  These discoveries suggest COL6A1 as potential tumour marker of 
astrocytomas and bladder cancer progression.  To the best of my knowledge the 
astrocytoma and this bladder study are the only studies to identify differential expression of 
COL6A1 with tumour grade.  
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5.4.2 The Modulation of the COL6A1 gene in vitro 
In this chapter it can be seen that the COL6A1 gene can be modulated by treatment with 
physiological doses of SF and IB in both bladder cell lines.  This down regulation of the 
gene is greater in the more invasive UM-UC-3 cell line.  This may be due to the basal 
expression of this gene being higher in the UM-UC-3 cell line due to the fact it originated 
from an invasive form of transition cell carcinoma.  As was first discovered in chapter 
three and confirmed in this chapter, the COLA1 gene increases with the 
severity/invasiveness of bladder cancer.  In contrast to the observed effect of ITC on 
COL6A1 gene expression, Se-methylselenocysteine (MSC) has been shown to 
significantly increase the expression of COL6A1 in LNCaP and PNT1A prostate cell lines 
(Hurst, Elliott et al. 2008).  Microarray analysis showed that the expression of several 
collagen genes were modulated by MSC treatment compared to the control.  A significant 
decrease in the expression of collagen type I alpha 1 genes and significant increases in 
COL6A1 and COL4A5 gene expression were observed in response to the MSC treatment 
(Hurst, Elliott et al. 2008). 
As discussed in chapter four, ITCs are unstable compound and readily dissociates 
into their N-acetylcysteine conjugates which are primarily concentrated in the urine and 
stored in the bladder.  As human bladder cancers occur almost exclusively in the bladder 
epithelium, which is directly exposed to the urine stored in the bladder it is important to 
assess the activity of the conjugates of both sulforaphane and iberin.  However due to the 
continuous reversible reaction from the parent ITC to their N-acetylcysteine conjugates it is 
questionable as to whether this activity is actually due to the conjugates themselves or 
because the ITC-NAC readily releases the parent compound that the observed down 
regulation of the COL6A1 is actually due to the SF.  To test this theory the UM-UC-3 
139 
 
bladder cell line were treated with just N-acetylcysteine (NAC), at the same concentrations 
and time scale as the previous experiment using SF-NAC (12µM for 48 hours).  In contrast 
to SF-NAC there is no significant effect of NAC alone on COL6A1 gene expression after a 
48hr treatment.  Therefore the observed down regulation of the COL6A1 gene expression 
(tables 5.3 and 5.4) may not be due to SF-NAC but in fact be caused by the SF, following 
the dissociation of the SF from the SF-NAC.  However this does not explain why the SF-
NAC appeared to have a greater effect on the COL6A1 gene down regulation than SF 
alone in the previous experiment.  The initial results of the SF-NAC are in accordance with 
the findings by Tang et al.(Tang, Li et al. 2006), that is, ITC conjugates elicit similar 
effects as their parent compounds in bladder cell cultures, although Tang’s experiments 
were investigating the apoptotic effects of ITC-NAC.   
 
5.4.3 Functional modulation of the COL6A1 protein 
Protein was extracted from UM-UC-3 cells to determine whether treatments with SF and 
IB have an effect on COL6A1 protein expression.  The resulting membrane picture showed 
the COLA61 protein to be undetectable.  To examine the possibility that the COL6A1 
protein was being excreted into the media, the protein lysate from the media was collected 
for Western Blot analysis.  It can be seen from figure 5.2 that the Western Blot with 
different protein concentrations from the media of the treated cells has led to the same 
membrane picture as the Western Blot with the UM-UC-3 cell lysate.  Again no bands 
were visible.  Neither isolations of protein from the UM-UC-3 cells, or from the media in 
which they were cultured, gave a positive result for the COL6A1 protein.  Reasons for this 
could be that the 48h treatment was not long enough to produce a functional change, or 
perhaps a different cell line should have been used.  The UC-UM-3 cell line is a human 
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bladder epithelial cell line, whereas COL6A1 is predominantly synthesized in vivo by 
fibroblasts.  Although I am not aware of any bladder fibroblast cell lines, if time was 
permitting the use of a primary fibroblast cell line may have shown a functional change in 
protein expression following treatment.  
In summary, although a functional change could not be established, the 
combination of the tissue gene expression results and the cell culture work is not only 
exciting, but also novel.  For the first time it has been shown that COL6A1 gene expression 
increases with the severity of bladder cancer in vivo and the gene can be down regulated by 
physiologically relevant doses of SF and IB in vitro.  These result suggest that both IB and 
SF may have important effects on the extracellular matrix (ECM), as collagen is a 
dominate component.  Therefore the following chapter will be investigating the effects of 
SF and IB on markers of bladder cancer progression and invasion, using the previously 
characterised UM-UC-3 human bladder cell line. 
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Chapter 6.0 Anticancer Effects Of Sulforaphane And Iberin On Makers Of Cancer 
Progression/Invasion In Cultured Human Bladder Cells 
6.1 Introduction  
In chapter three the COL6A1 gene encoding for the extracellular protein was identified by 
the array analysis to increase with the grade of bladder cancer.  These results were confirmed 
in chapter five by RT-PCR, showing that the degree of gene expression does follow a 
definite trend towards increasing with the severity of grade.  Furthermore in chapter five it 
was shown that physiologically relevant doses of sulforaphane and iberin could down 
regulate the expression of the COL6A1 gene in high grade human bladder cell culture.  
These results suggest that isothiocyantes may have an important effect on the extracellular 
matrix.  Since the majority of bladder cancer mortality is associated with invasion of 
cancerous cells into the extracellular matrix and the bladder muscle wall, leading to 
metastatic disease, the ability to inhibit cell motility and cell segregation from the primary 
tumour and invasion of surrounding tissues may significantly reduce bladder cancer-related 
morbidity and mortality.  When tumour cells invade extracellular matrix they produce 
proteases such as metalloproteinases (MMP), which degrade the extracellular matrix.  The 
aim of this chapter is to investigate the effects of SF, IB and their conjugates on the cellular 
motility of the UM-UC-3 cell line and their capability to reduce invasion into extracellular 
matrix by assessing their effects on the activity of both matrix metalloproteinases 2 and 9. 
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6.2 Specific Materials and Methods  
6.2.1 Semi-quantitative cell motility for in-vitro wound healing in the UM-UC-3 
bladder cell line. 
The wound-healing assay I employed provides semi-quantitative data on cell 
motility/migration.  The assay is simple, inexpensive, and one of the earliest developed 
methods to study cell motility/migration in-vitro (Rodriguez, Wu et al. 2005) . The basic 
steps involved displacing a group of cells by scratching a line through the monolayer with 
a pipette tip.  The open gap was inspected microscopically over time as the cells migrated 
to fill the damaged area.  The images were captured by photographing the cell monolayer 
at the beginning and at regular time points during cell migration.  Cell migration was 
quantified by measuring the distance between two standard points on either side of the gap 
to quantify the migration rate of the cells (chapter 2.6).  It has been suggested that this 
assay is particularly suitable for studies on the effects of cell-matrix and cell-cell 
interactions on cell migration (Rodriguez, Wu et al. 2005). 
 
6.2.2 The use of a BD Matrigel™ Matrix basement membrane to measure UM-UC-3 
cell invasiveness. 
BD Matrigel™ Matrix provides a biologically active basement membrane model for in-vitro 
invasion studies.  BD Matrigel™ Matrix is a soluble basement membrane preparation 
extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumour rich in ECM 
proteins.  Its major component is laminin, followed by collagen IV, heparan sulfate 
proteoglycans, and entactin(http://www.bdbeurope.com 2009).  Cells were grown in 10cm 
dishes to approximately 70% confluency and starved (serum free culture media) for a 24 
hour period.  Cells were harvested following the 24 hour period and re-suspended in 
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conditioned serum free media.  The cell suspension was seeded (3x105 cells per well) onto 
the BD Matrigel™ Matrix in the  top transwell insert (1.5 ml) and 2 ml of complete media 
was placed in the reservoir (bottom well).  The cultures were incubated for 24 hours.  The 
media was aspirated from the top transwell and the bottom receiver well and the Matrigel™ 
Matrix was washed away with warmed PBS solution.  The cells that penetrated to the lower 
surface of the transwell filter was fixed, stained, detached from the transwell and mounted 
on to a microscope slide.  The cells were 6 randomized fields at a X200  magnification.  
The cell counts were performed in at least four independent experiments.  
 
6.2.3 Investigation of the influence of physiologically relevant doses of sulforaphane, 
Iberin and their conjugates on metalloproteinases 2 & 9 production in the UM-UC-3 
cell line using the gelatin zymography assay.  
The extracellular proteinases MMP 2 and MMP 9 are secreted into the cell culture media 
which was collected after 48 hour.  The Invitrogen Novex® polyacrylamide zymogram 
gels were used for the gelatin zymography assay to enable the detection of matrix 
metalloproteinases 2 & 9.  Zymography is an electrophoretic technique, in which the 
substrate gelatin is copolymerized with the gel for the detection of the enzyme activity. 
Samples were prepared without denaturing the active enzymes (section 2.7) and, following 
electrophoresis, the gel was placed in an enzyme activation buffer which allows the 
enzymes present in the sample to become active and digest the substrates copolymerized in 
the gel.  The zymogram was subsequently stained and the areas of enzyme activity and 
digestion that became visible identified (chapter 2.7).  The Invasion Index (I %) is 
calculated to determine the invasive potential of the cell line: 
percentage of invasive cells = no. of invaded cells/no of migrated cells x 100.  
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6.3 Results  
6.3.1 Assessing the effects of SF, IB and their N-Acetylcysteine conjugates on UM-UC-
3 bladder cell line migration using the wound healing assay.  
The wound healing assay enables the motility of a particular cell line to be qualitatively 
assessed and thus enable investigation of the influence of SF, IB and their N-acetylcysteine 
conjugates.  Figures 6.1 and 6.2 show the capability of SF, IB and SF-NAC to reduce the 
mobility of the UM-UC-3 cell line following a 24 hour period of incubation.  IB-NAC also 
shows this capability, but to a much lesser extent.  Following a further 12 hour incubation 
SF and IB still reduce the cell lines mobility further by approximately 50%, however there 
conjugates do not.   
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Figure 6.1 Quantification of the time dependent effects of the indicated ITCs on cell motility. Measurement 
of the percentage of migration as the cells move to close the wound.  
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Figure 6.2 grap 
 
Figure 6.2 Graphical representation of the wound healing assay. The cellular motility was controlled by 24 
hour, 12µM treatments of SF, IB and to a lesser extent SF-NAC and IB-NAC.  Note SF-NAC, and to a lesser 
extent IB-NAC, exhibit an inhibitory pattern similar to that of their parent compounds treatment. 
 
SF, IB and their conjugates affected wound healing migration of UM-UC-3 cells.  The 
leading edge of the closing wound was compared between ITC treated, ITC-NAC treated 
and control.  As shown in figure 6.1, cellular migration was reduced by 12µM treatment of 
the SF, inhibited by 67% and 34% after 24 and 36 hours of incubation, respectively. 
Treatment with 12µM of IB also reduced cellular migration, inhibited by 53.4% and 33% 
after 24 hours and 36 hour of incubation, respectively.  SF-NAC at 12µM showed a similar 
inhibitory pattern on cell migration, but with a slightly stronger effect than its parent 
compound and IB at the same molar concentration following 12 hours of incubation.  SF-
NAC inhibited the migration rate of UM-UC-3 cells by 74% after 24 hour incubation; 
however no inhibitory effects were seen following 36 hour incubation.  IB-NAC appeared 
to have the same inhibitory effects on the cell migration of the UM-UC-3 cells as its parent 
compound following 24 hour incubation; IB-NAC inhibited the migration rate of the UM-
CTL      SF    SF-NAC      IB    IB-NAC  
    0 
Hours  
   24 
Hours  
     36 
Hours  
  93%      33%    26%   46.6%   46.6%  
      % of 
migration  
      % of 
migration     100%      66%     100%     100%         67%  
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UC-3 cells by 53.4% after the 24 hour incubation.  However no inhibitory effects were 
seen following 36 hour incubation with IB-NAC. 
 
6.3.2 Assessing the effects of SF, IB and their N-Acetylcysteine conjugates on UM-UC-
3 bladder cell line ability to invade extracellular matrix using matrigel invasion 
studies 
To assess the invasive ability of tumour cells in vitro a large variety of systems have been 
developed that permit the assessment of their capacity to invade through basement 
membranes.  Matrigel is widely accepted as a biologically active basement membrane 
mimic and numerous publications have proved its usefulness for in vitro invasion assays 
(Amar, DeArmond et al. 1994; Holting, Zielke et al. 1994; Okamura, Mori et al. 1996; 
Zielke, Hoffmann et al. 1999). 
 
Figure 6.3 UM-UC-3 bladder cells following staining with Gill’s No 1 Hematoxylin stain. The picture was 
taken at x200 magnification. The cells have an appearance intermediate between that of stratified cuboidal 
epithelium and stratified squamous epithelium, hence "transitional".  The Morphological characteristics of the 
UM-UC-3cell lines in tissue culture show large elongated cell morphology with a large prominent nucleus.  
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In order to visualise the cells under the light microscope the cell required fixing to the 
underside of the filter and staining.  It was determined that a fixing time of 3 minutes and a 
staining time of 4 minutes with Gill’s No 1 Hematoxylin stain gave the optimum results for 
this cell type.  Figure 6.3 represents the result of fixing and staining UM-UC-3 cells at 
x200 magnification and clearly shows the large prominent nucleus which enabled ease of 
cell counting.  The filters were fixed, stained, detached from the transwell casing and 
mounted on to a microscope, shown in figure 6.4.  
Figure 6.4 are photographic examples of the appearance of the filters following cell 
migration and cell invasion.  The cells were stained a pink/purple colour and a much 
greater degree of cell migration can be observed in comparison to cell invasion.  It may 
also be observed that the migrating cells have moved through the filter in a comparably 
even manner, giving an appearance of a relatively even distribution of cells on the 
underside of the filter.  Whereas the cells which invaded the ECM appear to have done so 
through the centre of the filter, giving the appearance of a dense congregation of cells just 
in the centre of the underside of the filter. 
 
  Cell invasion                                                Cell migration 
                                            
Figure 6.4 Appearance of the transwell filters following fixing and staining. 
A – Representation of a filter following cell invasion through the filter and the MatrigelTM ECM 
B – Representation of a filter following cell migration through the filter only.   
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Figure 6.5 Cells migrated through a filter with no extracellular matrix. Cell migration following 48hr 
treatment with SF, picture taken at x100 magnification. The cells were counted under the microscope in 13 
randomized fields at x 200 magnification. 
    
Figure 6.6 Cells invaded through the BD Matrigel™ Matrix. Cell invasion through the BD Matrigel™ 
Matrix following 48hr treatment with SF, picture taken at x100 magnification. The cells were counted under 
the microscope in 13 randomized fields at x 200 magnification. 
 
Figure 6.4 and 6.5 are photographic examples of the appearance of the filters under the 
microscope following cell migration and cell invasion.  The cells stained a pink/purple 
colour were clearly visible for cell counting at x 200 magnification.   
 
 
 
Stained cell 
Filter pore 
Filter pore 
Stained cell 
 
150 
 
 
 
 
 
 
Table 6.1 Determination of the invasive potential of the UM-UC-3 cell line by calculating the invasion index. 
To determine the invasive properties of the studied cell lines, the invasion index (I %) was calculated. 
Percentage of invasive cells = no. of invaded cells/no of migrated cells x 100. 
 
Table 6.1 represents the calculation of the invasion index of SF treated and untreated UM-
UC-3.  No reduction in invasiveness was observed when the cells were treated for 24hrs 
with SF.  Likewise no significant reduction in invasiveness was observed when the cells 
were treated for 24hrs with IB or the ITC conjugates, results not shown.  The invasion 
No Treatment SF Treatment 
Number of cells counted. 
(counts in six different fields on each plate) 
  
Plate 1 Plate 2 Plate3 Plate 1 Plate 2 Plate 3 
Cell migration (x 3) ctl 
plate 
210 178 185 176 149 173 
Mean cell count 191 166 
No Treatment SF Treatment 
Number of cells counted. 
(counts in six different fields on each plate) 
  
Plate 1 Plate 2 Plate3 Plate 1 Plate 2 Plate 3 
Cell invasion (x 3) test 
plate 
40 45 43 39 35 40 
Mean cell count 42.67 38 
% invasion 
 
42.67/191 X 100 = 
22.34 
38/166 X 100 = 
21.68 
invasion index 
                                                22.34/21.68 = 1.03 
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index of the UM-UC-3 cell line is very low (1.03) indicating a low metastatic potential of 
this cell line. 
 
6.3.3 Assessing MMP-2 and MMP-3 activity in UM-UC-3 bladder cell line following 
treatment with physiological relevant concentrations of SF, IB and their N-
Acetylcysteine conjugates using Gelatin Zymography. 
The substrate gelatin is copolymerized with the gel and upon enzyme activation by the buffer 
the enzymes present in the sample become active and digest this substrate.  When the 
zymogram is stained, the areas of enzyme activity/digestion become visible because there is 
no or less staining due to the digestion of the gelatin by the proteinases.  The original 
zymogram appears as follows:  
                       Showing less enzyme digestion 
 
 
 
 
 
         
                                    
 
                                
                                    Areas of greater enzyme digestion 
 
 
  
Figure 6.7 An example of Gelatin-SDS-PAGE zymography for semi quantitative study of MMP-9 and 
MMP-2 activity in treated and non-treated UM-UC-3 cell lines. This photograph of an electrophoresis gel is 
representative of three independent experiments that essentially gave the same result.  
 
 
Unlike western blotting the SeeBlue® marker is not being used to judge protein size, only 
the efficiency of electrophoresis.  The enzymes are not visible following electrophoresis, 
whereas the SeeBlue® marker is visible. Therefore if the marker can be seen to have 
MMP-2 
MMP-9 
SeeBlue® 
marker 
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electrophoresed through the gel, it confirms efficient electrophoresis of the target.  The 
zymogram was stained with Coomassie Brilliant Blue, and areas of digestion appear as 
clear bands against a darkly stained background where the substrate has been degraded by 
the enzyme.  However for the following results the membrane was reversed and changed to 
black and white for ease of digestion detection. 
 
Figure 6.8 Reversed images of zymography gels following either 10 µl or 5 µl aliquots of media from ITC 
treated cells following either 12 or 24 hour incubation of developing buffer.  Each electrophoresis gel 
photograph (A-D) is representative of three independent experiments that essentially gave the same result.   
 
 
MMP-2 
 
  
 marker    CTL 1    CTL 2   CTL 3     SF 1       SF2       SF3       IB 1       IB2        IB3 
 
CTL 1    CTL 2    CTL 3         SF 1         SF2          SF3         IB 1        IB2          IB3 
 
CTL 1    CTL 2   CTL 3   SF-NAC  SF-NAC  SF-NAC IB-NAC  IB-NAC   IB-NAC 
   CTL 1     CTL 2      CTL 3      SF 1       SF2        SF3        IB 1         IB2        IB3 
 
MMP-9 
MMP-9 
MMP-2 
MMP-9 
MMP-2 
MMP-9 
MMP-2 
A) 5 µl aliquot of media from SF treated cells and IB treated cells 
following a 24 hour incubation of developing buffer.  
B) 10µl aliquot of media from SF treated cells and IB treated cells 
and a 24 hour incubation of developing buffer.  
C) 10µl aliquot of media from SF-NAC treated cells and IB-NAC 
treated cells and a 24 hour incubation of developing buffer.  
D) 5 µl aliquot of media from SF treated cells and IB treated cells 
and a 12 hour incubation of developing buffer.  
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Zymography following a 5 µl aliquot of media from SF treated cells and IB treated cells 
following a 24 hour incubation of developing buffer (figure 6.3.4 A) showed that the 
MMP-9 enzyme has fully saturated its substrate and therefore little difference can be see 
between control and treated samples.  There is a small decrease in MMP-2 enzyme 
activity from the SF conditioned media.  Conjugates showed no difference at this volume 
and incubation time (picture not shown).  As a small decrease in MMP-2 could be 
observed in figure 6.3.4 A, the quantity of media applied to the gel was increased to 10 µl 
to increase the likelihood of digestion and incubated with the developing buffer for 24 
hours.  As expected the MMP-9 enzyme has almost fully saturated its substrate therefore 
there is little difference to be seen between the control and treated samples.  But there 
does appear to be a small reduction in MMP-9 following treatment with SF compared to 
control.  However, with this higher media loading, it can be seen that treatment with 12 
µM of SF and 12µM of IB can down regulate MMP-2 in UM-UC-3 human bladder cells 
(figure 6.3.4 B).   
Zymography following 10 µl aliquot of media from SF-NAC treated cells and IB-
NAC treated cell following a 24 hour incubation of developing buffer (figure 6.3.4 C) 
showed that MMP-9 enzyme has fully saturated its substrate, therefore little difference 
can be seen between the control and treated samples.  However at this media volume it 
can be seen that treatment with 12 µM of SF-NAC can down regulate MMP-2 in UM-
UC-3 human bladder cells.  IB-NAC showed no difference at this volume and incubation 
time.  To prevent the MMP-9 totally saturating the substrate a lower aliquot of 5 µl of 
media was applied and the developing buffer time was reduced to 12 hours.  Treatment 
with 12µM of SF or 12µM of IB down regulated both MMP-2 and MMP-9.  It can be 
seen in figure 6.3.4 D that by reducing the media loading dose and incubation time to 12 
154 
 
hours prevents the MMP-9 saturating its substrate and therefore a reduction in MMP-9 
enzyme by treatment with 12 µM of SF or IB can be observed.  Conjugates showed no 
difference at this load and incubation time (results not shown). 
In conclusion treating with 12 µM of SF, IB or SF-NAC has the capacity to down 
regulate the production of MMP-2 and 12 µM of SF or 12 µM of IB have the capability 
to down regulate the production of MMP-9 in the UM-UC-3 cell line. 
 
6.4 Discussion 
6.4.1 Reduction of UM-UC-3 cell migration/motility following treatment with SF, IB 
and their conjugates.  
The wound healing assay mimics cell migration during wound healing in vivo.  It is 
particularly suitable for studies on the effects of cell-matrix and cell-cell interactions on 
cell migration and the inhibitory effects of chemicals on the cell migration of a particular 
cell type.  In this model the gap is mainly covered by cells that move to close it, rather than 
cells that proliferate, at least at the early time points, when cells do not have enough time to 
proliferate (Androulidaki, Dermitzaki et al. 2009).  At the 36 hour time point the result is a 
combination of proliferation and motility of the UM-UC-3 cells.  In this wound healing 
assay it was demonstrated that SF, IB and SF-NAC have the capability to reduce the 
mobility of the UM-UC-3 cell line following a 24 hour period of incubation.  IB-NAC also 
shows this capability, but to a lesser extent.  Following a further 12 hour incubation, SF 
and IB still reduce the cell lines mobility by about 50%, but their conjugates do not. 
Ultimately these results suggest that the ITCs can reduce the motility that resulted in 
slower closure of the gap.  This wound healing model has been employed in many studies, 
such as the effect of corticotropin releasing factor on the breast cancer invasiveness and 
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demonstrating that activation of FAK/PI3K/Rac1 signalling inhibits cell motility in MCF7 
cells and A375 human melanoma cells (Kallergi, Agelaki et al. 2007).  Furthermore it has 
been shown that the migration of HMEC-1 cells in this wound healing assay was 
effectively prevented by SF.  In addition, within 6 hours of incubation, SF also inhibited 
tube formation of HMEC-1 cells on basement membrane matrix (Bertl, Bartsch et al. 
2006).   
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6.4.2 UM-UC-3 cell invasion through a BD BioCoat TM Matrigel TM invasion chamber. 
The inhibitory effects of SF, IB, SF-NAC and IB-NAC on the ability of UM-UC-3 cells to 
invade through a reconstituated extracellular matrix were examined.  Only invasive cells 
are capably of digesting the matrix and move through the insert membrane.  The BD 
BioCoatTM MatrigelTM invasion chamber is useful to study cell invasion of malignant cells 
and therefore make an assessment of their metastatic potential.  This matrix provides a 
barrier to non-invasive cells, while presenting an appropriate protein structure for invading 
cells to penetrate before passing through the membrane.  In vivo basement membranes are 
specialized extracellular matrixes that are comprised of several biological components 
including collagens, laminins, and proteoglycans.  They form thin continuous sheet like 
structures that separate epithelial tissues from the adjacent connective tissue stroma; thus, 
under normal conditions they form barriers, which block the passage of cells and other 
macromolecules.  In this study the inhibitory effects of SF and IB on the ability of UM-
UC-3 cells to invade through reconstituted ECM (MatrigelTM) with or without treatment 
were investigated.  The mean UM-UC-3 cells migration through the 8µm pore without 
reconstituted ECM was 191 for non treated cells and 166 for the treated cell.  The mean 
UM-UC-3 cells invasion through 8µm pore with reconstituted ECM was 43 for the non 
treated cells and 38 for the treated cells.  This resulted in 22% invasion potential for both 
the non treated and treated cell cultures, consequently an invasion index of 1.03 was 
calculated and therefore demonstrating that treatment with these ITCs do not modulate 
UM-UC-3 cell invasion.  Furthermore, the low invasion index suggests that UM-UC-3 
cells have a low-invasive phenotype, suggesting that the UM-UC-3 cell line has little 
metastatic potential.  However, it has been demonstrated in HT-1080 fibrosarcoma, MCF7 
breast carcinoma, and U251.3 glioma cell lines that tumour cell invasion through 
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MatrigelTM is regulated by activated MMP-2 (Deryugina, Luo et al. 1997) and as it was 
shown in 6.3.3 that the UM-UC-3 cell line appear to have low levels of MMP-2 secretion 
in comparison to MMP-9 and as such may contribute to a negligible metastatic potential.  
Therefore the cells have the capability to move and this capability is reduced by treatment 
with SF, IB and to a lesser extent by their conjugates as demonstrated in 6.3.1; however 
they have little capability to invade extracellular matrix.  
 The observation that migrating cells have moved through the filter in a comparably 
even manner, whereas the cells which invaded the ECM appeared to have dons so through 
the centre of the filter, may be a direct result of the influence of MatrigelTM MatrixTM on 
cell differentiation.  A study has shown that epithelial cells cultured on plastic continue to 
multiply and proliferate to the extent that they occupy the whole surface of a plastic dish 
and become confluent (Novin and Nouri 2007). While epithelial cells cultured on ECM 
undergo polarization and differentiation.  Using electron microscopy, the morphology of 
the cells appeared different compared to the cells grown on plastic, such as an increase in 
mitochondria and glycogen was observed. It was also observed that the amount of total 
RNA in cultured cells on ECM was 2.5 times more than the amount of RNA isolated from 
cells grown on plastics.  These results suggest that Matrigel™ ECM plays an important 
role in gene expression, polarization and differentiation of human epithelial cells and as 
such may account for the observed differences in cell movement (Novin and Nouri 2007). 
 In contrast to these results, an experiment with SK-Hep1 cells demonstrated the 
ability to invade through a similar reconstituted ECM and that this invasive potential of the 
cells were reduced my treatment with AITC and AITC-NAC in a dose dependent manner 
in the range 0.1-5µM.  A significant reduction in the number of invasive cells was seen 
when the cells were treated with AITC and AITC-NAC for 18 hours, as compared to level 
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of invasion in the controls.  The level of invasion being reduced to 60% and 53% of the 
control levels for 5µM of AITC and 5µM of AITC-NAC, respectively (Hwang and Lee 
2006). 
 
6.4.3 Modulation of Matrix metalloproteinases 2 and 9 following treatments with SF, 
IB or SF-NAC. 
Metalloproteinases play a significant role in the control of cellular interactions and 
response to their environment in physiological conditions that promote tissue turnover, 
such as normal development; or pathological conditions, such as inflammation and cancer.  
Matrix MMP, notably the gelatinases MMP-2 (gelatinase A) and MMP-9 (gelatinase B), 
are major contributors of stromal degradation and are vital to the process of cellular 
invasion (Nabeshima, Inoue et al. 2002).  
 MMP-2 and 9 have been correlated with the processes of tumour cell invasion and 
metastasis in many tissue and cell types.  MMP-2 and MMP-9 have been found in large 
quantities in cancer tissues (Liotta, Tryggvason et al. 1980).  Enhanced level of MMPs 
facilitate metastasis and cell invasion of tumour cells by removal of physical barriers, such 
as collagen, as well as modulation of biological activities of the proteins residing in the 
extracellular matrix (Yanagisawa, Geironson et al. 2005).  For instance, many studies have 
shown that MMPs are implicated in the functional regulation of non-ECM molecules that 
include growth factors and their receptors, cytokines and chemokines, adhesion receptors 
and cell surface proteoglycans, and a variety of enzymes (Beaudeux, Giral et al. 2004).  
 To my knowledge there is little concrete evidence in published data regarding the 
extent of MMP down regulation that would be effective for anticancer effects.  However it 
is known that decreased expression of MMP-2 and MMP-9 contributes to the inhibition of 
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lung metastasis of B16/F10 melanoma cells and have been correlated with the processes of 
tumour cell invasion and metastasis in many human cancers such as uterine neoplasms.  
Up-regulation of MMPs was associated with progression of cervical uterine neoplasms 
(Libra, Scalisi et al. 2009).  More specific to bladder cancer, an examination was carried 
out to determine if a tumour-specific pattern of appearance existed among the MMPs 
detected in the urine of 189 patients with prostate or bladder cancer and controls.  The 
frequency of detection of any MMPs was significantly higher in the urine from prostate 
and bladder cancer groups than controls.  Approximately 140 >220 kDa, and 
approximately 190 high molecular weight gelatinase species found in the urine were 
identified as MMP-9/tissue inhibitor of metalloproteinase 1 complex, MMP-9 dimer, and 
ADAMTS-7.  The study suggests identification of a tumour-specific urinary MMP 
fingerprint that may noninvasively facilitate identification of bladder and prostate cancer 
(Roy, Louis et al. 2008).  Furthermore, this study demonstrated that MMP-2 and 9 
activities in the urine of individuals with bladder tumours appeared to correlate with grade.  
Zymography showed gelatinolytic bands in the urine from individuals with bladder tumour, 
whereas only traces of MMP were detected in the urine of healthy subjects.  However the 
majority of cancerous urine samples showed MMP-9 lytic activity but only a few contained 
MMP-2.  The MMP-9 content was enhanced in the urine from patients with high-grade and 
advanced-stage bladder tumours (Roy, Louis et al. 2008), suggesting that elevated MMP-9 
levels in bladder cancer patients correlate with a more advanced stage.   
 This study examined the effect of SF, IB and their conjugates on the secretion of 
MMP-2 and MMP-9, to elucidate their possible antimetastasis effect.  Zymography 
revealed that the UM-UC-3 cell line constitutively secreted high levels of MMP-9 and 
lower levels of MMP-2, and that treatment of 12µM of SF, IB and SF-NAC reduced MMP-
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2 and MMP-9 activities.  Showing that 12µM of SF and IB can down regulate the 
production/secretion of MMP-2 and MMP-9 enzymes and also 12µM of SF-NAC can 
down regulate the production/secretion of the MMP-2 enzyme in the UM-UC-3 cell line.  
In a similar experiment to this using SK-Hep1 human hepatoma cells (Hwang and Lee 
2006), MMP-2 and MMP-9 activity were demonstrated to be reduced in a dose dependent 
manner at concentrations of 0.1-5µM by the presence of the ITC AITC and its conjugate 
AITC-NAC.  However in this experiment the AITC-NAC demonstrated a more potent 
inhibitory effect than the parent compound AITC at the same molar concentration.  MMP-9 
activity was suppressed by 20% and 50% by treatment with 5µM of AITC and 5µM AITC-
NAC, respectively.  MMP-2 activity was suppressed by 70% and 80% by 5µM treatments 
of AITC and 5µM AITC-NAC, respectively.  Zymography also revealed that the SK-Hep1 
cell line constitutively secreted high levels of MMP-9 and low levels of MMP-2 (Hwang 
and Lee 2006). 
 Human brain endothelial cells (HBMECs) are essential components of the blood 
brain barrier (BBB). While the secretion of MMP-9 by brain tumours has been well 
studied, secretion of MMP-9 by HBMECs themselves following treatment with a 
carcinogen (phorbol 12-myristate 13-acetate) has been little explored. In this study an 
increase of MMP-9 secretion upon treatment with phorbol 12-myristate 13-acetate was 
observed in HBMECs and SF was shown to inhibit both the excretion of MMP-9 enzyme 
and gene expression of MMP-9, although MMP-2 was not altered by the SF treatment 
(Annabi, Rojas-Sutterlin et al. 2008).  Also broccoli and watercress extracts have been 
shown to be responsible for inhibition of MMP-9 activity and invasiveness of human 
MDA-MB-231 breast cancer cells (Rose, Huang et al. 2005).  The effect of SF on the 
inhibition of lung metastasis in B16F-10 melanoma cells was studied. Gelatin zymographic 
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analysis showed that SF could inhibit the activation of matrix metalloproteinases in the 
B16F-10 melanoma cell line and proliferation assays showed that SF could inhibit the 
proliferation of B16F-10 melanoma cells in vitro. This suggests that SF reduced the 
invasion of B16F-10 melanoma cells by the inhibition of matrix metalloproteinases, 
thereby inhibiting lung metastasis. It was also shown in this study that in vivo metastatic 
control in C57BL/6 mice was found to be significantly lowered in the SF treated animals.  
There was 95.5% inhibition of lung tumour nodule formation and 94.06% increase in the 
life span of metastatic tumour bearing animals (Thejass and Kuttan 2006).  Molecular 
signalling pathways leading to activation of endothelial cell proliferation and degradation 
of the basement membrane were analyzed by RT-PCR in the HMEC-1 cell line, an 
immortalized human microvascular endothelial cell line.  It was suggested that SF could 
affect basement membrane integrity, as it suppressed transcription of endothelial 
metalloproteinase-2 and the tissue inhibitor of metalloproteinase-2 (Bertl, Bartsch et al. 
2006).  However when studying human umbilical vein endothelial cells SF induced a dose-
dependent decrease in the proliferative activity of the endothelial cells, which was 
dependent on cell apoptosis and also inhibited tube formation on Matrigel™, but did not 
affect MMP production (Asakage, Tsuno et al. 2006).  As all experiments were conducted 
in a single cells line, potential cell specific effects are not known.  
In summary the UM-UC-3 cell line was employed in this study as it is known to be 
from a high grade tumour and therefore was thought to also have a high metastic potential.  
However the study revealed that this cell line actually exhibited a low metastatic potential 
and therefore the capacity of ITCs to reduce invasiveness could not be assessed.  Although, 
the inhibitory effects on MMP 2 and 9 and the reduction in cell motility observed in this 
current study suggests that these dietary factors may be responsible for inhibition of 
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metastasis by reducing MMP production and cell motility in this cell line and may 
contribute to the suppression of carcinogenesis by diets high in cruciferous vegetables.  In 
the following chapter the in vivo effects of cruciferous vegetables are investigated 
following a human dietary intervention study which enabled the comparison of global gene 
expression before and after an acute intervention of a broccoli soup high in both SF and IB. 
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Chapter Seven 
A Human Dietary Intervention Trial With 
Purple Sprouting Broccoli Naturally High 
In Sulforaphane And Iberin. 
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7.0 Human Dietary Intervention Trial. 
7.1 Introduction.  
The first aim of this study was to compare gene expression in bladder tissue, before and 
after a 4 day intervention of purple sprouting broccoli soup.  To quantify changes in gene 
expression in bladder tissue from patients with recurring bladder cancer, following the 
consumption of purple sprouting broccoli containing naturally higher levels of iberin and 
sulforaphane.  The use of whole genome array analysis may enable the identification of 
genes which are modulated by the short intervention and can be selected for further studies 
in-vitro.  
Secondly in order to elucidate the mechanisms of chemoprevention of ITCs in bladder 
cancer, it is necessary to conduct a long term human intervention.  To be able to do this, 
firstly a pilot study has to be carried out.  Pilot studies are a crucial element for a good full 
study design. By conducting this pilot study it was hoped to fulfil a range of important 
functions, such as assessing the feasibility of a full-scale study, assessing whether the 
research protocol is realistic and workable, assessing the likely success of proposed 
recruitment approaches and identifying logistical problems which might occur using these 
proposed methods.  This was a novel pilot study and as such had a number of limitations.  
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7.2 Specific materials and methods 
7.2.1 Blood Samples 
Following consent, samples of blood (maximum of 20 ml) were taken from each volunteer 
and put into either pre-labelled EDTA tubes or pre-labelled PAXgene™ tubes.  The 
PAXgene™ blood RNA tube was intended for the collection, storage and transport of 
blood and stabilization of intracellular RNA.  Sample codes were doubly encrypted to 
protect the volunteer’s identity.  Following collection, blood samples were transferred to 
the IFR laboratory to be stored for RNA and DNA extraction at a later date.  
PAXgene™ Sample 
PAXgene™ samples were stored and total RNA isolated and purified from the nucleated 
blood cells with PAXgene™ Blood RNA kit (Becton, Dickinson) at a later date.  The 
quantity of RNA was assessed by absorbance at 260nm using a Beckman Coulter 
spectrophotometer and the quality of purified RNA assessed with the Agilent 2100 
Bioanalyser.  RNA was hybridized onto human Affymetrix U133Plus 2.0 probe arrays at 
the Nottingham Arabidopsis Stock Centre (NASC), University of Nottingham, and 
analysed for confirmation of expression via RT-PCR (section2).   
Note- The major focus of this study was to quantify changes in gene expression in bladder 
tissue in patients with recurring bladder cancer.  Therefore the RNA extracted from 
nucleated blood cells was stored anonymously in an IFR -80°C freezer until a later date for 
analysis when resources are available.  
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7.2.2 Biopsy Samples 
Pre-intervention Biopsy 
The Surrounding ‘benign’ bladder tissue biopsies taken during a flexible cystoscopy were 
obtained for research purposes only and were not part of routine procedure (refer to chapter 
one for detailed explanation of a flexible cytoscopy).  Samples were immediately 
immersed in RNALater™ (Ambion) at the point of collection and transported to the tissue 
bank at the NNUH, where they were stored at 4°C.  The samples were collected from the 
tissue bank and transported to IFR for analysis. 
 
Post-intervention Biopsy 
Two samples of surrounding ‘benign’ bladder tissue were taken during the TURBT/TURB 
for research purposes, in addition to routine biopsies taken for histological examination 
(refer to chapter one for a detailed explanation of the TURBT and TURB procedures).  
Samples were immersed in RNALater™ at the point of collection and transported to the 
tissue bank at the NNUH, were they were stored at 4 °C.  Benign and cancerous tissue was 
routinely taken during the TURBT/TURB for histological examination.  The samples were 
classified in accordance with the tumour node metastases (TNM) 1992 system and 
histologically graded according to the World Health Organisation criteria by NNUH 
histopathologist, Professor Richard Ball.  
Biopsies placed in RNALater™ were incubated at 4 °C overnight before being 
analysed.  RNALater™ stabilizes and protects RNA, and thus gene transcription, in fresh 
tissue specimens, so that the RNA can be extracted at a later stage.  Changes in gene 
expression can occur during sampling, harvesting and handling, and during RNA isolation. 
These changes can occur very rapidly, within seconds after harvest.  Stabilizing samples 
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minutes later is often insufficient to prevent artefacts and preserve the gene-expression 
pattern.  There are two major types of artefacts that can occur. Cell death and enzymatic 
degradation of RNA result in artefactual non-specific and specific reduction of mRNA 
species.  At the same time, specific genes can be induced or down-regulated during 
handling and processing of the sample.  The combination of these two effects can result in 
a transcription profile that differs considerably from the true in vivo gene expression 
pattern.  Therefore immediate protection with RNAlater™ technology ensures that 
downstream analyses truly reflect the expression profile of the intact tissues.  Total RNA 
was extracted directly from the pre and post biopsies following the overnight incubation at 
4°C in RNAlater.  Total RNA isolation was performed using RNeasy Micro Kit (QIAgen) 
according the manufacturer’s instructions. RNeasy Micro Kit was the kit of choice due to 
the small amounts of tissue received, varying form 1 - 5 mg of bladder tissue.  The RNeasy 
Micro Kit can purify RNA (maximum 45 µg) from very small amounts of tissue or cells 
(from a single cell to a maximum of 5mg).  Preliminary investigation has demonstrated that 
although the procedure is difficult for the small biopsy and variable from sample to sample, 
sufficient RNA of high quality can be obtained from a biopsy sample of ≤5 mg in weight.  
The protocol for fibrosis tissue was used due to the nature of bladder tissue.  RNA 
purification from fibrous bladder tissues can be difficult due to the abundance of 
contractile proteins, connective tissue, and collagen.  This protocol was a modification of 
the normal protocol of RNA extraction from tissue and included a proteinase K digestion to 
remove proteins which can interfere with RNA purification. 
Although the post intervention samples tended to be much larger (10 mg-20 mg), a 
≤5 mg sample was dissected from the biopsy and analysised using the same RNeasy Micro 
Kit to ensure consistent pre and post sample handling.  RNA extractions were hybridised 
168 
 
onto Affymetrix Microarray and analysed for confirmation of expression via RT-PCR 
(refer to chapter two for detailed methods). 
 
7.2.3 Supply of Vegetables 
Seeds were supplied by Elsoms Seeds Ltd, Pinchbeck Road, Spalding, Lincolnshire, PE11 
1QG, UK.  The Red Head (Red H4) purple sprouting broccoli was grown and harvested by 
Olga Ltd, Boston, Lincolnshire, and processed by Christian Salvesen.  It has attractive 
strong spears produced from a vigorous plant.  Up until the last few years, the majority of 
purple sprouting broccoli varieties available were open pollinated.  The line Red H4 is one 
of many ‘parent’ lines which are used to produce filial generation (F1) hybrids, its origin 
was an open pollinated variety called Red Head which has been commercially available for 
about 15 years and is quite variable in its characteristics.  However, like most varieties at 
this time, it is only available during a short harvest period between March and early May.  
Breeding programmes are used to extend harvest time, increase uniformity, increase yield 
and improve ease of harvest. 
The Red H4 hybrids offspring is a new uniform variety with specific and/or 
desirable characteristics from either or both parents.  It has taken about 8 years to produce 
the uniform line Red H4 by the process of single plant selection over a number of 
generations.  To produce consistent F1 hybrids, the original cross must be repeated each 
season.  As in the original cross, this is usually done through controlled hand-pollination, 
and explains why F1-seeds are so expensive.  Once a uniformed parent line is produced 
Elsoms Seeds test for glucosinolates levels and the Red H4 was shown to be a better line 
for its glucosinolate content.  
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The broccoli was made into a soup and packaged into 250 g portions and stored frozen at      
-20 oC until required.  Commercial soup was bought from a supermarket to be used as the 
control group following ITC quantitative analysis (Waitrose broccoli and potato soup).  
 
7.2.4 Broccoli soup preparation and storage 
Soup kitchen 
Following harvest of broccoli cultivars, individual soup portions were prepared at the 
Institute of Food Research (IFR) by the Human Nutrition Unit’s diet cooks in accordance 
with Environmental Health guidelines for the storage and cooking of food provided to 
study participants. 
The broccoli was washed in mineral water and left to drain in a colander.  500 g of 
broccoli florets were weighed out and place into a plastic bowl and 750g of water was 
added to each portion of broccoli.  A lid was placed on the bowl and microwaved on HIGH 
(700 W) for 2 minutes.  The broccoli was homogenised with water using the ‘mix’ setting 
on the Kenwood New York Smoothie Maker for approximately 20 seconds, and finishing 
the mixing on the ‘smooth’ setting for approximately 10 seconds.  The mixture was 
transferred into a large container, carefully blended together by hand with a spoon and 
portioned into 250 g bags. The 250 g bags were labelled and stored in the -20 oC freezer. 
 
7.2.5 Analysis of Sulforaphane and Iberin levels in soup samples by UV/HPLC 
A 250g bag of the homogenised soup portion was defrosted overnight in the fridge and one 
hour prior to analysis the soup was left out of the fridge to equilibrate to room temperature.  
For the control group soup, the commercial soup was heated according to the manufacturer’s 
recommendations.  For the broccoli group soup the 250 g portion of purple sprouting 
170 
 
broccoli was mixed with 150g of heated commercial soup and analysised.  Both soup 
mixtures waeremixed well and a 1 ml aliquot removed and placed into a 2 ml screw top 
microcentrifuge tube.  The homogenate was centrifuged at 13, 000 g for 20 minutes and 0.5 
ml of the supernatant was removed with a 1ml syringe.  This supernatant was filtered through 
a 0.2 µm PVDF aqueous filter into a glass HPLC vial.  SF and IB standards were made by 
serial dilution of a 50 mM stock solution.  For a 400µM standard 2.8µl of the 50 mM stock 
solution was added to 347.2µl of MilliQ-purified water.  A double dilution of 150µl of 
standard plus 150µl of MilliQ-purified water was made to make the remaining standards.  A 
calibration curve was run using 20µl injections of 400 µM, 200 µM, 100 µM, 50 µM and 25 
µM of SF and IB.  Test samples were diluted 1:10 and run directly after the calibration curve. 
 
7.3 Study design 
7.3.1 Study Protocol 
A flow chart of the overall study design is given in figure 7.1.  This pilot study consisted of 
a parallel dietary intervention trial studying male patients with superficial recurring 
transitional cell carcinoma of the bladder.  Volunteers were  allocated one of the two 
dietary groups: (i) consuming a soup consisting of 400g ITC-enriched purple sprouting 
broccoli /commercial soup mix per day for 4 days between diagnosis and treatment (n=3) 
or (ii)  consuming 400g of a commercial soup only, for the 4 days between diagnosis and 
treatment (n=1).  The commercial broccoli and potato soup was analysed and no SF or IB 
was found to be present in the soup.  This soup was used for the control group and also to 
mix with the purple sprouting broccoli soup to enhance palatability.  
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Figure 7.1 Study design 
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7.3.2 Patient Recruitment 
The recurrence rate of treated bladder cancer is high in comparison to other malignancies 
and therefore patients attend regular surveillance cystoscopy, which was thought would 
enable relatively easy recruitment of volunteers. There is a short time period of 
approximately three weeks between diagnosis and the treatment of recurring bladder 
cancer, as opposed to the first presentation of bladder cancer, where there is only one week 
between diagnosis and treatment.  Patients with recurring low grade bladder cancer were 
chosen for this study as the three week period gave an acceptable time to intervene, 
whereas to intervene in the one week period would have been impossible.  
Men aged 30-75 years who were deemed to be ‘at risk’ from recurring bladder 
cancer attend the NNUH urology day unit for their routine surveillance cystoscopy every 
six months.  They were seen by Robert Mills, consultant urologist or another member of 
his medical team.  Volunteer recruitment was a two stage process: 
 
7.3.3 Collection and storage of bladder tissue for research purposes by the NNUH 
tissue bank/histopathology department 
Firstly patients presenting with recurring bladder cancer at the time of their surveillance 
cystoscopy were asked by the urology medical team to consent to the collection and 
storage of benign bladder tissue for research purposes, on behalf of the NNUH tissue 
bank/histopathology department. The tissue bank consent form was used at this stage, 
because it was known which patients would have a recurrence until the cystoscopy had 
been performed.  Furthermore, it was crucial that tissue was removed at this time as this 
was the only opportunity to remove bladder tissue before the removal of the bladder 
tumour at a later date.  Although the rate of bladder cancer recurrence is high, some 
173 
 
patients will not have a recurrence and to identify and gain patient consent onto the study 
before cystoscopy would have been impractical and insensitive.   
Following a verbal explanation by the consultant urologist, patients were given a 
tissue bank information sheet and asked to sign a tissue bank consent form (annex 10.1) 
agreeing that if a recurrence was seen a biopsy of benign bladder tissue may be taken at the 
time of the flexible cystoscopy for the purpose of extracting RNA.  The tissue bank form 
has been re-worded to allow the NNUH trust to use the bladder tissue non-anonymously, at 
its discretion, within this bladder study.  The tissue bank consent form was signed by all 
complying volunteers at the time of the cystoscopy, in the presence of the consultant and 
copies accompanied all tissue transported to the tissue bank.  It was made very clear that if 
the patient decided to donate the samples to the hospital tissue bank this did not mean they 
were committed to participating in the study in any way. 
The amount of tissue removed at the time of the flexible cystoscopy was only very 
small, due to the narrow tube inserted into the urethra.  Optimisation studies showed that 
the quality of the RNA was very variable from these small tissue samples.  Therefore it 
was very important to extract RNA and check the quantity and quality, before contacting 
the patient and allowing them to consent to the intervention study.  The tissue was released 
to the IFR for analysis to determine the quality and quantity of RNA. 
Patients who met the following two criteria were given an invitation letter (annex 
10.2) and volunteer information sheet (annex 10.3) about the pilot study during their 
routine surveillance cystoscopy appointment by Mr Robert Mills or one of his team. 1) 
Reoccurring bladder cancer was detected at the routine surveillance cystoscopy 
appointment and 2) if they had consented and donated a biopsy of benign bladder tissue to 
the tissue bank.  If patients were interested in participating in the pilot study they were 
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informed that they would be contacted after 48 hours by the chief investigator (Melanie 
Dunk) by telephone.  48 hours was given to the patients to not only read the information 
sheet regarding the study and consider taking part, but also to come to terms with their 
diagnosis. The chief investigator’s telephone number was supplied to all potential 
volunteers in case they had any questions or required further information at any stage.      
 
7.3.4 Study Consent 
Interested patients were invited to attend the HNU at IFR where the chief investigator 
explained what the study involved and the patients had the opportunity to ask questions. 
Following a 72 hour consideration period, interested volunteers contacted the chief 
investigator to confirm their intention to participate.  It was hoped that recruitment would 
continue until a maximum of six volunteers in both treatment groups had completed the 
study.  However due to difficulties in patient recruitment and time restraints, only four 
patients were recruited.  Figure 7.2 is a flow diagram showing the route of patient 
selection. 
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Figure 7.2 Patient selection 
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7.3.5 Inclusion and exclusion criteria 
 
Inclusion criteria: 
• Diagnosed with recurring transitional cell carcinoma of the bladder at time of 
cystoscopy 
• A tissue bank sample had been donated at the time of their flexible cystoscopy 
• Males aged between 30 and 75 years 
• Smokers and non-smokers 
 
Exclusion criteria: 
• Undergone chemotherapy treatment within the previous 12 months 
• Received any blood product transfusion in the last 4 months 
• Type 1 diabetic  and non-diet-controlled types 2 diabetics 
• Acute infection (assessed by consultant urologist) 
• The results of the health declaration and/or screening questionnaire form indicate that 
patient was not eligible to take part in this study (assessed by consultant urologist) 
• Allergies to any ingredients in the soup 
• If the tissue bank sample did not yield sufficient good quality RNA 
 
7.3.6 Consent and study procedures 
All volunteers responding positively following the period of consideration (minimum 72 
hours) were invited to the HNU to sign a consent form and to give blood sample.  On 
arrival at the HNU, the chief investigator went through the study consent form with the 
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volunteer (annex 10.4) and encouraged any questions they may have had at this stage; after 
which the volunteer signed the consent form agreeing to participate in the study.   
A copy of the consent forms were kept in the study records; the patients’ hospital 
notes and a copy was given to the volunteer to keep.  Patients’ general practitioners were 
informed by letter (annex 10.5) of their patient’s participation in the study.  The volunteers 
were required to sign a medical declaration form (Annex 10.6) and the study scientist 
completed a short screening questionnaire with the volunteer (Annex 10.7).  
After signing the study consent form, blood samples totalling a maximum of 20 ml 
were taken by venepuncture by an appropriately trained HNU Research Nurse.  Four blood 
samples of 2.5 ml were put into PAXgene™ blood RNA tubes.  This sample was required 
for RNA extraction for Microarray gene expression profiling of white blood cells at a later 
date. The remaining blood was put into EDTA tubes for DNA extraction to determine 
genotypes for GSTT1, GSTM3 and GSTpi genes at a later date. Volunteers were allocated 
into one of the two dietary groups.  
Once recruited onto the study, volunteers were assigned a code, only the chief 
investigator, approved by the Ethics Committee, being able to link codes to volunteers.  
Samples to be used for determining GST genotypes were doubly encrypted so that 
individuals could not be linked to the resulting genotype.  All personal information was 
kept confidential and known only to the chief investigator. 
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7.3.7 Collection of bladder Biopsy Samples 
Benign biopsies of the cancerous bladder were taken before and after the 4-day dietary 
intervention.  The collection of all biopsy samples occurred at the NNUH.  The first 
biopsies (a maximum of two) were taken during the flexible cystoscopy examination.  The 
post intervention biopsies (a maximum of four) were taken at the time of TURB/TURBT.  
Small amounts of tissue (10-20 mg each) were removed pre intervention and small 
amounts of tissue (0.5-1 mg each) were removed post intervention.  All patients received 
an explanation of the procedure by their consultant prior to examination and a standard 
information sheet.  Figure 7.3 is a flow diagram representing sample collection. 
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Figure 7.3: Plan of Sample Collection 
* Note- The major focus of this study was to quantify changes in gene expression in bladder tissue in patients 
with reoccurring bladder cancer.  Therefore the RNA extracted from nucleated blood cells was stored 
anonymously in an IFR -80°C freezer for analysis until a later date, when resources are available.  
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7.3.8 Dietary Intervention 
After giving fully informed, signed consent, the volunteers were selected for either broccoli 
group or control group.  Under supervision at the HNU, the volunteers allocated into the 
control group were asked to consume four portions (400 g each) of commercial soup over 
four consecutive days as part of their normal diet.  Under supervision at the HNU,  the 
broccoli group were asked to consume four portions (250 g of high ITC broccoli soup mixed 
with 150 g of commercial soup) of the special purple sprouting broccoli (PSB) soup, 
selectively grown for its enhanced ITC (SF and IB) content over four consecutive days as 
part of their normal diet.  The volunteers managed to consume all their soups over the four 
day period.  
The 250 g portions of purple sprouting broccoli soup were defrosted overnight in the 
fridge.  One hour prior to consumption, the soup was left out of the fridge to equilibrate to 
room temperature.  The commercial soup was heated according to the manufacturer’s 
recommendations.  For the broccoli group the 250 g portion of purple sprouting broccoli was 
mixed with 150g of heated commercial soup and served immediately.  The control group had 
400 g of heated commercial soup only.  All volunteers were given a bread roll to eat with 
their soup.  Volunteers were asked to refrain from eating any food for 1 hour before and after 
their soup, on the day of dietary intervention.  A small aliquot of each volunteer’s soup was 
collected on each day to analyse the level of ITCs. 
 
7.3.9 Safety considerations 
Risk factors: There can be a small amount of discomfort associated with taking blood and 
a small bruise may develop at the site of needle insertion, however the HNU nurses are 
trained and very experienced at taking blood and no adverse effects were seen or reported.  
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During the cystoscopy and the transurethral resection of the bladder tumour (TURBT), 
additional biopsies were taken for research purposes.  Taking biopsy samples is painless 
but there is a small risk of damage to the bladder, infection and bleeding.  Most would have 
some bleeding as a result of a biopsy that is not cauterised but perhaps < 1% would have 
either significant bleeding or infection (information obtained from Mr Robert Mills, 
consultant urologist).  Should any bleeding or infection have occurred the patient would 
have been treated appropriately by the consultant urologist at the NNUH or their GP.  
However no adverse effects were seen or reported.  
 
Food safety: The HNU at IFR complies with Environmental Health guidelines for the 
storage and cooking of food provided to study participants.  These guidelines are an 
integral part of IFRs recognition as ISO 9001:2000 compliance and constitute part of our 
process working to the standards of Good Clinical Practice and Environmental Health 
Standards.  
 
Toxicity: There is no evidence from animal or human studies that broccoli is harmful.  
However, toxic effects of indolyl glucosinolate have been identified in animals, causing 
goitre in animals with a deficiency in dietary iodine.  The mechanism of this action is not 
well understood and there is no evidence of such acute effects in humans with intakes of 
glucosinolate below 50 mg/day.  This level far exceeds the concentration consumed by 
volunteers in this study.  As broccoli and broccoli sprouts are being used as vehicles for the 
delivery of glucosinolates and isothiocyanates in many human studies and clinical trials, a 
formal phase I study looking at the safety, tolerance, and pharmacokinetics of broccoli 
sprouts was carried out in 2006.  A placebo-controlled, double-blind, randomized clinical 
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study of broccoli sprout extracts containing either 25 µmol of glucosinolate, 100 µmol of 
glucosinolate, or 25 µmol of isothiocyanate was conducted on healthy volunteers (Shapiro, 
Fahey et al. 2006).  These doses are much higher than that ingested in this pilot study.  
Thirty-two haematology and biochemistry tests were done before, during and after the 
treatment period and no significant or consistent abnormal events (toxicities) associated 
with any of the sprout extract ingestions were observed (Shapiro, Fahey et al. 2006).  
 
7.4 Statistical Power of the intervention study 
It is not possible to calculate the power for differences in gene expression between the two 
intervention groups because to date there are no relevant publications that describe the 
effects of the ITC iberin on gene expression in vivo.  This was a pilot study designed to 
provide data from which to calculate power for future studies in this field.  The nature of a 
power calculation is to obtain the probability of detecting a difference that is true as 
opposed to a false negative result.  It is arguable as to the appropriateness of such 
calculations when applied to Affymetrix gene expression data because the number of genes 
is so large (>47,000).  Therefore the study is more concerned with controlling false positive 
results (type I error). 
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7.5 Ethical approval for research study  
Research involving human subjects may not be carried out at the IFR without prior 
scientific peer approval from the IFR Human Research Governance Committee (HRGC) 
and a properly constituted human research ethics committee such as the Norfolk Research 
Ethics Committee.  Also, as this study involved recruitment of Norfolk and Norwich 
University Hospital (NNUH) patients, the proposal was also submitted to the East Norfolk 
and Waveney Research Governance Committee for scientific peer review and NNUH 
research management approval.  The Norfolk Research Ethics Committee is part of the 
National Research Ethics Service (NRES) formally called Central Office of Research 
Ethics Committees (COREC).  They provide a standardised and robust ethical review to 
protect the safety, dignity and well being of research participants as well facilitating ethical 
research within the NHS.  The NNUH East Norfolk and Waveney Research Governance 
Committee ensures the area of the hospital being utilised for the project is an appropriate 
environment for research into human physiology, disease or the  development of new 
treatments.  Figure 7.4 shows a flow chart developed by the senior research nurse at the 
HNU of the processes involved in submitting a human study for scientific and ethical 
approval.  Annex 11.8 – 11.17 show the correspondence between the chief investigator and 
the above committees to gain ethical approval for the human intervention trial.  
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Figure 7.4  Flow chart for submitting a human study for ethical approval 
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7.6 Results 
7.6.1 Intervention bladder tissue Affymetrix Array 
Using whole genome array analysis enables the detection of changes in gene expression of 
novel genes due to the acute intervention of purple sprouting broccoli and these genes can 
be investigated in more dept in the characterised cell culture models.  Although it must be 
highlighted that micro array analysis and the demonstration of particular gene expression 
cannot necessarily predict the production of a functional protein.  
RNA was successfully extracted from seven pre and post dietary intervention 
bladder tumour biopsy samples for Affymetrix microarray analysis.  Unfortunately one 
post sample was not received.  Data analysis was performed in R. R is distributed by the 
Comprehensive R Archive Network (CRAN) and is available from the URI: http://cran.r-
project.org.  Normalisation of the signal intensities across all the arrays was performed in 
R to achieve signals that would be comparable between them.  Following calculation of 
expression values for each probe set the data were submitted to higher-level analysis.  Pair-
wise comparisons between the pre and post samples were performed in R to identify genes 
that were differentially expressed more than two-fold at a statistical significant level 
(p<0.005). Sample and gene clustering was performed, the former to identify any similarity 
between the two groups and the latter to identify genes with similar patterns of expression 
across all samples.  The resulting dendrogram in figure 7.5, where red illustrates an 
increase in probe expression and green represents a decrease in probe expression.  Larger 
gene lists were produced by specifying less stringent statistical criteria and lower fold 
changes.  In contrast much smaller gene lists were produced with more stringent criteria.  
However a gene list of 18 was thought to be a manageable list to investigate further. 
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Figure 7.5  Hierarchical clustering dendrogram of 18 genes (P value of ≥0.005).  Comparing pre dietary 
intervention samples with post dietary intervention samples. 
 
The 18 genes are listed in table 7.1, and it should be noted that at this statistical criteria the 
majority of gene modulation, when comparing pre with post, is a down regulation of probe 
intensity in the post dietary intervention samples.  It can also been seen that the COL6A1 
gene previously investigated (chapter 5) is not significantly modulated at the statistical 
criteria, however collagen, type I, alpha 2 which is also a abundant ECM protein is down 
regulated.  
 
 
 
187 
 
Accession No Gene title1 
Fold 
change2  P-value3 
NM_002160 Tenascin C (hexabrachion) -2.18 0.0008 
NM_020991 Chorionic somatomammotropin hormone 2 -2.11 0.001 
NM_006347 Peptidylprolyl isomerase H (cyclophilin H)             -2.19      0.002            
NM_000923 
Phosphodiesterase 4C, cAMP-specific 
(phosphodiesterase E1 dunce homolog, 
drosophila) -2.08 0.004 
NM_003638 Integrin, alpha 8 -2.25 0.0008 
NM_177966 2'-phosphodiesterase -2.03 0.002 
X864000 
gb:X86400 H.sapiens mRNA for gamma 
subunit of sodium potassium ATPase.                            -2.95     0.005 
NM_014095 gb:NM_014095. -2.13 0.0042 
NM_000024 adrenergic, beta, receptor kinase 2             -2.35      0.002 
AA628535 Collagen, type I, alpha 2 -4.01 0.001 
NM_020403 Protocadherin 9 -2.01 0.004 
AA469917 Chromosome 8 open reading frame 72 -2.28 0.0002 
NM_001099678 leucine rich repeat containing 58 -2.01 0.004 
NM_001714 Bicaudal D homolog 1 (Drosophila) -2.12 0.005 
BF447682 gb:BF447682  -2.06 0.004 
AK054653 hypothetical protein LOC153577 -2.35 0.003 
NW_927317 cystatin pseudogene -2.01 0.002 
 NW_923572 hypothetical protein LOC284661 -2.04 0.0004 
 
Table 7.1 A list of probes altered in bladder tissue when comparing superficial pre and post intervention 
samples (18 probes)1.  The fold change shown represents the mean gene expression ratio calculated using R 
between the pre and post intervention cancer tissue. The negative values represent a down-regulation and as 
such correspond to green of the heat map in figure 7.1.2  Genes that were differentially expressed more than 
two-fold at a statistical significant level (p<0.005)3. 
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7.7 Discussion 
7.7.1 Dietary Intervention Study 
Some of the genes uncovered in this intervention study were very interesting, such as 
COL1A2 and Tenascin-C. However the recruitment was not as successful as one would 
have hoped i.e. although the rate of reoccurrence of TCC is high and as such, the amount of 
patients seen for routine surveillance is high, the uptake into the intervention study was 
low.  There may be several contributing factors to this, such as the exclusion criterion was 
too strict. Although men are at more risk of bladder cancer, including women into the study 
could have increased recruitment numbers significantly.  Secondly, the time of year may 
have had an impact on the patient’s decision to participate in the study.  Unfortunately 
recruitment coincided with Christmas and New Year and as such may have deterred 
patients from being involved.  This was not planned and if time restraints were not an issue 
the study would have been delayed until January.  Thirdly, the feedback from many 
patients suggested that they were discouraged about having to travel to the IFR/HNU on 
four consecutive days prior to their operation.  Many of the patients who had shown an 
interest in being involved in the study lived some distance away from the NNUH/IFR and 
therefore felt they could not travel in every day.  As a consequence all patients who 
participated in the study were from the nearby Norwich area.  In hindsight, travelling to the 
participants’ homes would have improved recruitment.  Finally, considering the target 
patients/participants had very recently been diagnosised with reoccurring bladder cancer, it 
is not surprising that the recruitment was slow.  This may have been corrected if the 
recruitment period was longer; however time restraints forced the study to come to an end.   
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7.7.2 Gene ontology 
Chorionic somatomammotropin hormone 2 
This gene encodes for the chorionic somatomammotropin hormone 2, is a member of the 
somatotropin/prolactin family of hormones and plays an important role in growth control. 
This particular family member is expressed mainly in the placenta and is up regulated 
during development and increases by term of pregnancy.  Genetic variation in the 
somatomammotropin hormone 2 gene have been associated with low body weight at birth 
and in infancy, and  metabolic syndrome later in life (Day, Chen et al. 2004), but to my 
knowledge has not been associated with cancer. 
 
Peptidylprolyl isomerase H (cyclophilin H)  
The protein encoded by this gene is a member of the peptidyl-prolyl cis-trans isomerase 
(PPIase) family.  The protein has been shown to possess PPIase activity and may act as a 
protein chaperone that mediates the interactions between different proteins inside the 
spliceosome; however there are no associations with cancer. 
 
Phosphodiesterase 4C, cAMP-specific (PDE4A) (phosphodiesterase E1 dunce 
homolog, Drosophila) 
There is very little literature regarding this gene, however it has been suggested that the 
expression of a specific isoforms of PDE4A is reduced in patients with bipolar disorder 
(Fatemi, Reutiman et al. 2008). There are no associations with cancer. 
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Integrin, alpha 8 (ITGA8) 
The protein encoded by this gene is an extracellular matrix receptor of the integrin family 
and is known to regulate cell adhesion, migration, and proliferation (Prols, Hartner et al. 
1999) and appear to be the major receptors by which cells attach to extracellular matrices.  
It has been reported that alpha8 integrin could play an important role in maintaining tissue 
integrity in the glomerulus during glomerular injury.  Alpha8 integrin is involved in the 
regulation of the mesangial cell phenotype and seems to promote adhesion, but inhibit 
migration and proliferation of mesangial cells (Bieritz, Spessotto et al. 2003).  Also a 
polymorphism of the ITGA8 promoter modifies the progression of renal failure in 
autosomal-dominant polycystic kidney disease (Zeltner, Hilgers et al. 2008).  There 
appears to be some work regarding renal abnormalities, however more specific to bladder 
cancer, the expression rate of integrin beta 4 subunit in renal cell carcinoma lines are lower 
than that in other urological tumour cell lines (Takiuchi, Kanokogi et al. 1994). 
 
Collagen, type I, alpha 2 (COL1A2) 
The COL1A2 protein is a component of the extracellular matrix and is involved in matrix 
integrity.  It is found in most connective tissues and is abundant in bone, cornea, dermis 
and tendon.  Type I collagen is the most abundant bone protein and considering the most 
frequent site of prostate cancer metastasis, along with many other cancers, is the bone, a 
study set out to determine whether prostate cancer bone metastasis is mediated by binding 
to type I collagen.  They concluded that collagen I attachment mediated by alpha(2)beta(1), 
which is the type I collagen receptor, initiates motility programs through RhoC and suggest 
a mechanism for prostate cancer metastasis to the bone (Hall, Dai et al. 2006).  In this 
bladder study the COL1A2 gene was seen to be was down regulated 4 fold in the micro 
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array analysis (table 7.1).  A study involving quantitative methylation-specific PCR and 
RT-PCR showed that COL1A2 gene inactivation/down regulation through CpG 
hypermethylation may contribute to proliferation and migration activity of bladder cancer.  
Comparing 67 bladder cancer specimens (BCs) and 10 normal bladder epithelia it was 
determined that the methylation index of COL1A2 was significantly higher in the 67 BCs 
than in the 10 normal bladder epithelia (p=0.0011) (Mori, Enokida et al. 2009).  Like 
COL6A1, which was explored in chapter five, this collagen gene/protein also appears to be 
very relevant to bladder cancer invasiveness and metastasis. 
    
Protocadherin 9 (PCDH9) 
This gene belongs to a subfamily of the cadherin superfamily, but little appears to be 
known about its functions.  One study suggests that PCDH20 hypermethylation may be a 
factor in the carcinogenesis of non-small-cell lung cancer (Imoto, Izumi et al. 2006). 
However there is little literature regarding PCDH9 and cancer. 
 
Tenascin-C will be discussed in the following chapter. 
 
There is little literature about the following genes functions and no association with 
cancer: 
2'-phosphodiesterase 
gb:X86400 H.sapiens mRNA for gamma subunit of sodium potassium ATPase. 
gb:NM_014095.adrenergic, beta, receptor kinase 2 
Chromosome 8 open reading frame 72 
leucine rich repeat containing 
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Bicaudal D homolog 1 (Drosophila) 
gb:BF447682 
hypothetical protein LOC153577 
cystatin pseudogene 
hypothetical protein LOC284661 
 
In summary, this novel short term intervention trial was successful as a pilot study.  
It highlighted some important issues relating to the study protocol which need to be 
changed before embarking on a full long term study, such as the inclusion/exclusion 
criteria and logistic issues creating problems with patients attending the HNU.  However, 
this small pilot study did suggest that sequential sampling of bladder tissue before and after 
dietary intervention may provide insight to how certain diets may be able to reduce bladder 
cancer incidence and progression.  Some very interesting genes were uncovered in relation 
to bladder cancer and this preliminary data in combination with the first array data, suggest 
that effects on the extracellular matrix may be of importance.  In particular tenascin-C was 
a gene which was found to be increased with the severity of cancer grade, as seen by the 
first array analysis however the expression of this gene is decreased following the 
intervention with the broccoli soup.  Tenascin-C is an extracellular matrix glycoprotein and 
promotes cell migration and proliferation.  This gene has been shown to be expressed in 
bladder tumour stroma and positively correlated with tumour grade, stage and proliferative 
activity.  Furthermore, tissue remodelling during carcinogenesis is associated with 
expression of specific tenascin-C splice variants and this will be explored in the following 
chapter.  
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Chapter Eight 
The Relationship Of Tenascin-C Expression 
With The Grade Of Bladder Cancer. 
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8.0 Relationship Of Tenascin-C (Tn-C) Gene Expression With The Grade Of Bladder 
Cancer 
8.1 Introduction 
While the broccoli intervention did not induce genes involved in phase II detoxification of 
xenobiotics, as may have been expected from studies with cell models, the intervention did 
highlight the decreased expression of an important extracellular matrix gene encoding for a 
protein called Tenascin-C.  The expression is in an opposing manner to that observed with 
tumour progression.  That is, results from the first array analysis, comparing superficial to 
invasive TCC in chapter three, showed a 4.5 increase in this gene expression, while the 
results from the second array analysis comparing expression pre and post broccoli 
intervention, showed a 2.18 decrease in Tn-C expression.  In neoplastic tissues the 
alternative splicing of the Tn-C pre-mRNA is deregulated leading to the generation of a 
number of repeats which are absent from all normal adult human tissues, but are present in 
cases of tissue re-modelling, such as in foetal tissues and many types of solid tumours, 
ultimately leading to varied forms of the Tn-C protein.  Among these repeats, domain A1, 
D and C are said to be particularly suitable markers for anti-angiogenesis targeting.  The 
aim of this final chapter is to identify five splice variants of the Tn-C gene in 8 UM-UC-3 
cell culture samples and 29 tissue samples and to assess whether there is a higher degree of 
these splice variants being expressed in the more invasive tissue/cell type.   
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8.2 Specific materials and methods 
8.2.1 RNA extraction from UM-UC-3 cell culture and human bladder tissue 
RNA was extracted from cell cultures and human bladder tissue using RNeasy Blood and 
Tissue Kit (Qiagen) according to the protocol described in the handbook for the 
purification of RNA from animal or cells spin-column protocol method, (section 2).  RNA 
was extracted from eight treated and untreated cell cultures and 29 bladder tissue biopsies 
of varying grades.  The diagnosis and histological staging of the tissue samples were 
established according to the WHO classification (Section 1) (Oosterlinck, Lobel et al. 
2002). 
  
8.2.2 Cycling conditions for Tn-C primers 
Primers were used as designed by Mighell et al.(Mighell, Thompson et al. 1997) and Bell 
et al. (Bell, Pringle et al. 1999) and ordered from Sigma Genosys (Table 8.1).  The 
reactions were carried out in triplicate.  The samples were run on a Whatman Biometra® T 
gradient thermocycler.  Cycling conditions for Tn-C primers, as described by Berndt et al. 
(Berndt, Anger et al. 2006), were 50 oC reverse transcription for 30 minutes, incubation at 
95 oC for 15 minutes and PCR at 94 oC for 1 minute, 57 oC for 1 minute and 72 oC for 1 
minute, for a total of 40 cycles.  Ten µl of RT-PCR were mixed with the appropriate 
amount of 6X loading dye (Promega) and the product were electrophoresed through a 2% 
agarose gel in Tris-acetate (TAE) buffer (0.04 M Tris acetate 0.001 M EDTA) against 100 
bp ladder (Promega).  The length of the potential RT-PCR products were calculated 
according to published data of human Tn-C studies(Sriramarao and Bourdon 1993).  The 
RNA was visualied using Ethidium bromide chelation to the RNA and observed under UV 
light.  
196 
 
 
Table 8.1 RNA was amplified using primers for Tn-C and for Tn-CL splicing domains as described by Bell et 
al. and Mighell et al. To evaluate the RT-PCR system and RNA integrity, amplification of β-actin mRNA 
was performed as described my Katenkamp et al. To assess the whole amount of Tn-C mRNA a primer pair 
mapping the C-terminal domains F3-F5 was amplified (Berndt, Anger et al. 2006). 
 
 
 
 
 
 
Primers for RT-PCR analysis of splicing domains of Tenascin-C 
 
Primer                     Sequence         Reference* 
T1 AGGCAGACACAAGAGCAAGC Mighell et al. (1997) 
T6 GCTACCCCCTAGTACTGATTTTATTGTCTA Mighell et al. (1997) 
T8 CATTGGCTATGAGGTTATGG Mighell et al. (1997) 
T9 CTGGTCTGAGTCTTGGTTCCGTTCC Mighell et al. (1997) 
T12 TGTAATGACAAAGGCAGTGA Mighell et al. (1997) 
T15 TGAGATTGTGAGCCTCTTCC Mighell et al. (1997) 
T16 GCTGCCTCTACTGTGTCAGC Mighell et al. (1997) 
T25F TGAACAAAATCACAGCCCAG Bell et al. (1999) 
T27R CAGTGGAACCAGTTAACGCC Bell et al. (1999) 
β-Actin 1 CCTTCCTTCCTGGGCATG QIAGEN GmbH 
β-Actin 2 GAGCAATGATCTTGATCTTC QIAGEN GmbH 
   
*Mighell (Mighell, Thompson et al. 
1997)    
  Bell (Bell, Pringle et al. 1999)    
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Primers Target splicing domains                   bp 
  5-   3-     
1 T1  T16 5-A1-A3 454 
2 T1  T15 5-A1-A2-A3 737 
3 T6  T12 B-ADI 346 
4 T6  T9 B-B-D-6 531 
5 F8  T9 C-D-6 519 
6 25F  27R Tn-C(s) 322 
7 β-actin 1   β-actin 2     
Table 8.2 Summary of primers for RT-PCR analysis and their target splicing domains. 
 
 
Table 8.3 Primer and probe designed and used in the real time RT-PCR analysis of the two Affymetric probe 
areas areas 216005_at and 201645_at 
 
 Forward primer sequence 
(5’-3) 
Reverse primer sequence 
(5’-3) 
Probe sequence 
(5’-3) 
Tenascin 
C 
216005_at 
 
TCACAGGAGCTTTGGATGCA 
 
AATTGTCCAAGGTAACACAGTCTGTAA 
 
CAGGCTGGCGCTCTGATCCTGAC 
Tenascin 
C 
201645_at 
 
GGGCCAACGGCAACAG 
 
CAGAAACATGTTGGAGACTGATGTC 
 
ATGGGCCTCACCTCCTCTGTGATTTCTT 
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8.3 Results 
8.3.1 Comparison of Tenascin-C expression between the two Affymetrix microarray 
studies (Chapter 3 and chapter 7) 
From table 8.4 it may be seen that, not only does the expression of Tn-C increase with the 
severity of cancer grade, as seen by the first array analysis (chapter 3), but the expression 
of this gene is decreased following the intervention with the broccoli soup (chapter 7). 
 
Broccoli Dietary intervention Superficial versa  invasive bladder cancer 
Tenascin-C gene expression fold change 
2.18 decrease following dietary 
Intervention 
4.51 increase in invasive tissue when compared to 
superficial tissue 
 
Table 8.4 Comparison of Tenascin-C expression (fold change) between the two micro array studies.  
 
The microarray dietary intervention data showed the expression of Tn-C is opposite to that 
observed with microarray data generated when comparing superficial bladder cancer 
samples with invasive bladder cancer samples.  
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8.3.2 Differential expression of Tenascin-C slicing domains in treated cell cultures and 
human bladder tissue 
 
The Tn-C transcript, exhibiting a length of 332 bp (constant region, lane 7, in all gels, see 
annex 11.18) was very distinctive in all of specimens under investigation and independent 
from their diagnostic status.  Figure 8.1 gives two examples of RT-PCR gels showing the 
different splicing domain patterns of RNA extracted from a superficial and an invasive 
bladder tissue biopsy.  All gels can be seen in the appendix (a total of 48 gels), annex 
11.18. 
 
 
 
03TB179* G2pTa** – superficial TCC                 02TB044* G3pT3b**– invasive TCC 
 
 
* Sample number; ** Histological grade of tissue biopsy 
 
Figure 8.1 Example RT-PCR gels showing the different splicing domain patterns of RNA extracted from a 
superficial and an invasive bladder tissue biopsy. The biolab 100bp DNA ladder is in lanes 1. Lanes 2 – 6 
represent splicing domains   5-A1-A2, 5A1-A2-A-3, B-ADI, B-D6 and C-D-6 respectively. Lane 7 represents 
a region which is always constant in the Tn-C gene and therefore serves as a positive control for the 
presences of the Tn-C gene. Lane 8 represents the positive control β-actin.  
 
Generally all 39 samples showed Tn-C splice variant synthesis on different levels.  Table 
8.5 shows qualitative analysis of the five splice variants and in general the low grade 
(superficial) TCC samples expressed less Tn-C slice variants than the invasive TCC.  All 
the samples expressed the constant region of the Tn-C gene (332bp, lane 7) and therefore 
 
1      2      3     4     5      6     7     8 
 
1      2     3     4      5      6      7    8 
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demonstrated the presences of the gene.  The high grade UM-UC-3 cell culture samples 
expressed all five splice variants and the prior treatment with ITC did not modulate the 
expression of Tn-C variants.  Samples 04TB125 and 02TB125, which are high grade TCC, 
both samples being graded as G3pT3b, also expressed all five splice variants.  In 
accordance with published data, only high grade TCC tends to express the C-D-6 splice 
variant, lane 6 (Berndt, Anger et al. 2006), 04TB125, 02TB044, O4TB093 and cell culture 
samples were the only samples to express C-D-6.  Interestingly, while the broccoli 
intervention (samples before (b) and after (a) in red, Figure 8.2) did not modulate the 
expression of Tn-C splice variants, in general the samples expressed more slice variants 
than the other TCC graded as superficial and as such gave a phenotype more comparable to 
that of the invasive TCCs.  Samples 03TB146, 03TB165, 07TB020 and 04TB269, all 
graded as superficial TCC only expressed one splice variant, 5-A1-A2, lane 2, B-ADI, lane 
4, B-ADI and B-D-6, lane 6 respectively.  Apart from the intervention samples and sample 
02TB023, which expressed three of the five splice variants, the maximum splice variants 
expressed by the superficial samples was two and predominately B-D-6, lane 5. The work 
of Berndt et al. reported that the B-ADI domain was rarely expressed; however 
examination of the work indicates that the expression of the B-ADI domain is actually only 
rarely expressed in the superficial TCC, which is consistent with my work.  Only two high 
grade TCC samples did not express this splicing domain and nine out of eleven of the 
superficial TCC also did not express this splicing domain.  The C-D-6 splice variant of the 
B-D region is rarely expressed in any of the samples at any grade except the cell culture 
samples.  Only samples 02TB044, 04TB125 and 02TB093 expressed the C-D-6 domain.  It 
as been reported that this splicing domain appears only to be expressed in tumours with  
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compact invasion patterns (Berndt, Anger et al. 2006).  In accordance with this 
observation, samples 02TB044 and 04TB125 are graded as G3pT3b and as such are  
undifferentiated cells which have invaded the bladder wall giving rise to an extravesical 
mass which could be seen macroscopically by the urologist.  Sample O2TB093 is also 
undifferentiated cells and the tumour would have begun to invade the bladder wall also.    
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Grade Splicing domains 
  1    2     3     4     5      6   7 
  A1-A3 region B-D region constant Ctl 
  5-A1-A2 
5-A1-A2-
A3 B-ADI B-D-6 C-D-6 Tn-C β-actin 
Bladder cells 
following 
treatment with:  453 bp 737 bp 346 bp 531 bp 519 bp 332 bp 204 bp 
sf ctl (DMSO) High √ √ √ √ √ √ √ 
Sf High √ √ √ √ √ √ √ 
ib ctl (DMSO) High √ √ √ √ √ √ √ 
Ib High √ √ √ √ √ √ √ 
sf-nac ctl (DMSO) High √ √ √ √ √ √ √ 
sf-nac High √ √ √ √ √ √ √ 
sf/ib ctl (DMSO) High √ √ √ √ √ √ √ 
sf/ib High √ √ √ √ √ √ √ 
Human bladder 
tissue: 
03TB135 High √ x √ √ x √ √ 
03TB163 Low √ x x √ x √ √ 
03TB180 High √ √ √ √ x √ √ 
03TB189 High √ √ √ √ x √ √ 
03TB192  Low x x √ √ x √ √ 
03TB195 High √ x √ x x √ √ 
04TB018 High √ x x √ x √ √ 
04TB023 Low √ x √ √ x √ √ 
04TB035 High √ √ √ √ x √ √ 
04TB099 High √ √ √ √ x √ √ 
04TB269 Low x x x √ x √ √ 
04TB280 High √ x √ √ x √ √ 
04TB192 Low x x √ √ x √ √ 
03TB165 Low x x √ x x √ √ 
02TB067 low √ x x √ x √ √ 
02TB044 High √ √ √ √ √ √ √ 
02TB093 High √ x √ x √ √ √ 
03TB179 Low x √ x √ x √ √ 
04TB119 High √ √ √ √ x √ √ 
04TB125 High √ √ √ √ √ √ √ 
04TB021 Low √ x x √ x √ √ 
03TB132 Low √ x x √ x √ √ 
03TB146 Low √ x x x x √ √ 
07TB0322 Low √ √ √ √ x √ √ 
07TB0338 Low √ √ √ √ x √ √ 
07TB0339 Low x √ x √ x √ √ 
07TB0344 Low √ √ √ √ x √ √ 
07TB0340 Low √ √ √ √ x √ √ 
08TB0007 Low x √ x √ x √ √ 
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Table 8.5 Identification of five splice variants of the Tn-C gene in 8 UM-UC-3 cell culture samples and 31 
tissue samples. To assess whether there is a higher degree of these splice variants being expressed in the more 
invasive tissue/cell type.  
 
Indicates the splice variant is being expressed                               Indicates intervention samples           
Indicates the splice variant is not being expressed                                                                                                 
 
Sample Grade A1-A3 region B-D region  constant Ctl 
  
5-A1-
A2 
5-A1-A2-
A3 B-ADI B-D-6 C-D-6  Tn-C β-actin 
  453 bp 737 bp 346 bp 531 bp 519 bp  332 bp 204 bp 
sfn ctl High                
Sfn High                
ib ctl High                
Ib High                
sfn-nac ctl High                
sfn-nac High                
sf/ib ctl High                
sf/ib High                
03TB135 High                
03TB180 High                
03TB189 High                
03TB195 High                
04TB018 High                
04TB035 High                
04TB099 High                
04TB280 High                
02TB044 High                
02TB093 High                
04TB119 High                
04TB125 High                
03TB163 Low                
03TB192  Low                
04TB023 Low                
04TB269 Low                
04TB192 Low                
03TB165 Low                
02TB067 Low                
03TB179 Low                
04TB021 Low                
03TB132 Low                
03TB146 Low                
07TB0322 b Low                
07TB0338 b Low                
07TB0339 b Low                
07TB0344 b Low                
07TB0340 a Low                
08TB0007 a Low                
08TB0018 a Low                
06TB0208 Low                
07TB020 Low                
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Figure 8.2 Graphical representation of five splice variants of the Tn-C gene in 8 treated UM-UC-3 cell 
culture samples and 31 tissue samples. 
 
 
8.3.3 Mapping of the Tenascin-C gene to identify the location of splicing domains and 
the Affymetrix probe 201645_at and 216005_at locations for RT-PCR analysis. 
The Tn-c gene was mapped to identify the locations of all splicing domains and the 
Affymetrix probes 201645_at and 216005 to enable the design of primer and probes for 
RT-PCR analysis.  To identify all relevant sequences, genomic, mRNA and protein the 
NCBI Sequence Viewer (www.ncbi.nlm.nih.gov/projects/sviewer) and the Human Genome 
Browser was used (www.genome.ucsc.edu/cgi-bin/hgGateway). BLAST was used to 
identify where the array sequences for the Affymetrix probe locations are on the gene and 
also exons AD1 and AD2.                      
NH2HOOC 123 45678
A
1
A
2
A
3
A
4
BCD
A  
D1
A
D2
8 7 6 D C AD1 AD2 B A4 A3 A2 A1 5 4 3 2 1
T1T6T8T25F
T15 T16T12T9T27R
T1T15 T16T6T8T9T27R T25F
201645_at 216005_at
AD1 AD2
T12
 
Figure 8.3 Mapped Tenascin-C gene to locate primers, splicing domains and Affymetrix probes 201645_at 
and 216005_at locations (Figure created by Dr Caroline Furniss of the Institute of Food Research). 
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8.3.4 Confirmation of dietary intervention array analysis (chapter 7) 
When comparing superficial TCC with invasive TCC there was a significant 3.24 fold 
increase in Tn-C expression in the microarray analysis in the invasive group at the 
Affymetrix probe location 201645_at (figure 8.4) and a 2.18 fold decrease in Tn-C 
expression at this probe location post dietary intervention (figure 8.4 and chapter 7).  The 
microarray analysis at the Affymetrix probe 21005_at did not show any significant 
difference between the invasive and superficial sample groups or the pre and post dietary 
intervention.  To confirm these finding the Tn-C gene was mapped for the Affymetrix 
probes 216005_at and 20645_at target locations (Figure 8.3), primer and probes were 
designed and optimised (Table 8.3).  Tn-C gene expression was determined via RT-PCR in 
RNA extracts from six pre and post dietary intervention tissue samples (figures 8.4 and 
8.5) and 20 remaining tissue samples of varying grade (figures 8.6 and 8.7).  Unfortunately 
the 20 remaining tissue samples were not analysised in triplicate due to insufficient RNA 
sample/tissue sample and as such do not have error bars. 
 The Tn-C gene at the Affymetrix 201645_at probe location showed a significant 
(*p<0.05) decrease in expression in patient one and two following the dietary intervention 
(post biopsy sample).  Patient three showed no change in Tn-C gene expression (figure 8.4) 
There was no significant change in Tn-C gene expression at the 216005_at Affymetrix 
probe location (figure 8.5). 
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Figure 8.4 Tn-C gene expression in six pre and post dietary intervention tissue biopsies (three individuals) at 
the 201645_at probe target. Data is shown from three biological replicates. The error bars represent the SD of 
these biological replicates, * p<0.05, n=3.  
 
 
 
 
Figure 8.5  Tn-C gene expression in six pre and post dietary intervention tissue biopsies (three individuals)  
at the 216005_at probe target. Data is shown from three biological replicates. The error bars represent the SD 
of these biological replicates n=3. 
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Tn-C gene expression at the 20645_at Affymetric probe
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Figure 8.6 RT-PCR of the 201645_at Affymetrix probe target region of the Tn-C gene in 20 bladder tissue 
biopsy samples.  
Tn-C mean gene expression is significantly increased (*p<0.05) in the invasive samples 
compared to the mean Tn-C gene expression in the superficial samples at the Affymetrix 
probe location 20645_at. Tn-C mean gene expression was also significantly increased 
(*p<0.05) in the invasive samples compared to the mean Tn-C gene expression in the 
superficial samples at the Affymetrix probe location 216005_at. 
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 Figure 8.7 RT-PCR of the 216005_at Affymetrix probe target region of the Tn-C gene in 20 bladder tissue 
biopsy samples.  
 
Invasive tissue * 
Superficial tissue 
Invasive tissue * 
Superficial tissue  
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8.4 Discussion  
Tenascin-cytotactin (Tn-C), also known as hexabrachion, is from a family of large 
multimeric extracellular matrix glycoproteins; Tenascin -C, -R, -X and -W are all present 
in mammalian connective tissue (Chiquet-Ehrismann 2004).  Six monomers are disulphide 
linked at their N-terminal from a central core as seen in the rotary shadowing image, figure 
8.8 below.  
 
                          
Figure 8.8 A Rotary shadowing image showing the highly symmetrical structure of the hexabrachion (Jones 
and Jones 2000). 
B A key feature of Tn-C is the assembly into hexamers creating a six-armed structure of the hexabrachion 
(Jones and Jones 2000)  
 
The subunits are composed of structural domains that include the globular amino terminal 
domain, 14.5 epidermal growth factor like repeats, a carboxy-terminal sequence with 
homology to the globular domain of β- and γ-chains of fibrinogen (Bell, Pringle et al. 
1999) (Erickson 1993), as seen in figure 8.3.  There also eight constant fibronectin type III-
like domains (FN III ); nine additional fibronectin type III-like domains can be included or 
omitted in a combinatorial manner by alternative splicing repeats, generating structurally 
and functionally different Tn-C isoforms (Siri, Carnemolla et al. 1991; Borsi, Balza et al. 
1995; Berndt, Anger et al. 2006).  These low splicing large Tn-C (Tn-CL ) are 
preferentially expressed during tissue remodelling processes including embryogenesis, 
A B 
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organogenesis, wound healing and carcinoma development and are known to modulate 
cancer adhesion to ECM (Bell, Pringle et al. 1999; Hauptmann, Budianto et al. 2003; Tse 
and Kalluri 2007).  
  It is this alternative splicing within the stretch of FN III domains which results in 
the great number and diversity in Tn-C isoforms.  Therefore, depending on the variant 
generated by this alternative splicing, each subunit may have a molecular mass in the range 
of 190-300 kDa (Kammerer, Schulthess et al. 1998).  
 
8.4.1 Confirmation of Tn-C array results by RT-PCR analysis of Affymetric probe 
locations 201645_at and 216005_at  
Comparing superficial TCC with invasive TCC there was a 3.24 fold increase in Tn-C 
expression at the Affymetrix probe location 201645_at in the invasive sample group when 
compared to the superficial group.  This confirms the array results; indicating that the 
expression of Tn-C increases with the grade and severity of bladder cancer. The 
Affymetrix  probe 21005_at also showed a mean significant increase in the invasive 
sample group compared with superficial sample groups.  This was not shown by the array 
results, as no significant difference at the probe location was seen in the array analysis.  
 
8.4.2 Differential expression of Tn-C splicing domains in TCC biopsy tissue and UM-
UC-3 cell line in relation to grade.  
In order to reveal information about possible differentational expression of the Tn-C splice 
variants in TCC and bladder cell culture, an examination of the mRNA expression of five 
splice variants were investigated via RT-PCR.  Figure 8.1 represents just two RT-PCR gels 
from superficial and invasive TCC and all gels can be seen in the appendix (a total of 48 
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gels).  Tn-C is an adhesion-modulating extracellular matrix molecule that is highly 
expressed in tumour stroma and stimulates tumour cell proliferation and is said to promote 
cell migration and proliferation demonstrated in vitro (Yoshida, Yoshimura et al. 1999; 
Orend and Chiquet-Ehrismann 2000).  Tsunoda et al. found that Tn-C variants were found 
at only low levels in normal breast tissues, but were highly expressed at invading sites of 
intraductal cancers and in the stroma of invasive ductal cancers and in addition the splice 
variants of these proteins, which are generally absent in normal adult tissues, become 
predominant in cancerous tissue (Adams, Jones et al. 2002; Tsunoda, Inada et al. 2003).  
Tn-C has been shown to stimulate invasion line via up-regulation of MMP-1 
expression through activation of mitogen-activated protein kinase (MAPK) cascade 
activation in a chondrosarcoma cell line.  The analysis of gene expression in JJ012 cultured 
cells grown under different conditions indicated a significant 100% increase of MMP-1 
mRNA levels in the cells treated with Tn-C bp320, compared cells treated with Tn-C 
bp220.  Tn-C bp320 was not a splicing domain analysis in this experiment and Tn-C bp220 
is a constant region of the Tn-C gene (such as 332bp in my experiments) and as such 
served as a control (Galoian, Garamszegi et al. 2007).  Furthermore invasion activity 
assays demonstrated a 3-fold difference in invasion potential compared in cells treated with 
Tn-C bp 320 in comparison with the control.  
 Functional analysis of the Tn-C gene in mice has revealed its role in 
regulating the migration of tumour cells and the formation distant new tumour tissue.  The 
research also found that reduced expression of Tn-C resulted in a decrease in tumour 
growth, tumour relapse following surgical removal and reduced metastasis in the lung 
(Albini, Mirisola et al. 2008).  As in my research, Tn-C has been shown to be expressed in 
bladder tumours and was positively correlated with tumour grade and also appears to 
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correlate with proliferative activity, as seen in the invasive grades of TCC.  Patients treated 
with TURBT alone and who had low expression of Tn-C, had a longer tumour-free interval 
than those with high expression of Tn-C.  This observation maybe poignant when 
considering the intervention biopsies/patients and some of the other superficial bladder 
biopsies with high Tn-C splicing domain expression studied in this RT-PCR investigation.  
This may be of significance, as all patients taking part in the intervention study had a 
reoccurrence of TCC; for two patients this was the third reoccurrence of TCC.  All patients 
underwent TURBT post intervention and it is evident from the results that they have high 
levels of Tn-C splicing domains.  It may be postulated that the presence of these splicing 
domains may contribute towards this observed short tumour-free intervals in these patients.  
It would be of interest to follow up these patients to discover whether they continue to have 
shorter tumour-free interval in comparison to patients with low levels of splicing domains.  
In summary, these findings suggest that differential expression of Tn-C splicing 
variants in these TCC samples increase with grade of TCC tumour.  Treatment of cell 
cultures with 12µM SF or 12µM IB and the consumption of broccoli high in SF and IB did 
not modulate Tn-C splicing domain expression in this experiment.  However, these finding 
along with other study findings suggest that the detection of Tn-C splicing domains or 
perhaps particular Tn-C splicing domain expression patterns could be useful for the 
assessment of and diagnosis of muscle invasion TCC, tumour surveillance, as well as target 
structures for antibody based tumour detection and therapy.  Moreover, the over expression 
of Tn-C may identify groups of patients with poor tendency to disease recurrence and 
longer relapse-free time.      
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Chapter 9:  General Discussion 
Bladder cancer is the fourth most common cancer among males and the eleventh most 
common cancer among women in the UK (Cancer Research UK).  Additionally, bladder 
cancer has the highest recurrence rate of any malignancy (Grossman, Soloway et al. 2006) 
and most patients will experience either recurrence or progression.  Therefore the need for 
accurate and diligent surveillance is paramount and consequently biological markers in the 
diagnosis and monitoring of reoccurring bladder cancer is of the upmost importance 
(Mohammed, Khan et al. 2008).  
Many epidemiological studies have shown that the consumption of cruciferous 
vegetables can reduce the risk of developing bladder cancer and it is thought that 
isothiocyanates may play an important role in mediating the chemo preventative activity of 
cruciferous vegetables (Larsson, Andersson et al. 2008; Kim and Park 2009). SF is one of 
the prominent ITCs in calabrese and IB is one of the prominent ITC in purple sprouting 
broccoli.  While SF is the most extensively studied ITC, there is very little literature 
regarding the biological effects of IB and cancer in general, and none regarding IB and 
bladder cancer.  IB may have comparable biological effects to SF due to its similar 
structure (Chambers, Bacon et al. 2009).  
There were five main aims of this thesis; 
1) To characterise superficial and invasive bladder tissue.  To compare global gene 
expression profiles between superficial and invasive transitional cell carcinoma and define 
gene expression profiles or selective genes that are characteristic of aggressive clinical 
behaviour in invasive bladder tumours for further studies in-vitro. 
2) To characterise human bladder cell cultures and assess the effects of sulforaphane and 
iberin and their N-acetylcysteine conjugate on phase II gene expression. 
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3) To use whole genome array analysis to enables the identification of genes which are 
modulated by a short term dietary intervention in bladder tissue from patients with recurring 
bladder cancer, and to select genes for further studies in-vitro.  
4) To investigate the effects of sulforaphane, iberin and their conjugates on the cellular 
motility of the characterised UM-UC-3 cell line and their potential capability to reduce 
invasion into extracellular matrix.  
5) To evaluate the differential expression of Tn-C splicing domains in human transitional cell 
carcinoma of the bladder with respect to the invasive behaviour. 
 In this thesis there are two main objectives, firstly what are the molecular differences 
between superficial and invasive bladder tissue, and secondly what molecular changes are 
induced in bladder tissue by ITCs/Broccoli; specifically, can these compounds induce a more 
‘superficial profile’ in bladder tissue and bladder cell cultures. Through the use of 
Affymetrix arrays, to quantify differences in global gene expression profiles between 
superficial and invasive transitional cell carcinoma, clear molecular differences between 
the two forms of cancer were observed. Non hierarchical analysis clustered gene 
expression into two clinically distinct groups; the superficial transitional cell carcinoma of 
the bladder (Ta- T1) into one group and the muscle invasive transitional cell carcinoma of 
the bladder (≥T2) into another (Figure 3.1).  This analysis identified, for the first time, two 
clinically distant phenotypes in accordance to their grade.  In most invasive bladder cancer, 
muscle invasion is present at the time of first diagnosis and as such is classified as the 
primary tumours, in the remainder of patients muscle invasion is caused by progression of 
superficial tumours to invasive tumours (also known as progressive tumours). Prognosis of 
patients with progressive tumours is worse than prognosis of patients with primary invasive 
tumours and therefore it is of great importance to detect superficial tumours in their pre-
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invasive stage, when they can be treated successfully and microarray analysis may be a 
good diagnostic tool. A list of probes which altered in bladder tissue when comparing 
superficial bladder cancer with invasive bladder cancer was generated (Table 3.3); 
identifying some putative markers that may be useful in diagnosis of progressive tumours 
and as such improve prognosis.  The array analysis also supported the field effect theory of 
urothelial cell carcinogenesis by highlighting molecular changes in tissue which appeared 
histologically benign; sample 6, in the dendrogram (Figure 3.1), exhibited an invasive-like 
pattern in the bladder tissue taken from a histologically ‘normal’ area of the cancerous 
bladder of patient 02TB040.  It has been shown that multiple coexisting tumours often 
arise before clinical symptoms become apparent and that separate tumours may or may not 
share a similar histology.  Recurrences occur in more than 60% of patients and over 50% 
of these reoccur at a higher grade and are found at sites remote from the primary tumour. 
Therefore the field effect theory may not only account for the frequent development of 
genetically unrelated tumours within the bladder, but also the high rate of reoccurrence of 
bladder TCC.  Obviously it is of clinically important to develop genetic detection for 
recurrent or residual tumour cells, and these results provide evidence to suggest that 
diagnosis and treatment of bladder cancer should not only be focused on the tumour but 
also on the field from which it developed.  Furthermore the array analysis highlighted a 
significant fold change in COL6A1 gene expression that exhibited an increase in 
expression in the invasive bladder tissue compared to the superficial bladder tissue (Figure 
3.1).  This finding was investigated further using RT-PCR analysis of independent TCC 
biopsy samples and the results indicated a definite trend towards an increase of COL6A1 
gene expression with the grade of TCC (Figures 3.2 and 5.2).  The expression of this gene 
has significantly different means when superficial TCC tissue is compared with invasive 
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TCC tissue, being much greater in higher grade samples, thus rendering it a possible 
powerful tumour marker in TCC. To the best of my knowledge, COL6A1 has never been 
described in bladder cancer and these results warrants further investigation. Finally in 
chapter three I sought to characterise GST genotype in the invasive and superficial TCC, 
although in hindsight perhaps too much emphasis was made in this area considering the 
limitations due to sample size.  However due to the few tissue samples analysed in this 
study, any firm conclusions regarding grade of TCC and GST genotype/ gene expression 
was not established.  
 Multiple mechanisms have been suggested to be activated in the response to ITCs 
such as, Nrf2-mediated induction of phase II detoxification enzymes, suppression of 
cytochrome P450 enzymes, induction of apoptotic pathways, suppression of cell cycle 
progression, inhibition of angiogenesis and anti-inflammatory activity (Juge, Mithen et al. 
2007; Hayes, Kelleher et al. 2008).  Most studies regarding ITCs and bladder cancer have 
mainly centred on the ability of ITCs to induce apoptotic pathways and cell cycle 
suppression (Algaba, Trias et al. 2003; Tang and Zhang 2004; Tang and Zhang 2004; Tang 
and Zhang 2005; Tang, Li et al. 2006). The human bladder cell lines UM-UC-3 and RT4 
were characterised and the effects of sulforaphane and iberin and their N-acetylcysteine 
conjugate on phase II gene expression was assessed.  The UM-UC-3 cell line showed a 
significant up regulation in GSTP1 gene expression, whilst the RT4 cell line showed no 
significant change (Tables 4.4 and 4.5).  Both cell lines showed up regulation of GSTM3 
expression and this expression was also up regulated by treatment with SF-NAC in the 
RT4 cell line.  NQO1 expression was up regulated in both cell lines by treatment with SF, 
IB and their conjugates (Tables 4.4 and 4.5).  This illustrates that different cell lines 
responded differently to detoxifying gene inducers, such as ITCs.  Another cell based study 
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also concluded this, with seven well-established mammalian cell lines, which had different 
origins (Jiang, Chen et al. 2003).  This study suggested that as different cell lines 
responded differently to individual detoxifying gene inducers, including ITC, that the 
selection of the appropriate cell line is important for screening potential chemo preventive 
agents.  However whilst it is important to characterise cell cultures so that it is known that 
it has the capacity to respond to the particular external stimuli of interest, caution must be 
excised in only selecting hyper-sensitive cell lines, giving rise to miss-leading results.  
 COL6A1 is an extracellular matrix protein and like other collagen proteins plays 
an important role in maintaining the integrity of the ECM (see section 1).  The array 
analysis in Chapter three highlighted a significant fold change in COL6A1 gene expression 
showing for the first time a significant increase in COL6A1 gene expression in the invasive 
bladder tissue compared to the superficial bladder tissue (Figure 3.1).  This finding was 
investigated further using RT-PCR analysis of independent TCC biopsy samples and the 
results indicated a definite trend towards an increase of COL6A1 gene expression with the 
grade of TCC (Figure 3.2, 5.1 and 5.2).  To the best of my knowledge this bladder study is 
the only studies to identify differential expression of COL6A1 with tumour grade.  
Furthermore the modulation of COL6A1 expression in the previously characterised 
human bladder cell was investigated by exposing the cell lines to nutritionally relevant 
doses of SF, IB and their conjugates were investigated.  It was demonstrated that COL6A1 
gene expression is significantly down regulated following 48hr treatments of 12µM of SF, 
IB and SF-NAC in both UM-UC-3 and RT4 human bladder cell line (figure 5.3 and 5.4), 
although the UM-UC-3 cell line showed a greater degree of down regulation of COL6A1 
gene expression.  To conclude; COL6A1 gene expression was shown to be up-regulated in 
the invasive bladder TCC tissue in comparison to the superficial TCC and treatment with 
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ITCs was able to down regulate COL6A1 gene expression in the human bladder cell lines. 
For the first time it has been shown that COL6A1 gene expression increases with the 
severity of bladder cancer in vivo and the gene can be down regulated by physiologically 
relevant doses of SF and IB in vitro.  These result suggest that both IB and SF may have 
important effects on the extracellular matrix (ECM), as collagen is a dominate component.  
Very few studies have investigated the effects of ITCs on the transition from 
superficial bladder cancer to invasive bladder cancer and its subsequent modulation of the 
ECM.  The effect of SF and IB on markers of progression and invasion of cultured human 
bladder cells was investigated in Chapter six.  Results suggest that SF, IB and SF-NAC 
have the capability to reduce the mobility of the UM-UC-3 cell line following a 24 hour 
period of incubation (Figure 6.2).  Invasion analysis demonstrated that treatment with these 
ITCs do not modulate UM-UC-3 cell invasion and furthermore the resulting low invasion 
index suggests that UM-UC-3 cells have a low-invasive phenotype suggesting that the 
UM-UC-3 cell line has little metastatic potential (Table 6.1).  Further studies would 
involve using a more invasive cell line to investigate the possible inhibitory effects of these 
ITCs on cell invasion.  Finally the effects of SF, IB and their conjugates on the secretion of 
MMP-2 and MMP-9 were investigated to elucidate their possible antimetastasis effect.  
The results indicated that the UM-UC-3 cell line secretes high levels of MMP-9 and lower 
levels of MMP-2, and that treatment with SF, IB and SF-NAC reduced MMP-2 and MMP-
9 activities in this cell line, figure 6.8.  In this study, it was show for the first time the 
antimetastatic effects of SF and IB in human cancerous bladder cells. SF and IB had an 
inhibitory effect on cell migration. Protein levels of MMP-2 and MMP-9 were reduced by 
SF and IB. Enhanced level of MMPs is known to facilitates metastasis and cell invasion of 
tumour cells by removal of physical barriers and the observed down regulation of these 
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enzymes by ITCs suggests that these dietary factors may be responsible for inhibition of 
metastasis by reducing MMP production and cell motility in this cell line and may 
contribute to the suppression of carcinogenesis by diets high in cruciferous vegetables. 
These findings suggest that SF and IB have potential as an antimetastatic agent. 
The biological activities of cruciferous vegetables and ITCs have been almost 
exclusively investigated in cell and animal models.  In chapter seven I sought to extend this 
study to an in vivo pilot dietary intervention study with bladder tissue I obtained before and 
after a short diet of interest.  With the use of whole genome array analysis to enable the 
identification of genes which where modulated by the short term dietary intervention. In 
contrast to the results of the previous in vitro study, phase II gene expression was not 
modulated in this short term intervention study.  Moreover, to my knowledge this is the 
first dietary intervention undertaken with bladder cancer patients using whole genome 
arrays.  The recruitment of patients into the dietary intervention study was more difficult 
than expected and due to the sensitive nature of the patients, was a challenging research 
area.  The pilot study was very successful in identifying important issues relating to the 
study protocol.  With protocol adjustment, this will hopefully lead to a successful, novel 
long term study of the effects of broccoli consumption on bladder cancer.  It was notable 
that certain genes involved in regulation of the ECM such as collagen genes and Tn-C 
which were seen to be modulated in the first array from superficial to invasive tissue 
(Chapter three), were also modulated by the dietary intervention study.  Further to this, Tn-
C splicing domains were investigated in bladder tissue and findings suggest that 
differential expression of particular Tn-C splicing variants in TCC samples increase with 
grade of TCC tumour.   
  
222 
 
Affix an addressograph label here or 
complete the following details: 
Patient’s name…………………………... 
………………………………………….. 
Date of birth…………………………….. 
Hospital number………………………... 
10.0 annex 
10.1 Tissue bank information and consent form 
 
 
 
                  
                     
 
 
 
I agree that the following tissue or other material may be used for research, including genetic 
(DNA and/or RNA) studies and for the possible development of commercial products for the 
improvement of patient care, from which I would receive no financial benefit: 
 
 
 
 
I also agree that (Please initial small boxes, as appropriate):  
This tissue or other material becomes the property of the Norfolk & Norwich 
University Hospital NHS Trust ("the Trust")  
 
The Trust may store this tissue or other material in a Tissue Bank  
 
Benign and cancerous bladder tissue 
EDTA blood sample 20ml (two teaspoons) 
Consent form for the collection and 
storage of human tissue and/or fluids 
for research 
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The Trust may use this tissue or other material at its discretion within the research 
programme of Ms Melanie Dunk and Professor Richard Mithen of the Institute of Food 
Research. 
 
The Trust may disburse this tissue or other material at its discretion to other 
approved tissue banks and/or companies in properly approved research 
programmes  
                               
 
Information about my case may be kept on the Tissue Bank database  
 
Such information may be passed to Ms Melanie Dunk and Professor Richard Mithen of 
the Institute of Food Research in connection with research, and may be published 
anonymously with any research findings 
 
I agree that appropriately qualified staff employed by the Trust may review my hospital 
case notes, as appropriate, for the purposes of research using my donated tissue 
 
I confirm that: 
I have read and understand the Information Sheet for Patients, Version 8, dated 11 
November 2006 
 
The issues have been explained to me, and that I have had the opportunity to ask questions. 
 
Signed _____________________________________ Date ________________ 
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Relationship to patient (if relevant) _________________________________________ 
I have explained the request for tissue for research purposes and answered such questions as 
the patient (parent/guardian) has asked. 
 
Name ______________________________________ 
Medical / Nursing Practitioner 
 
Signed______________________________________ Date ________________ 
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CONSENT FOR TAKING EXTRA SAMPLES FOR RESEARCH 
 
Please initial the appropriate box for each item: YES NO 
In addition to the removal of tissue, blood or other fluid samples as a 
necessary part of my procedure, I also consent to the removal of additional 
tissue, blood or other fluid samples from the operation site during my 
procedure PROVIDED THAT SUCH REMOVAL CAUSES ME NO HARM 
now or in the future, is limited to what I and the doctor treating me (or a 
research nurse or nurse practitioner delegated by him/her) have discussed and 
agreed, and which is specified below. * 
 
Please initial appropriate box 
  
 
 
*Additional samples to be taken: a maximum of two benign bladder tissue biopsies and one 
20ml (two teaspoons) blood 
sample._______________________________________________________ 
 
Affix an addressograph label here or 
complete the following details: 
Patient’s name…………………………... 
………………………………………….. 
Date of birth…………………………….. 
Hospital number………………………... 
Consent form for the collection 
and storageof human tissue 
and/or fluids for research 
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Patient name__________________________________ 
 
Signed _______________________________________ Date ________________ 
 
 
Relationship to patient (if relevant) _____________________________________ 
 
 
I have explained the request for tissue for research purposes and answered such questions as 
the patient (parent/guardian) has asked. 
 
Name ______________________________ 
Medical / Nursing Practitioner 
 
Signed_____________________________ Date ________________ 
Medical / Nursing Practitioner 
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Consent for the collection, storage and use of tissue 
and/or fluids for research 
Information sheet for patients - Version 8 (11 November 2006) 
(i)  
(ii)  
(iii) WHAT WILL HAPPEN 
During your procedure it will be necessary 
to remove tissue, blood or other samples for 
diagnosis and treatment of your condition. 
The samples will be sent to the Pathology 
Laboratories where they will be tested to 
decide exactly what they are and whether 
any further treatment will be necessary. This 
is a standard part of treatment.  Only as 
much tissue or fluid as is needed will be 
removed. 
 
1) MEDICAL RESEARCH AND 
WHY THIS PROGRAMME IS 
IMPORTANT 
When all the routine tests have been done, if 
any samples are left over, with your consent, 
they could be donated for use in medical 
research. As part of a research program set 
up by the Norfolk and Norwich University 
Hospital NHS Trust, the James Paget 
Healthcare NHS Trust, the School of 
Biological Sciences at UEA and the Institute 
of Food Research, some of the sample or 
material extracted from it will be stored in a 
Tissue Bank for use by ourselves or by 
researchers from other centres at a later date.   
Some of this research may involve an 
assessment of genetic material (DNA and/or 
RNA) to help us understand the genetic basis 
of health and disease.   
 
The purpose of this research is to understand 
more about human health and disease, and to 
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develop new methods of prevention or new 
treatments for the benefit of future patient 
care. Some of these research programmes 
could lead to the development of new 
products and processes, which may be 
developed commercially for the 
improvement of patient care, in which case 
there would be no financial benefit to you. 
 
Medically qualified doctors or other suitably 
qualified staff at the hospital may need to 
review your case notes as part of this 
research.  It is important to see how you 
progress after the donation of tissue or other 
samples, and to see how your condition 
relates to what we learn in the research 
project(s). 
 
The research may also involve training 
doctors and scientists in scientific medicine, 
and may lead to higher qualifications for 
them (e.g. PhD or MD degrees).  This is 
important for future research into diseases 
and for looking for new, more effective, 
treatments for them.  
   
LINKS WITH OTHER 
ORGANISATIONS 
If you agree, we may send stored material or 
products derived from it to other approved 
tissue banks or companies to support their 
research programmes or the research 
programmes of those companies’ clients.  
Such outside organisations will provide 
financial support for our Tissue Bank, to 
help it recover its operating costs.   
                                              
Continued…………                         We   are 
not, however, allowed to sell tissue or other 
samples in order to make any financial profit 
from these commercial links.   
 
SCIENTIFIC AND ETHICAL 
APPROVAL 
The Tissue Bank acts as a custodian of the 
samples it holds and releases them only to 
individuals or organisations that have an 
acceptable scientific background and work 
to high ethical standards.  We require that all 
such medical research has been properly 
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approved by the Trust’s Research 
Governance Committee and by an NHS 
Research Ethics Committee before it starts. 
These committees look particularly at the 
purpose and validity of the research 
proposal, the welfare of any participating 
patients, and issues of consent and 
confidentiality.  We will release tissue or 
other samples to commercial companies only 
if they work to appropriate ethical and 
scientific standards. 
 
i) DONATING EXTRA 
SAMPLES FOR RESEARCH 
In certain circumstances you may be asked 
by the doctor treating you (or by a doctor, 
research nurse or nurse practitioner working 
with him/her) to consider donating tissue or 
other samples in addition to those to be 
removed as part of your diagnostic 
investigation or treatment.  Such extra 
samples will be taken only if you give your 
consent and if their removal does not 
cause you any harmful effects now or in 
the future. 
2) YOUR RIGHTS 
If your samples are stored, information about 
your case will be kept on a computer in the 
Tissue Bank. This will help us understand 
what your illness was like and relate what 
we find in the laboratory to what happens to 
patients. Under the Data Protection Act you 
are entitled to ask to see what is recorded 
about you by applying to the Chairman of 
the Human Tissue Bank Committee, Norfolk 
& Norwich University Hospital, c/o Dept. of 
Histopathology, Cotman Centre, Colney 
Lane, Norwich, NR4 7UB. No one other 
than you has the right to see these records 
and any information needed for research 
purposes will be made anonymous before it 
is given to the researcher.                                                                                                        
You will have the opportunity to discuss 
with a doctor issues relating to the possible 
use of your tissue or fluids for research 
purposes. He or she will answer any 
questions you may have.   
If you decide that you want your tissue, 
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etc., to be stored in the Tissue Bank and 
used for research purposes, you will be 
asked to sign a special Consent Form 
confirming your decision and stating that 
you have read and understood this sheet.  
When you sign the form you will give the 
ownership of the tissue or other samples to 
the Norfolk & Norwich University Hospital 
NHS Trust. The tissue or other samples will 
then belong to the Trust, which will store it 
for an indefinite period of time and will able 
to decide how it should be used for research. 
It will also have the right to dispose of 
unused stored material in an appropriate and 
ethical manner following normal procedures.   
 
If you do not want your tissue to be stored in 
the Tissue Bank please tell us and do NOT 
sign the special Consent Form.  
 
If you do not sign this form, the tissue or 
other samples will still be sent to the 
laboratory to undergo those tests that are 
necessary for your care but they will not be 
used for research                                
purposes. All unused tissue from your 
procedure will be disposed of using normal 
hospital methods. We will respect your 
decision and it will not affect in any way the 
treatment you receive.  
Annual progress report Version 1: March 2007 
 
231
10.2 Patient etter 
Institute of Food Research      
and 
 
 
Melanie Dunk, BSc PDipBiomedSc 
Phytochemicals and Health programme 
Institute of Food Research 
Norwich Research Park 
Colney 
Norwich 
NR4 7UA 
 
Tel:    01603-255048 (direct) 
Fax:   01603-507723 
Email: melanie.dunk@bbsrc.ac.uk 
Web:  www.ifr.ac.uk 
 
Date 
 
 
Dear 
 
The ‘broccoli and bladder’ study at the Institute of Food Research. 
 
 
I enclose the information about my current study, as your details may fit the necessary 
criteria. This will depend on the findings of this routine day unit appointment with your 
urologist and analysis of any biopsy taken at that time. Perhaps you would kindly let me 
know as soon as conveniently possible whether you are interested in participating in this 
study. Please don’t hesitate to call me on the number above if you have any queries 
regarding the study. 
 
Thank you.  
 
Yours sincerely, 
 
Melanie Dunk BSc PDipBiomedSc (study scientist)  
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10.3 Voluneer information sheet 
 
 
 
   
Volunteer information sheet 
(b)  
(c) GENE EXPRESSION IN  
(d) BLADDER CANCER FOLLOWING CONSUMPTION OF HIGH 
GLUCOSINOLATE BROCCOLI: a pilot study  
 
 
Short title: Broccoli and the bladder  
 
 
 
You are being invited to take part in a research study. Before you decide it is important for you 
to understand why the research is being done and what it will involve for you. Please take time 
to read the following information carefully.  Talk to others about the study if you wish. 
• Part 1 tells you the purpose of this study and what will happen if you take part 
• Part 2 gives you more detailed information about the conduct of the study 
Annual progress report Version 1: March 2007 
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Please ask us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
This information sheet is yours to keep. 
Thank you for reading this. 
 
 
…………………………………………………………………………………………. 
 
 
                Contact Details: 
 
 Research Scientist 
 Melanie Dunk                                                          Research Nurses 
 Phytochemicals & Health Programme                       Human Nutrition Unit 
 Institute of Food Research                         Institute of Food Research 
 melanie.dunk@bbsrc.ac.uk                                         Tel: 01603 255305 
 Tel: 01603 255048 
 
  
 
 
 
 
 
…………………………………………………………………………………………. 
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PART 1 of the information sheet 
 
What is the purpose of the study? 
Cruciferous vegetables, such as purple 
sprouting broccoli contain  
Phytochemicals (plant chemicals) called 
glucosinolates. During chopping, 
chewing and digestion, these 
phytochemicals change into substances 
called isothiocyanates. Many scientists 
believed that these isothiocyanates play 
a role in preventing cancer.  
Isothiocyanates have been shown to 
hinder the growth of bladder cancer 
cells. However, there is no evidence that 
consuming broccoli for the course of this 
study will have any direct medical 
benefits with regards to your treatment 
or prognosis. In this study we will be 
using a variety of purple sprouting 
broccoli which is naturally high in these 
isothiocyanates. This broccoli will be 
made into a soup for participants to eat, 
once a day for 4 consecutive days. This 
study will also form part of the 
scientist’s PhD. 
  
Why should I take part in the study? 
It is unknown to what extent broccoli 
can really fight bladder cancer, and how 
much a person needs to eat to prevent or 
slow down the progression and re-
occurrence of bladder cancer.  
Finding answers to these questions could 
help us create functional foods that 
benefit health beyond providing just 
basic nutrition.  
 
 
 
 
Why have I been invited? 
You have been invited to participate 
because you may fit the criteria for this 
study.  
We are aiming to recruit a total of 
• 10 patients 
 • aged 30-75 years 
• male 
Please note: You will not be able to  
volunteer if: 
• The screening questionnaire  
       indicates that you are not  
      suitable to take part in this study. 
• Results from your cystoscopy 
suggest you are not eligible for the 
study.  
• You have undergone  
      chemopreventative therapy  
      within the previous 12 months 
• You are unable to give written, 
informed consent to take part 
• You have been diagnosed with 
diabetes which can not be controlled 
by your diet 
• You have any known allergies to any 
of the ingredients in the soup 
• You have an acute infection 
requiring treatment 
• The donated tissue bank sample is of 
insufficient quality 
• You have received a blood product 
transfusion within the previous four 
months 
• You are related to someone in the 
study team i.e. spouse, partner or 
immediate family member 
 
Do I have to take part? 
It is up to you to decide.  
If you are interested in participating in 
the study you should contact the 
researchers named on this information 
sheet. Please feel free to say no by not 
responding to the letter we have sent 
you. Do not worry, no one will contact 
you and try to persuade you to join the 
study. 
 
After you have replied to tell us you are 
interested in participating, a member of 
the study team will contact you.  
You are free to withdraw from the study 
at any time, without giving a reason.  
  
An expression of interest does not mean 
you are committed to participating in the 
 study and a decision to withdraw or not 
to take part will not affect the standard 
of care you receive.   
 
What will happen to me if I take part? 
If you decide to take part in the study 
you will be required to attend the Human 
Nutrition Unit (HNU) at the Institute of 
Food Research (IFR) which is near to 
the hospital on six occasions, four of 
these will be consecutive days to eat 
broccoli soup.  During the study the 
study team will keep in contact with you 
to check that you are ok and to discuss 
any questions you may have about the 
study. 
For the purpose of this study we will be 
collecting four extra biopsies from your 
bladder at the same time as your routine 
biopsies are taken (at the NNUH) and 
we will also be taking blood samples of 
20ml (4 teaspoons), one at the second 
visit and one on day four of the 
intervention period.  The blood samples 
will be taken at the Human Nutrition 
Unit by the Human Nutrition Unit 
research nurses.  Where possible 
appointments at the Human Nutrition 
Unit will be made to suit you.  More 
information about each visit is listed 
below: 
 
Visit 1 - Informal meeting to discuss the 
study.  
The meeting will last for about one hour, 
during which time the researchers will 
go through this information sheet with 
you and answer any questions you may 
have.  
After this meeting you will be given at 
least 72 hours to decide whether or not 
you wish to take part in the study. 
During this time we will not contact you. 
After the 72 hours if you decide to take 
part contact Melanie Dunk and an 
appointment will be arranged for you to 
attend for visit 2. 
 
Visit 2 - Screening and Informed 
Consent. 
This visit will take place at the Human 
Nutrition Unit and will be approximately 
 60-90 minutes. Before we complete the 
screening questionnaire and take your 
blood sample you will be asked to sign a 
consent form agreeing to participate in 
the study and a medication declaration 
form. These forms will also be signed by 
the researcher and you will be given a 
copy of them to keep.  
Once you have signed the consent form 
you are still free to withdraw from the 
study at any time and without giving a 
reason.  The study scientist will 
complete the screening questionnaire 
with you and the Human Nutrition Unit 
nurse will then take a 20ml (4 teaspoons) 
blood sample from a vein in your arm.  
The nurses in Human Nutrition Unit are 
trained and experienced in taking blood. 
 
Visit 3 - Study days 
Once a date has been set for your 
operation, you will be contacted by 
Melanie Dunk who will give you any 
instructions in preparation for the study 
days. You will be asked to visit the 
Human Nutrition Unit at lunchtime on 
four consecutive days to eat the broccoli 
soup.  You will be allocated into either 
the control group or the broccoli group 
partly by chance (randomly) and partly 
depending on your genetic makeup. (See 
genetic testing in section 2).  You will be 
required to eat one portion of soup each 
day for four days and on the fourth day 
you will also have the second 20ml (4 
teaspoons) blood sample taken by the 
Human Nutrition Unit nurses. Ideally the 
dietary intervention will commence the 
week prior to your surgery.  Therefore 
dates will be arranged once an operation 
date has been set by the NNUH.  
 
Access to your personal information 
Once recruited onto the study you will 
be given a code number which will be 
used to make your information and 
samples anonymous. Your personal 
information will only be accessed by the 
research team, Human Nutrition Unit 
nurses and your GP.  Although all 
research is subject to Inspection and 
Audit and your records may be accessed 
 for this purpose. All your personal 
information will remain confidential. 
 
Blood and bladder tissue sample 
The sample you donated to the NNUH 
tissue bank at the time of your routine 
cystoscopy will be brought over to the 
IFR for testing. Also, in addition to the 
routine biopsies taken for hospital 
laboratory diagnostic examination 
during the transurethral resection of the 
bladder tumour (TURBT), two tumour 
samples and two surrounding benign 
bladder tissue samples will be taken for 
research purposes.   
The tissue and blood samples donated by 
you will be examined to find out if the 
compounds present in the purple 
sprouting broccoli have had a protective 
effect on the bladder. 
 
 
 
 
 
Expenses and payments. 
Participating in these studies is done on 
a voluntary basis. However we do 
recognise that being involved in the 
study can cause you some inconvenience 
and that there are travel costs associated 
with you visiting the HNU.  Travelling 
expenses to and from the HNU will be 
reimbursed on production of a receipt 
for buses or trains or at 35p/mile for 
private cars.  If you require transport to 
and from the HNU please let us know. 
We will order a taxi and pay for it. 
Travelling expenses to and from the 
NNUH will not be reimbursed. 
 
Will my GP be informed? 
Yes, it is routine practice for us to 
inform your GP that you are 
participating in a study at IFR. This is 
one of the things you are agreeing to 
when you sign the consent form. 
Although analysis of your samples in 
 this study will not have any prognostic 
or predictive results with regards to your 
illness or treatment and therefore your 
GP will not receive any of your results. 
 
What are the risks or side affects from 
participating in this study? 
There can be a small amount of 
discomfort associated with taking blood. 
Obviously this affects some people more 
than others but the discomfort occurs 
generally only on insertion of the needle.  
You should not experience pain during 
the procedure or afterwards. You may 
develop a small bruise at the site of the 
blood sample but this will fade like any 
bruise. The HNU nurses will be happy to 
answer any questions you may have 
about this procedure.  
 
During the cystoscopy and the 
transurethral resection of the bladder 
tumour (TURBT), additional biopsies 
will be taken for research purposes. 
Taking biopsy samples is usually 
painless but there is a small risk of 
damage to the bladder, infection and 
bleeding. This may be slightly increased 
by taking additional biopsies. Most 
would have some bleeding as a result of 
a biopsy but perhaps less than 1% would 
have either significant bleeding or 
infection.  Should either of these occur 
you may need to be seen by a doctor and 
may require treatment.  Your consultant 
will be happy to answer any questions 
you may have about this procedure. 
 
What are the potential benefits of 
taking part? 
There are no direct benefits for you 
taking part in this study.  However, the 
information we find out from this study 
will help us to find out the beneficial 
effects of eating broccoli. This research 
will also contribute to a higher 
qualification (PhD) and expand 
scientific knowledge, which is very 
important for future research. 
 
What if there is a problem whilst I am 
on the study? 
 Any complaint about the way you have 
been dealt with during the study will be 
addressed.  Detailed information on this 
is given in Part 2 of this information 
sheet. 
 
Will my taking part be kept  
confidential? 
Yes. We will follow ethical and legal 
practice and all information about you 
will be handled in confidence.  More 
details about this are in Part 2. 
 
This completes Part 1 of the information 
sheet.  If the information in Part 1 has 
interested you and you are 
considering taking part, please read 
the additional information in Part 2 
before making any decision. 
 
 
 
 
 
 
 
 
PART 2 of the information sheet 
 
What will happen if I don’t want to 
carry on with the study? 
If you withdraw from the study, we will 
destroy all your identifiable samples, but 
we may need to use the data collected up 
to your withdrawal. Withdrawal from 
the study will not affect the standard of 
care you receive. 
 
Complaints 
If you have a concern about any aspect 
of the study, you should ask to speak to 
Melanie Dunk who will do her best to 
answer your questions. Alternatively you 
may wish to speak to Ms Dunk’s 
academic supervisor, Professor Richard 
Mithen (255259). If you remain unhappy 
 and wish to complain formally about any 
aspects of the study at IFR, you can do 
this through the IFR Human Research 
Governance Committee chairperson – 
Dr David Hughes (255345). If your 
concern is about any aspect of your care 
within the NNUH you may contact the 
ppatient advice and liaison service 
(PALS) staff (289036) or the complaints 
manager (287475) who will do their best 
to help you. 
 
Harm 
Up to the point of tissue transfer release 
to IFR researchers from the NNUH, 
NHS indemnity will apply. All 
procedures carried out in the Human 
Nutrition Unit at IFR will be covered by 
IFR indemnity.  
IFR accepts responsibility for carrying 
out trials and as such will give 
consideration to claims from participants 
for any harm suffered by them as a result 
of participating in the trial, with the 
exception of those claims arising out of 
negligence by the participant. Like all 
publicly funded bodies, the institute is 
unable to insure and thus cannot offer 
advance indemnity cover for 
participants. The institute will not fund 
any legal costs arising from any action 
unless awarded by a court. 
 
Will my taking part in this study be 
kept confidential? 
Any information which is collected 
about you during the study will be kept 
strictly confidential and stored in locked 
filing cabinets at the Institute of Food 
Research (IFR).    
When you are recruited onto the study 
you will be issued with a volunteer code 
number. This number will be used on 
your  
samples and information so that no one 
will be able to work out that they are 
yours.  
Access to your personal records is 
restricted to the study team, the HNU 
research nurses and your GP.  The data 
will be kept for 15 years in a secure 
 archive at IFR and will be destroyed by 
incineration.  
 
What will happen to the samples I 
give? 
Your samples will be assigned a code 
number which will be used to make your 
samples anonymous. These samples will 
be securely stored at IFR.  All of the 
blood and tissue samples you provide 
will be used to obtain study specific 
information, measurements and analysis. 
Any samples remaining after all the 
information has been collected will be 
stored under their code numbers for 
possible further anonymous research at a 
later date.  
 
Genetic tests 
This study will predominately involve 
genetic analysis of both blood and 
bladder tissue.  We will be investigating 
if the protective compounds present in 
broccoli can switch off or switch on 
genes in the bladder tissue, after a short 
intervention study. This is called gene 
expression analysis. Also we will be 
looking for a particular group of genes 
which form part of the body’s defence 
system against environmental substances 
and carcinogenic compounds. These 
genes can alter toxic compounds and 
help their discharge from the body.  This 
kind of analysis is called genotyping. 
However, this genetic analysis of your 
blood and bladder tissue would not have 
any significance for you, your relatives 
or the treatment you receive. 
 
What will happen to the results of the 
research study? 
As a volunteer you are valuable to us but 
we are unable to tell you any of your 
individual results. Some results will be 
published anonymously. At the end of 
the study we will try to provide feedback 
about what we have found as a result of 
your help and what it may mean for the 
future research. 
  
Who is organising and funding this 
study? 
 This study is being organised by 
Melanie Dunk and Professor Richard 
Mithen. The study is sponsored and 
funded by the Biotechnology and 
Biological Sciences Research Council 
(BBSRC). 
 
Who has reviewed this study? 
This study has been reviewed, and given 
favourable opinion by The Institute of 
Food Research (IFR) Human Research 
Governance Committee (HRGC), 
Norfolk Research Ethics Committee 
(NREC) and East Norfolk & Waveney 
Research Governance Committee 
(ENWRGC). 
These committees are made up of 
independent groups of people to protect 
your safety, rights, wellbeing and 
dignity.  
 
 
Taking part in the research is entirely 
voluntary!  You are free to withdraw 
from the study at any time. 
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Please affix an addressograph label here 
or complete the following details: 
Patient’s name…………………………... 
………………………………………….. 
Date of birth…………………………….. 
Hospital number………………………... 
11.4 Study consent form 
Institute of Food Research         
and 
 
INFORMED CONSENT FORM FOR RESEARCH STUDY 
 
 
 
 
 
Full Study Title:  GENE EXPRESSION IN BLADDER CANCER FOLLOWING 
CONSUMPTION OF HIGH       
 GLUCOSINOLATE BROCCOLI                                                                                                                                                                
Vol. Initial                                           
Have you read the Volunteer Information Sheet; Version No: …………Date: 
…………………………………...YES/NO    
 
Do you agree that you do not fall within the basic exclusion criteria listed for this research 
study?........................YES/NO*  
*If you have answered NO to this question we are unable to accept you on this study.   
 
  
 
Have you had an opportunity to discuss this study and ask questions; including the exclusion 
criteria 
and your responsibilities as a 
volunteer?...................................................................................................................YES/NO    
 
With whom have you discussed the information for this research study? 
........................................................................... 
 
Have you received sufficient information about the study? 
................................................................................... .YES/NO    
 
Have you received satisfactory answers to all your questions? 
……………………………………………………YES/NO   
Do you understand that you are free to withdraw from the study: 
• at any time 
• without having to give a reason for withdrawing 
• without withdrawal affecting future participation in other research 
studies………………………………YES/NO   
 
Are you aware that your personal information will be held 
confidentially?.............................................................YES/NO   
 
Do you agree to us informing your General Practitioner of your participation in this study and  
  
 
of all clinical 
results?................................................................................................................................................
YES/NO*  ⁭ 
* If you have said NO to this question then we are unable to accept you on this study. 
 
Name and address of your General Practitioner? 
……………………………………………………………………………… 
……………………………………………………………………………… 
……………………………………………………………………………… 
Do you understand that all research is subject to Inspection and 
Audit*…………………………………………YES/NO    ⁭  
*Although your records may be accessed for this purpose your personal information remains 
confidential  
Do you agree to take part in this 
study?..................................................................................................................YES/NO    ⁭ 
Signed:   …………………  (Name in BLOCK 
Letters:)…………………………………Date:………………                                                                            
Date of Birth:………………………Scientist (I confirm that the volunteer above has been given a 
full verbal and written explanation of the study) 
 
Signed:………………………… Name in BLOCK Letters: ……………………………………… 
Date:……………                                                                                              
 
 
 
  
 
10.5 General Practioners letter 
Institute of Food Research   
and       
 
 
Melanie Dunk, BSc PDipBiomedSc 
Phytochemicals and Health programme 
Institute of Food Research 
Norwich Research Park 
Colney 
Norwich 
NR4 7UA 
 
Tel:    01603-255048 (direct) 
Fax:   01603-507723 
Email: melanie.dunk@bbsrc.ac.uk 
Web:  www.ifr.ac.uk 
 
Date!! 
 
 
Dear Doctor ………….. 
 
This is to inform you that your patient …………………..date of birth………………has  
consented to participate in a human nutrition study at the Institute of Food Research.  
 
The pilot study; a human intervention trial studying gene expression in bladder cancer following 
consumption of high glucosinolate broccoli has been approved by the Norfolk Research Ethics 
Committee and the East Norfolk & Waveney Research Governance committee. The study co-
ordinator Melanie Dunk can be contacted on the above number if you require further information. 
 
We anticipate your patient will complete this study by…………………………… 
 
Yours sincerely, 
 
 
Melanie Dunk BSc PDipBiomedSc (study scientist) 
 
 
 
  
 
10.6 Medical declaration form 
 
 
 
 Institute of Food Research      
and 
 
 
MEDICATION/MEDICAL CONDITIONS DECLARATION  
AGREEMENT 
 
Full Study Title:  GENE EXPRESSION IN BLADDER CANCER FOLLOWING 
CONSUMPTION OF HIGH GLUCOSINOLATE BROCCOLI                                                  
 
 
Certain illnesses and medication may affect the outcome of research studies. 
Therefore, we would like you to inform the study organisers if you 
 
• start taking medication 
• suffer from any illness 
 
Please sign below to confirm that you have agreed to this request. 
 
 
  
 
 
I……………………….consent to inform the study organiser of the 
 
      commencement of any medication/medical changes whilst participating in the 
 
      study 
 
 
 
   Signature of volunteer………………………Volunteer number………………….. 
 
 
   Date……………………….. 
 
 
 
  Signature of scientist…………………………………………………………. 
Contact Details 
Research Scientist 
 Melanie Dunk                                                           
 Phytochemicals & Health Programme                         
 Institute of Food Research                           
 Tel: 01603 255048 
 
  
  
 
10.7 Volunteer Screening questionnaire 
 
 
 Institute of Food Research      
and 
 
BROCCOLI AND THE BLADDER 
 
CONFIDENTIAL 
 
Volunteer Screening Questionnaire 
 
Volunteer code number……………………                 Sex:……………………................. 
 
Date of birth:……………………………….                  Age:……………………………….. 
 
                    
 
 
Are you currently on any the following: 
 
  
 
If yes, give details below each relevant section of brand, dosage, frequency, when started 
etc. 
 
Prescribed medication:     Y         N   
……………………………………………………………………………………………………… 
 
……………………………………………………………………………………………………… 
 
……………………………………………………………………………………………………… 
 
Dietary Supplements:         Y       N                      Herbal remedies:       Y          N   
………………………………………….                   …………………………………………….. 
 
……………………………………………                 
……………………………………………… 
 
……………………………………………                  
……………………………………………… 
 
…………………………………………… 
 
Do you OR have you ever smoked?         Y      N  If yes how much do you smoke……………… 
 
 
Have you had a major operation in the last year:        Y           N 
  
 
If yes give details below: 
………………………………………………………………………………………………………
….. 
………………………………………………………………………………………………………
….. 
………………………………………………………………………………………………………
….. 
 
Have you received a blood or blood product transfusion in the last 4 months    Y      N 
 
 
 
Volunteer code number:………………………………………..                                               1of 2 
 
 
Are you currently suffering from any illness/injury:     Y          N 
(Other than bladder cancer) 
If yes give details below: 
………………………………………………………………………………………………………
…. 
………………………………………………………………………………………………………
…. 
 
 
Have you any known allergies:                                 Y          N 
  
 
 
Food:………………………………………… 
Drugs:………………………………………………. 
 
Other:………………………………………………………………………………………………
…. 
 
………………………………………………………………………………………………………
….. 
 
Special dietary requirements:                                  Y           N 
 
If yes 
state:…………………………………………………………………………………………… 
 
………………………………………………………………………………………………………
….. 
 
Do you agree to us informing your General Practitioner of your participation in the study or of 
any results found:                                                          Y           N 
 
If you have answered NO to this question then we are unable to accept you on this study. 
 
Name and Address of your General Practitioner: 
  
 
………………………………………………………………………………………………………
…… 
………………………………………………………………………………………………………
…… 
………………………………………………………………………………………………………
…… 
 
Telephone number:………………………………. 
 
Form completed by (print):………………………..          
Signature:………………………………. 
 
Date:…………………………………………………. 
 
 
 
 
Volunteer code number:……………………………………….. 
 
 
 
 
 
 
 
  
 
10.8 Coorospondance from the IFR Research Governance Commimitte (HRGC) 
Institute of Food Research         
 
Article II. Direct Dial Tel: +44 (0) 1603 255345  Direct Dial Fax: +44 (0) 1603 
255167  E-mail: davidA.hughes@bbsrc.ac.uk 
 
2 March 2007 
 
Ms M Dunk 
H1 Programme 
IFR 
 
Dear Melanie, 
 
HRGC ref: IFR01-2007            Short title: Broccoli and the bladder 
 
As you know, your revised protocol was discussed at today’s meeting of the IFR Human 
Research Governance Committee (HRGC). Following discussion, the committee’s 
decision was that the proposal could be submitted to the East Norfolk & Waveney 
Research Governance Committee and the Norfolk Research Ethics Committee (Norfolk 
REC) once further minor changes have been made.  
 
The Committee wish to congratulate you on the significant improvements you have made 
to the paperwork. 
 
I list the main changes we request/comments to consider. Once again, please use the 
electronic version of this letter to detail your response to each of the bulleted points (eg. 
“Done”, or any argument for not agreeing with any point) and please highlight the 
changes in your revised documents. 
 
 Protocol version 2, dated 22.02.07 
• p2. As Amy Gasper may be taking consent from volunteers, please add her name to 
the “Researchers” at the top of this page. 
• p8. Append to first sentence of “Hypothesis”: …in men” (and make “phase II 
enzyme” plural). Change “hypnosis’s” to “hypotheses”! 
• p8. bottom line, replace “as part of” with “in addition to the”. 
• p10. Typo bottom box. “Consderation”. 
• p12. para 2. There will only be 2 criteria, since criteria 3, as it’s written, will not be 
known at this time point. Therefore, please delete this 3rd criteria. 
  
 
• p12 para 3. Change “disbursed” to “sent”. 
• p12. The number of volunteers you wish to recruit to each group needs to be stated, in 
a form that allows you to keep recruiting until you reach your required number, eg. 
“Recruitment will continue until 5 volunteers in both treatment groups have 
completed the study.” 
• p12. Inclusion criteria: remove “Smokers and ex-smokers” and “Diet-controlled 
diabetes”, as you are effectively stating this in the exclusion criteria. 
• p13. We suggest you state in brackets why you are excluding “never smokers” (see 
previous HRGC letter). 
• p13. bottom para. Remove “using a BD vacutainer safety lok blood collection set”, as 
this would limit the choice for the nurses if a situation arose where this could not be 
used. 
• p14. top para. typo, should be “doubly”. 
NNUH Tissue consent form: 
• In sentence, “Such information may be passed in an anonymous form to Ms Melanie 
Dunk..”, delete “in an anonymous form”. 
 
NNUH Tissue information sheet:  
• Where you have typed “(Delete)”, use format font to strike through the text in bold 
type. 
 
Volunteer information sheet: 
• p1. Do you have an answerphone linked to your contact number? The Committee 
recommends this and that you state “(linked to answerphone)” after the phone 
number. 
• p2. top para. Remove “crucial”, as this is still uncertain and conflicts with text in next 
section. 
• p2. section 2. We suggest you remove the first sentence “It is recommended….” and 
begin with “It is unknown to what extent…” 
• p2. last para. We suggest you insert “(near to the hospital)” after IFR. 
• p3. top para. For clarity, we suggest you revise the beginning of the first sentence to 
“For the purpose of this study we will be collecting four extra biopsies from your 
bladder at the same time as any routine biopsies…” (and make teaspoon plural). 
• p3. Visit 2. typo with ½ (or state “60-90 minutes”). 
• p3. top of column 2. Clarification is needed that, as well as by genotype, the treatment 
allocation they will receive is random, eg. insert “..or the broccoli group partly by 
chance (randomly) and partly depending on your genetic makeup..” 
• p3. Blood and bladder tissue sample. Correct spelling of “tumor” in 2 places.  
• p4. typo in GP section. “you’re GP”. 
• p5. Harm. We have been advised to remove the word “sympathetic” from the 
indemnity statement. Please also delete it in the COREC form sections A35-1to3. 
• p6. Typos, Add “by the” before BBSRC, and capitals for “Governance Committee”. 
 
COREC form: 
• A3. typo, start date 2008! 
• A7. Suggest you remove “crucial”. 
• A8. Please convert “key polymorphic genes” into lay language. 
  
 
• A10-1. Suggest you finish hypothesis sentence after “…enzyme gene expression.” 
and then “The resulting changes may contribute…” 
• A22. Remove last 3 inclusion criteria.  
• A23. Insert “never smokers” and justify. 
• A26. Insert “minimum” prior to “…72 hour consideration….” 
• A39. Tick which of the devises the data will be stored on. 
• A68. Suggest move the last 2 para to the top, as these are probably the most important 
ethical considerations. 
• p46. The Director has delegated signing off the final box to Dr Mary Anderson, Head 
of Contracts, so please insert Mary’s name and position at “Print Name:”. 
  
Please send me your response to this letter with the revised paperwork for Chairman’s 
action to approve submission to the relevant committees. We will provide a letter to this 
effect, which you should submit with your paperwork, together with this letter.  
 
Best wishes. 
Section 2.01  David A Hughes PhD, RNutr, Cert CRGCP 
Chair, IFR Human Research Governance Committee                        
  cc. Prof R Mithen; HRGC members 
  
 
10.9 Corrospondance from the IFR Human Research Governace Committee post 
amendments 
 
Institute of Food Research         
 
Article III. Direct Dial Tel: +44 (0) 1603 255345  Direct Dial Fax: +44 (0) 1603 
255167  E-mail: davidA.hughes@bbsrc.ac.uk 
 
13 March 2007 
 
Ms M Dunk 
H1 Programme 
IFR 
 
Dear Melanie, 
 
HRGC ref: IFR01/2007 
Short title: Broccoli and the bladder 
  
The revised documentation you have provided has been reviewed by Liz Lund and myself 
and we are happy to take Chairman’s Action on behalf of the Human Research 
Governance Committee to give approval for this proposal to be submitted to the East 
Norfolk & Waveney Research Governance Committee and the Norfolk Research Ethics 
Committee (Norfolk REC). This approval implies that the Human Research Governance 
Committee is satisfied both with the originality and with the quality of the science 
proposed and considers that adequate expertise and manpower are available to undertake 
the work. 
 
Please remember to mention in your covering letter that you have made an alteration to 
the information sheet that accompanies the tissue bank Consent Form. 
 
Please enclose this letter, along with the previous correspondence from the Human 
Research Governance Committee (05.02.07 & 02.03.07), with your ethical submission. 
 
  
 
Please provide me with a copy of the letters you receive from the Research 
Governance and Research Ethics Committees, giving their responses to your 
proposal. 
 
Best wishes. 
 
Yours sincerely, 
 
 
David A Hughes, PhD, RNutr, CertCRGCP 
Chair, IFR Human Research Governance Committee 
  
 
10.10 Corrospondance with Norwich Research Ethics Committee for ethical 
approval 
 
Institute of Food Research         
 
Melanie Dunk, BSc PDipBiomedSc 
Phytochemicals and Health programme 
Institute of food research 
Norwich Research Park 
Colney 
Norwich 
NR4 7UA 
 
Tel:    01603-255048 (direct) 
Fax:   01603-507723 
Email: melanie.dunk@bbsrc.ac.uk 
Web:  www.ifr.ac.uk 
 
19TH March, 2007  
 
 
Dear Katherine Norton and committee members, 
 
Re: GENE EXPRESSION IN BLADDER CANCER FOLLOWING CONSUMPTION OF 
HIGH GLUCOSINOLATE BROCCOLI: a pilot study  
 
I would like to submit a research protocol for the above pilot study for consideration by the 
Norwich Research Ethics Committee at their next meeting on the 2nd of April.  This study has 
been reviewed and approved by the IFR Human Governance Committee and will be submitted to 
East Norfolk and Waveney Research Governance Committee for consideration at their next 
meeting on 4th of  April.  
 
The submission comprises the following documents: 
Study Protocol version 3, dated 2nd March 2007 
Annex 1 Tissue bank form* version 8, dated 2nd March 2007 
Annex 2 Volunteers letter version 2, dated February 2007 
Annex 3 Volunteers information sheet version 4, dated 2nd March 2007 
Annex 4 Consent Form version 1, dated January 2007 
Annex 5 GP letter version 1, dated January 2007 
Annex 6 Medical declaration form version 1, dated January 2007 
  
 
Annex 7 Health questionnaire version 1, January 2007 
Annex 8 NNUH Cystoscopy information sheet version 1, January 2007 
COREC form parts A & B and SSI form 
 
* Please note that the NNUH tissue bank information and consent form has been modified to 
allow the trust to use tissue or other material in a non anonymous form at its discretion within this 
research study only. 
 
 
Please note that the principle investigator and clinical director (Mr. Robert Mills, NNUH) 
signature are absent from the SSI. Mr. Rob Mills will be sending an email to the East Norfolk and 
Waveney Research Governance Committee to approve/authorize this study and signatures will be 
obtained prior to the meeting. (As advised by Julie Dawson) 
 
I look forward to receiving feedback from the committee in due course 
 
Yours sincerely, 
 
 
Melanie Dunk BSc PDipBiomedSc (study scientist) 
 
 
 
  
 
10.11 East Norfolk and Waveney Research Governance Committee  
 
Institute of Food Research         
 
Melanie Dunk, BSc PDipBiomedSc 
Phytochemicals and Health programme 
Institute of food research 
Norwich Research Park 
Colney 
Norwich 
NR4 7UA 
 
Tel:    01603-255048 (direct) 
Fax:   01603-507723 
Email: melanie.dunk@bbsrc.ac.uk 
Web:  www.ifr.ac.uk 
 
16TH March, 2007  
 
 
Dear Julie Dawson and committee members, 
 
Re: GENE EXPRESSION IN BLADDER CANCER FOLLOWING CONSUMPTION OF 
HIGH GLUCOSINOLATE BROCCOLI: a pilot study  
 
I would like to submit a research protocol for the above pilot study for consideration by the East 
Norfolk and Waveney Research Governance Committee at the next meeting on the 4thApril.  This 
study has been reviewed and approved by the IFR Human Governance Committee and will be 
submitted to the Norwich Research Ethics Committee for consideration at their next meeting on 
the 2nd of April. 
 
The submission comprises the following documents: 
Study Protocol version 3, dated 2nd March 2007 
Annex 1 NNUH tissue bank information and consent form * version 8, dated 2nd March 2007 
Annex 2 Volunteers letter version 2, dated February 2007 
Annex 3 Volunteers information sheet version 4, dated 2nd March 2007 
Annex 4 Consent Form version 1, dated January 2007 
Annex 5 GP letter version 1, dated January 2007 
Annex 6 Medical declaration form version 1, dated January 2007 
Annex 7 Health questionnaire version 1, January 2007 
Annex 8 NNUH Cystoscopy information sheet version 1, January 2007 
COREC form parts A & B and SSI form 
 
  
 
* Please note that the NNUH tissue bank information and consent form has been modified to 
allow the trust to use tissue or other material in a non anonymous form at its discretion within this 
research study only. 
 
Please note that the principle investigator and clinical director (Mr. Robert Mills) signature are 
absent from the SSI. Both will be sending emails to approve/authorize this study and signatures 
will be obtained prior to the meeting on the 4th April. (As advised) 
 
I look forward to receiving feedback from the committee in due course  
 
Yours sincerely, 
 
 
 
Melanie Dunk BSc PDipBiomedSc (study scientist) 
 
 
 
  
 
10.12 Corrospondance with Norfolk Research Ethics Committee response letter 
 
 
Norfolk Research Ethics Committee 
c/o The Norfolk & Norwich University Hospital NHS Trust  
First Floor, Aldwych House  
57 Bethel Street  
NORWICH 
NR2 1NR 
 
Telephone: 01603 286323  
Facsimile: 01603 286573 
11 April 2007 
 
Ms Melanie Dunk 
PhD student 
Institute of Food Research 
Norwich Research Park 
Colney, Norwich 
NR4 7UA 
 
Dear Ms Dunk 
 
Full title of study: Gene expression in bladder cancer following consumption of 
high glucosinolate broccoli: a pilot study 
REC reference number: 07/Q0101/32 
 
The Research Ethics Committee would like to thank you and Dr David Hughes for attending the 
review of your application at the meeting held on 02 April 2007.  
 
Ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a conditional favourable ethical opinion for 
the above research on the basis described in the application form, protocol and supporting 
documentation as revised.  
  
The favourable ethical opinion is subject to the following amendments being made:  
  
1) In the Human Tissue Bank (HTB) consent form, two references are made (in the third text 
box on page 1 and in the sentence with the asterisk on page two) to the 4ml sample being 
equivalent to 2 teaspoons; this is incorrect. The correct amount is expressed in the participant 
information sheet as 20ml being equivalent to 2 teaspoons, therefore please amend the HTB 
consent form accordingly.  
 
2) Please correct clause 6 of the HTB consent form so that it reads “…and may be published 
anonymously with any research findings.” 
 
3) Please ensure the presentation of the last sentence of the final paragraph of the HTB 
information sheet is corrected so that it makes sense. 
 
  
 
4) In the letter to the volunteer, members suggest that the tense is changed as currently the letter 
is confusing.  
 
5) Members suggest that the fist paragraph of the participant information sheet (PIS) is amended 
to understate the benefits of eating broccoli as the consumption of broccoli will not change 
the course of study participants’ disease. Members appreciate that this has been mentioned 
later on in the PIS but felt it should be clearly stated earlier on. 
 
6) It is suggested that as this research is being undertaken by a PhD Student the Supervisor’s 
contact details ought to be included in the PIS as well.  It is therefore recommended you 
include Professor Mithen’s details under ‘Complaints’ in Part 2 of the PIS.  
 
7) During the discussion at the meeting Members expressed a concern that apart from the 
participant’s name and the IFR volunteer number, there is no other identifier on the standard 
HRGC consent form. The concern being that once the consent form has been placed in the 
participants' hospital notes this could be lost/fall out and if there is more than one person with 
the same name it could be misfiled. In order to prevent this it was agreed at the meeting that 
the consultant responsible for placing the copy of the consent form in the hospital notes could 
be asked to place a 'short form patient sticker' on the form.  
 
8) As the study PIS has both IFR and NNUH headers please also incorporate the NNUH header 
on the study consent form. 
 
9) In the GP letter it was noted that the name of the Committee was incorrect and should read 
the 'Norfolk Research Ethics Committee'. 
 
10) Please include the IFR and NNUH header on the Medication/Medical Conditions Declaration 
Agreement, the study title, and a section for the volunteer number and contact details of the 
researcher. 
 
Please ensure revised documentation is presented to the Norfolk REC Office.  A Site Approval 
Form (SF1) listing approved sites for this study will then be issued.    
 
Conditions of approval 
 
The favourable opinion is given provided that you comply with the conditions set out in 
paragraph Ethical Opinion above and the attached document.  You are advised to study the 
conditions carefully. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
  
Document    Version    Date    
Application  5.3 Checklist  19 March 2007  
Application  5.3; Parts A&B  20 February 2007  
Application  5.3; SSI - NNUH     
Investigator CV  1; Ms Melanie Dunk - CI  01 February 2007  
Investigator CV  Professor Richard Mithen -    
  
 
Supervisor  
Investigator CV  Mr Robert Mills - PI  01 October 2004  
Investigator CV  Professor Richard Ball     
Protocol  3  02 March 2007  
Covering Letter  From Melanie Dunk  19 March 2007  
Summary/Synopsis  3; Protocol Pg 9 - Study Design  02 March 2007  
Summary/Synopsis  3; Protocol Pg 10 - Patient 
Selection  
02 March 2007  
Letter from Sponsor  From David Hughes  13 March 2007  
Peer Review  From D. Hughes, HRGC  13 March 2007  
Compensation Arrangements  From David Hughes  13 March 2007  
Questionnaire: Volunteer Screening  1; Annex 7  01 January 2007  
Letter of invitation to participant  2; Annex 2  01 February 2007  
GP/Consultant Information Sheets  1  01 January 2007  
Participant Information Sheet:  
NNUH Standard Cystoscopy Info Sheet  
1; Annex 9  01 January 2007  
Participant Information Sheet:  
Broccoli Study  
4; Annex 3  01 February 2007  
Participant Information Sheet:  
NNUH collection, storage & use of 
Human tissue/fluids for research  
8 Annex 1  11 November 2006 
Participant Consent Form:  
Broccoli Study  
1  01 January 2007  
Participant Consent Form:  
NNUH Collection & Storage of Human 
Tissue/fluids for research  
8; Annex 1   11 November 2006 
Medication/Medical Conditions 
Declaration Agreement  
1; Annex 6  01 January 2007  
Correspondence  From D. Hughes HRGC  05 February 2007  
Correspondence  From D. Hughes, HRGC  02 March 2007  
 
 
R&D approval 
The study should not commence at any NHS site until the local Principal Investigator has 
obtained final approval from the R&D office for the relevant NHS care organisation. 
 
Membership of the Committee 
The members of the Ethics Committee who were present at the meeting are listed on the attached 
sheet.  
 
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees (July 2001) and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
 
  
 
07/Q0101/32  Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
 
 
The Reverend Walter Currie 
Chairman 
 
Email: janette.guymer@nnuh.nhs.uk 
 
Enclosures: List of names and professions of members who were present at the meeting and those 
who submitted written comments 
Standard approval conditions 
 
 
Copy to: HRGC, Institute of Food Research 
East Norfolk & Waveney Research Governance Committee  
Norfolk Research Ethics Committee 
 
Attendance at Committee meeting on 02 April 2007 
 
Committee Members: 
 
Name Profession Present? Notes 
The  Reverend Walter Currie Retired Yes  Chairman 
Dr Elizabeth  Lund  Senior Research 
Scientist  
Yes  Alternate Vice-Chair 
Dr  Robert  Stone  General Practitioner  Yes  Vice-Chair 
Mr William Allen Retired No   
The  Reverend Bill Bazely  Senior Chaplain  No   
Mr Michael Flowerdew Acupuncture 
Practitioner and Writer  
Yes   
Miss Sheila Ginty Senior Sister Yes   
Mr  Colin  Green  Drugs & Therapeutics 
Pharmaceutical 
Advisor  
Yes   
Mrs  Belinda  Hoste  Case Worker No   
Miss  Rosemary  Jackson  Midwife  Yes   
Mrs  Pamela  Keeley  East Anglian Eye 
Bank Nurse Manager 
Yes   
Mr  Azad  Mathur  Consultant Paediatric 
Surgeon  
Yes   
Dr  Michael  Sheldon  Retired - Clinical 
Psychologist  
Yes   
  
 
 
Also in attendance: 
 
Name  Position (or reason for 
attending) 
Mrs Janette Guymer REC Manager Yes   
Miss  Katherine  Norton  Assistant 
Administrator 
Yes  Minuting Secretary 
Mrs Samantha Podmore Assistant 
Administrator 
Yes  Minuting Secretary 
 
  
 
10.13 Corrospondance with Norfolk Research Ethics Committee reply with amendments 
Institute of Food Research         
 
Melanie Dunk, BSc PDipBiomedSc 
Phytochemicals and Health programme 
Institute of food research 
Norwich Research Park 
Colney 
Norwich 
NR4 7UA 
 
Tel:    01603-255048 (direct) 
Fax:   01603-507723 
Email: melanie.dunk@bbsrc.ac.uk 
Web:  www.ifr.ac.uk 
 
17 April, 2007  
 
 
Dear Reverend Walter Currie and committee members, 
 
Re: GENE EXPRESSION IN BLADDER CANCER FOLLOWING CONSUMPTION OF 
HIGH GLUCOSINOLATE BROCCOLI: a pilot study   
 
REC REF: 07/Q0101/32 
 
I would like to re-submit this research protocol for the committee’s favourable ethical opinion.  
This study was reviewed and given conditional favourable ethical opinion by the Norwich 
Research Ethics Committee on the 2nd of April 2007.  The following documents have been 
amended in accordance with your recommendations: 
 
Annex 1 Tissue bank form version 9, dated April 2007 
Annex 2 Volunteers letter version 3, dated April 2007 
Annex 3 Volunteers information sheet version 5, April 2007 
Annex 4 Consent Form version 2, April 2007 
Annex 5 GP letter version 2, dated April 2007 
Annex 6 Medical declaration form version 2, dated April 2007 
 
The following amendments were made and are highlighted in orange in the corresponding 
documents: 
 
1) In the Human Tissue Bank (HTB) consent form- 4ml sample being equivalent to 2 teaspoons 
has been changed to 20ml being equivalent to 2 teaspoons. 
 
  
 
 2) HTB consent form- reads “ …and may be published anonymously with any research 
findings.”  
 
3) The presentation of the last sentence of the final paragraph of the HTB information sheet has 
been corrected so that it makes sense.  
 
4) Letter to the volunteer - The tense has been changed…..‘I enclose information’ 
 
5) PIS - The first paragraph of section one has been amended to understate the benefits of eating 
broccoli. 
 
6) PIS - Professor Richard Mithen’s details have been added under ‘Complaints’ in Part 2.  
 
 7) Three forms of patient identification – the consultant or a member of the urology team will be 
asked by the chief investigator to place a 'short form patient sticker' on the copy of the consent 
form before placing it into the patents hospital notes. An area has been made on the form as a 
reminder. 
 
8) Study consent form - NNUH header has been incorporate.  
 
9) GP letter - name of the Committee is corrected to read the 'Norfolk Research Ethics 
Committee'.  
 
10) Medication/Medical Conditions Declaration Agreement - The IFR and NNUH header, the 
study title, and a section for the volunteer number and contact details of the researcher have been 
incorporated. 
 
I do hope these amendments are agreeable and I look forward to receiving feedback from the 
committee in due course 
 
Yours sincerely, 
 
 
Melanie Dunk BSc PDipBiomedSc (study scientist) 
 
 
  
 
 
10.14 Norfolk Research Ethics Committee approval letter 
 
Norfolk Research Ethics Committee 
c/o The Norfolk & Norwich University Hospital NHS Trust  
First Floor, Aldwych House  
57 Bethel Street  
NORWICH 
NR2 1NR 
 
Telephone: 01603 286 397 
Telephone: 01603 286 323  
14 May 2010 
 
Ms Melanie Dunk, PhD student 
Institute of Food Research 
Norwich Research Park 
Colney, Norwich 
NR4 7UA 
 
Dear Ms Dunk 
 
Full title of study: Gene expression in bladder cancer following consumption of 
high glucosinolate broccoli: a pilot study 
REC reference number: 07/Q0101/32 
 
Thank you for your e-mail correspondence of 17/18 April 2007 and your letter dated 
17 April 2007, responding to the Committee’s conditions of approval and submitting revised 
documentation. 
 
I can confirm that you have responded appropriately. 
    
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
 
Document    Version    Date    
Application  5.3 Checklist  19 March 2007  
Application  5.3; Parts A&B  20 February 2007  
Application  5.3; SSI - NNUH     
Investigator CV  1; Ms Melanie Dunk - CI  01 February 2007  
Investigator CV  Professor Richard Mithen - Supervisor     
Investigator CV  Mr Robert Mills - PI  01 October 2004  
Investigator CV  Professor Richard Ball     
Protocol  3  02 March 2007  
Covering Letter  From Melanie Dunk  19 March 2007  
Summary/Synopsis  3; Protocol Pg 9 - Study Design  02 March 2007  
Summary/Synopsis  3; Protocol Pg 10 - Patient Selection  02 March 2007  
  
 
Letter from Sponsor  From David Hughes  13 March 2007  
Peer Review  From D. Hughes, HRGC  13 March 2007  
Compensation Arrangements  From David Hughes  13 March 2007  
Questionnaire: Volunteer Screening  1; Annex 7  01 January 2007  
Participant Information Sheet:  
NNUH Standard Cystoscopy Info 
Sheet  
1; Annex 9  01 January 2007  
Correspondence  From D. Hughes HRGC  05 February 2007  
Correspondence  From D. Hughes, HRGC  02 March 2007  
*Letter of invitation to participant  3; Annex 2  01 April 2007  
*GP/Consultant Information Sheets  2; Annex 5  01 April 2007  
*Participant Information Sheet:  
Broccoli Study  
5; Annex 3  01April 2007  
*Participant Information Sheet:  
NNUH collection, storage & use of 
Human tissue/fluids for research  
9 Annex 1 1 01 April 2007  
*Participant Consent Form:  
Broccoli Study  
2  01 April 2007  
*Participant Consent Form:  
NNUH Collection & Storage of 
Human Tissue/fluids for research  
9; Annex 1   01 April 2007  
*Medication/Medical Conditions 
Declaration Agreement  
2; Annex 6  01 April 2007  
*E-mail Correspondence of response 
to conditional favourable opinion 
letter 
From M. Dunk 17/18 April 2007 
*Hard copy of response to conditional 
favourable opinion letter 
Original signature from M. Dunk  
*E-mail including correspondence to  
Ms Dunk 
From ENWRGC 23 April 2007 
* E-mail including correspondence to 
ENWRGC to REC 
From M. Dunk 23 April 2007 
* E-mail including correspondence 
confirming approval for the study 
From ENWRGC Ref: 2007IFR01S 01May 2007 
*Documents which have been forwarded and updated to meet the favourable conditional opinion 
and to be used or the study and as confirmation of support for the study. 
 
Ethical review of research sites 
The favourable opinion applies to the research sites listed on the attached form.  
 
Research governance approval 
The study should not commence at any NHS site until the local Principal Investigator has 
obtained final research governance approval from the R&D Department for the relevant NHS 
care organisation.  You should ensure that R&D have received any amended study documentation 
as a result of the REC review. 
                                                 
1
 Please amend the version number in the title to correspond with the version number in the footer on this document 
  
 
 
Statement of compliance  
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees (July 2001) and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK.  
 
07/Q0101/32 Please quote this number on all correspondence 
 
With the Committee’s best wishes for the success of this project 
 
Yours sincerely 
 
 
 
Janette Guymer   
REC Manager 
 
Email: janette.guymer@nnuh.nhs.uk 
 
Enclosed: SF1 Form 
Copy to: HRGC, Institute of Food Research 
East Norfolk & Waveney Research Governance Committee 
  
 
 
 
 
 
 
Norfolk Research Ethics Committee 
 
LIST OF SITES WITH A FAVOURABLE ETHICAL OPINION 
 
For all studies requiring site-specific assessment, this form is issued by the main REC to the Chief 
Investigator and sponsor with the favourable opinion letter and following subsequent notifications 
from site assessors.  For issue 2 onwards, all sites with a favourable opinion are listed, adding 
the new sites approved. 
 
 
REC 
reference 
number: 
 
 
07/Q0101/32 
 
Issue 
number: 
 
1 
 
Date of 
issue: 
 
01 May 2007 
 
Chief 
Investigator: 
 
 
Ms  Melanie Dunk 
 
Full title of 
study: 
 
 
Gene expression in bladder cancer following consumption of high glucosinolate 
broccoli: a pilot study 
 
This study was given a favourable ethical opinion by Norfolk Research Ethics Committee on 02 
April 2007. The favourable opinion is extended to each of the sites listed below.  The research 
may commence at each NHS site when management approval from the relevant NHS care 
organisation has been confirmed. 
 
 
Principal 
Investigator 
 
Post 
 
Research site 
 
Site assessor 
 
Date of 
favourable 
opinion for 
this site 
 
 
Notes (1) 
Mr  Robert 
Mills 
Consultant 
Urologist 
Norfolk and 
Norwich 
University 
NHS Trust 
Norfolk 
Research 
Ethics 
Committee 
03/04/2007  
Ms Melanie 
Dunk 
PhD Student Institute of 
Food 
Research, 
Human 
Nutrition Unit 
Human 
Research 
Governance 
Committee, 
Institute of 
Food Research 
03/04/2007 07/Q0101/47 
[IFR01/2007] 
 
 
Approved by the Chair on behalf of the REC: 
 
.……………………………………………… (Signature of Chair/Co-ordinator)  
(delete as applicable) 
 
………………………………………………. (Name) 
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10.16 East Norfolk and Waveney Research Governace committee reply letter 
 
Melanie Dunk, BSc PDipBiomedSc 
Phytochemicals and Health programme 
Institute of food research 
Norwich Research Park 
Colney 
Norwich 
NR4 7UA 
 
Tel:    01603-255048 (direct) 
Fax:   01603-507723 
Email: melanie.dunk@bbsrc.ac.uk 
Web:  www.ifr.ac.uk 
 
19th April, 2007  
 
 
Dear Dr Lain Brooksby and committee members, 
 
Re:  2007IFR01S (49-04-07) GENE EXPRESSION IN BLADDER CANCER FOLLOWING 
CONSUMPTION OF HIGH GLUCOSINOLATE BROCCOLI: a pilot study  
 
This study was submitted to the East and Waveney Research Governance Committee for scientific 
peer review and research management approval on 4th April.  Three points were raised to be 
addressed prior to your approval. My supervisor, Professor Richard Mithen has discussed these 
with Julie Dawson and explained that due to time constraints the protocol has been submitted and 
approved by the Norfolk Research Ethics committee. She suggested that we wrote to you without 
amending the protocol. 
 
Firstly, it was considered that the exclusion criterion stating that the result of the health 
declaration needed to be expanded. It was considered to be impractical to list all the potential 
medical conditions that may result in exclusion. An important function of the health declaration is 
that it requires the volunteer to disclose all medical conditions and medications both before and 
during the study. This enables the principle investigator to decide upon inclusion or exclusion 
based upon clinical judgement.   
 
Secondly, it was advised that participants taking food supplements containing broccoli extracts 
should be excluded. We agree with this. Potential participants are required to disclose all dietary 
supplements in the screening questionnaire (annex 7), and appropriate decisions will be taken. 
The exclusion criteria (page 13) states that the results of the screening questionnaire may results 
in someone being ineligible for the study. Thus, we do not think any amendments are required. 
 
Thirdly, we agree with the comments that the numbers in each arm are low. However, this is 
intended as a pilot study to assess feasibility. If successful, we seek to expand the intervention to 
larger numbers. 
 
We hope that you will be satisfied with these responses, without the need to amend the protocol 
itself. 
 
Yours sincerely, 
Melanie Dunk BSc PDipBiomedSc (study scientist) 
  
 
 
 
10.17 East Norfolk and Waveney Research Governace committee approval letter 
 
  
 
 
 
 
  
 
 
 
10.18 Tenascin-C RT-PCR gels  
 
 
  
                    
1 - SF ctl  (All gels follow the same lane format)  2 – SF treated 
 
                    
3 – IB ctl                                              4 – IB treated 
 
 
                     
5 – SF-NAC ctl                                   6 – SF-NAC treated 
 
                     
7 – SF/IB ctl                                       8 – SF/IB treated 
 
1    2      3    4     5   6     7     8 
  
 
 
 
                     
9 – 03TB135                                     10 – 03TB165 
 
 
                 
11 – 03TB180                                12 – 03TB189 
 
 
                
  13 -03TB192                                   14 – 03TB195     
 
        
  
 
 
 
                        
15 – 04TB018                                               16 – 04TB023 
 
                            
17 – 04TB035                                                18 – 04TB099 
 
                            
19 – 04TB269                                                20 – 04TB280 
 
                           
21 – 04TB192                                                22 – 03TB165 
 
  
 
 
 
                                
23 – 02TB040                                                     24 – 02TB058 
 
                                
26 – 02TB067                                                   27 – 02TB044 
 
                                
28 – 02TB093                                                   29 – 03TB179 
 
  
 
 
 
                                 
30- 04TB119                                                    31 – 04TB125 
 
                                  
32 – 04TB021                                                  33 – 03TB132 
 
                                
34 – 03TB146                                                   35 – 07TB0322 
 
  
 
 
 
                              
36 – 07TB0338                                                      37 – 07TB0339 
 
                            
38 – 07TB0344                                                    39 – 07TB0340 
 
                             
40 – 08TB0007                                                 41 – 06TB0018 
                                
 
  
 
 
 
                                  
42 – 06TB0208                                                    43 – 07TB020 
 
 
                                  
45 – 06TB0010                                                    46 – 07TB0299 
 
                                     
 
47 – 06TB0991                                                    48 – 05TB0237 
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